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The main psychoactive and therapeutic effects of Δ9-tetrahydrocannabinol (THC) are
mediated through cannabinoid type 1 receptors (CB1Rs). The therapeutic uses of THC are
mitigated by the development of tolerance to these therapeutic effects, whereas tolerance does
not readily develop to some of the side-effects of THC, like motor impairment and reward. The
development of tolerance occurs through adaptations at CB1Rs, which include desensitization
(G-protein uncoupling) and downregulation (receptor degradation). Brain region-dependent
differences in THC-mediated adaptations are proposed to explain the differences in tolerance to
various THC-mediated effects. These studies focused on whether ΔFosB, a stable transcription
factor, could regulate CB1R adaptations since regions resistant to CB1R adaptations, like the
basal ganglia, exhibit THC-mediated ΔFosB induction. The studies in this dissertation tested the
hypothesis that THC-mediated induction of ΔFosB is regulated through interactions between
cannabinoid and dopamine systems and that brain region-dependent differences in ΔFosB
transcriptional regulation could explain some aspects of long-term CB1 R signaling and CB1R
adaptations. Results determined that THC induced ΔFosB primarily in forebrain areas, like
striatum, that are innervated by midbrain dopamine neurons. An inverse, brain region-dependent

correlation was found between CB1R desensitization and ΔFosB induction. Studies utilizing
bitransgenic mice with overexpression of ΔFosB, or its dominant negative ∆cJun, determined
that ΔFosB regulates CB1R signaling and reduces CB1R desensitization. Based on this regional
profile, studies determined the role of dopamine signaling in THC-mediated ∆FosB induction.
Results showed that THC-mediated induction of ΔFosB required dopamine type 1 receptors, but
not the dopamine-and cAMP-dependent phosphoprotein of Mr 32kDA. Finally, the functional
consequences of THC-mediated ΔFosB induction were assessed by measuring expression of
known targets of ΔFosB following both acute and repeated THC administration. Results found
that, in prefrontal cortex, known targets of ΔFosB exhibited functionally different signaling
expression patterns when comparing acute THC with THC-challenge in THC-experienced mice,
which enhanced ΔFosB induction. These studies establish a role for ΔFosB in regulating longterm CB1R signaling/adaptation following repeated THC administration and could have
implications for changes in the effects of THC during repeated administration, including the
development of differential tolerance to motor-impairing and rewarding effects of THC versus
other pharmacological effects.

Introduction
0.1 History of cannabis use
Marijuana is derived from the Cannabis sativa plant, which provides food from its seeds,
fiber from its stalks and intoxicating preparations from its flowers, leaves and resins. Marijuana
was first used in making fibers, known as hemp, as early as 8000 B.C. (Kabilek, 1960). Hemp’s
most important uses historically were for bow strings and rope for sailing, with minor uses for
paper and clothing. Although it is not clear when the marijuana plant was first used for
medicine, historical records indicate that the first prescribed uses were around 2737 B.C. by
Shen Neng, a Chinese emperor. He recommended the use of marijuana tea for gout, malaria,
beriberi, rheumatism and poor memory (Abel, 1980). The use of marijuana for medicine
migrated to India, and it was listed in the Indian text Artharvaveda as a holy plant that relieved
stress. Pliny the Elder, a Roman philosopher, also mentioned the use of marijuana as a
painkiller, although the side effect of impotency was noted. Pedacius Dioscrides, a physician in
Nero’s army compiled a pharmacopoeia in 70AD that listed marijuana for earaches and other
medical applications. Side effects were also noted for the use of marijuana; Ibn Wahshiyah’s
Arabic text On Poisons mentioned that hashish produced blindness and muteness.
W. B. O’Shaunessey, an Irish physician serving in the British army, familiarized the
medicinal properties of marijuana to the Western world after studying it in India and produced a
treatise in 1839 describing its medicinal properties (Adams and Martin, 1996). His studies
focused on the safety of marijuana in animals and determined that even high doses did not
produce death (Snyder, 1971). He recommended marijuana as an anticonvulsant, analgesic,
antiemetic and antianxiety agent, promoting its use in both the United Kingdom and throughout
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Europe (Mechoulam and Feigenbaum, 1987). The Ohio State Medical Society listed several
medicinal uses for marijuana in 1860. By the 1900s, pharmaceutical companies like the Squibb
Company, Eli Lilly and Parke-Davis provided tinctures of the extract. The disuse of marijuana
as medicine coincided with the Marijuana Tax Act of 1937, which resulted in the removal of
marijuana from the U.S. Pharmacopoeia in 1941 and criminalization of marijuana in every state.
This also ended most research into marijuana for medicinal purposes in the United States and
abroad. In the 1960s, states began to decriminalize marijuana use, but criminalization of
marijuana returned in the 1980s. More recently, several states have approved marijuana for
medicinal and recreational uses. Marijuana is the most commonly abused illicit drug, with 46%
of Americans having tried marijuana and ~9% of marijuana users considered dependent based on
DSM-IV-R criteria (SAMHSA, 2010).

Figure 0.1. Representative chemical structures of A) phytocannabinoids B) synthetic
cannabinoids C) endogenous cannabinoids and D) CB1R inverse agonist

2

0.2 THC and Synthetic Cannabinoids
Although marijuana is composed of more than 60 cannabinoid constituents (Mechoulam
and Parker, 2013), Δ9-tetrahydrocannabinol (THC) is the main psychoactive constituent. Roger
Adams first isolated the main constituents of marijuana in the 1940s, but these compounds did
not have psychoactive properties (Adams, 1940). Raphael Mechoulam first reported the
isolation of several active compounds of similar lipid structure, including the structure of THC
(Gaoni, 1964; Mechoulam and Gaoni, 1965). Based on this structure, several synthetic
cannabinoid ligands have been produced and are grouped by structure (Figure 0.1). Synthetic
compounds used in research include HU-210, an ABC-tricyclic dibenzopyrans, that was
synthesized by Mechoulam in 1988 (Mechoulam et al., 1988), the AC-bicyclic, ((-)-cis-3-[2hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol)(CP55,940)
and the aminoalkylindole (R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate) (WIN55,212-2), which has a very
different structure from other cannabinoids (Howlett et al., 2002). From the structure of these
compounds, the antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3pyrazole-carboxamide (SR141716A) was also created by Sanofi Aventis (Rinaldi-Carmona et
al., 1994). CP55,940 is a high efficacy partial agonist at the cannabinoid type 1 receptor (CB1R)
and is a full agonist at the cannabinoid type 2 receptor (CB2R), with similar binding affinities for
both CB1Rs and CB2Rs (Howlett et al., 2002). [3H]CP55,940 is one widely used radiolabeled
cannabinoid ligands and has historical significance, as it was first used to demonstrate a specific
cannabinoid binding site (Devane et al., 1988) and to anatomically map the distribution of
cannabinoid receptors in rat brain (Herkenham et al., 1991b) using autoradiography.
WIN55,212-2 is a full agonist at CB1Rs, and the prototype of the aminoalkylindole family whose
3

structure is not based on the structure of THC (Figure 0.1). WIN55,212-2 has also been used in
autoradiographic studies (Jansen et al., 1992). Synthesis of a CB1R-selective antagonist
SR141716A, which was determined to be an inverse agonist (Gueudet et al., 1995; Landsman et
al., 1997) (Gifford and Ashby, 1996), was critical in establishing the specificity of CB1Rmediated effects, and demonstrated that the centrally-mediated in vivo and behavioral effects of
cannabinoids are CB1R-dependent (Rinaldi-Carmona et al., 1994). SR141716A has also been
used to map CB1Rs in rodent brain (Rinaldi-Carmona et al., 1996).

Figure 0.2. Schematic diagram of the endogenous cannabinoid system. Neurotransmitter
released from the presynaptic terminal causes on-demand synthesis of 2-arachindonoylglycerol
(2-AG) and arachidonoylethanolamine (AEA). 2-AG is degraded by monacylglycerol lipase
(MAGL) and AEA is degraded by fatty acid amide hydrolase (FAAH). Both 2-AG and AEA are
agonists at the cannabinoid type 1 receptor (CB1R). Cannabinoid type 2 receptors (CB2Rs), not
pictured here, are found primarily on non-neuronal cells. Adapted from (Guzman, 2003)
4

0.3 The endogenous cannabinoid system
Based on the lipid structure, early researchers suggested that THC acted directly on the
cell membrane as opposed to a specific receptor system (Martin et al., 1988). The first evidence
of a specific receptor-mediated mechanism of action for THC was provided by Howlett and
colleagues. They discovered that THC inhibited adenylyl cyclase (AC) activity in
neuroblastoma cells under both basal and hormone-stimulated conditions (Howlett, 1984;
Howlett and Fleming, 1984). This group later reported that THC required the G-protein subunit
Gαi to produce their biological responses (Howlett et al., 1986). The role of Gαi was determined
by using pertussis toxin, which is derived from Bordetella pertussis. Pertussis toxin ribosylates a
cysteine on Gαi and Gαo subunits when they are associated with βγ subunits (Locht and Antoine,
1995; Mangmool and Kurose, 2011). The creation of a tritiated form of CP55,940 led to the
discovery of a specific binding site for cannabinoid compounds in the brain (Devane et al.,
1988). This study also determined that the nonhydrolyzable guanosine triphosphate (GTP)
analog, guanylylimidodiphosphate, displaced CP55,940 from its binding site, suggesting that
CP55,940 coupled to a site that also coupled to G-proteins. Two cannabinoid receptors were
subsequently cloned from cDNA libraries; the CB1R from rat cerebral cortex (Matsuda et al.,
1990) and CB2R from spleen (Munro et al., 1993). The CB1R gene in mice and rats encodes a
473 amino acid protein and is composed of two encoding exons and one non-encoding exon.
Amino acid identity between mouse and rat CB1Rs is 99.5% while mouse and human sequence
identity approaches 97% (Abood et al., 1997). Phylogentically, CB1Rs and their homologuesare
expressed in animals of the chordate phylum, as well as invertebrates in the annelid phylum
(McPartland and Glass, 2003). CB1Rs and CB2Rs share 44% structural homology and THC
binds to both receptors with similar potency. CB2Rs are commonly found on immune cells
5

(Cabral and Marciano-Cabral, 2005; Pettit et al., 1998), but may also be expressed by neurons
(Onaivi et al., 2006; Van Sickle et al., 2005). CB2Rs have also been implicated in the rewarding
properties of cocaine (Xi et al., 2011), nicotine (Ignatowska-Jankowska et al., 2013) and ethanol
(Ortega-Alvaro et al., 2013). Herkenham and collaborators used [3H]CP55,940 autoradiography
to localize CB1R in the rodent central nervous system (CNS) (Herkenham, 1991).
The discovery of endogenous cannabinoid receptors was followed by identification of
endogenous ligands. Although several putative lipid-based endogenous ligands have been
discovered, arachidonoylethanolamine (anandamide, AEA) (Devane et al., 1992) and 2arachindonoylglycerol (2-AG) (Mechoulam et al., 1995; Stella et al., 1997; Sugiura et al., 1995)
are considered the only confirmed endocannabinoids (Figure 0.2). Although AEA and 2-AG
have similar binding affinities, 2-AG exhibits higher efficacy than AEA at both CB1Rs and
CB2Rs (Pertwee, 2005). Because AEA is highly susceptible to metabolism, synthetic derivatives
such as (R)-(+)-methanandamide have been developed that exhibit greater metabolic stability,
affinity, and CB1R selectivity (Di Marzo et al., 2001; Lin et al., 1998).

Unlike classical

neurotransmitters, endocannabinoids are produced on demand (Marsicano et al., 2003) following
increases in intracellular calcium (Rodriguez de Fonseca et al., 2005) and undergo retrograde
transmission. Initial studies had suggested that AEA was primarily synthesized by hydrolysis of
N-acyl-phosphatidylethanolamines (NAPE) by NAPE phospholipase D (NAPE-PLD) (Schmid et
al., 1990). However, AEA is produced in mice with genetic deletion of NAPE-PLD (Leung et
al. 2006) suggesting that alternative pathways include double-deacylation of NAPE by α/βhydrolase 4 (ABH4) followed by phosphodiesterase-mediated cleavage by
glycerophosphodiesterase 1 (GDE1) (Simon and Cravatt, 2006) and phospholipase C-catalyzed
cleavage of NAPE and dephosphorylation of NAPE (Liu et al., 2006). The production of AEA
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in mice with genetic deletion of both GDE1 and NAPE further suggests that multiple
biosynthesis pathways exist for AEA (Leung et al., 2006; Simon and Cravatt, 2010). The
synthesis of 2-AG has been more clearly defined. 2-AG is synthesized in a phospholipase Cdependent manner by the cleavage of sn-1-acyl-2-arachidonoylglycerols (DAGs) by DAG lipase
(DAGL). Two isoforms of DAGL exist, DAGLα and DAGLβ, although DAGLα appears to
predominant in the CNS (Gao et al., 2010; Tanimura et al., 2010). AEA and 2-AG are rapidly
degraded following release by two separate enzymes, fatty acid amide hydrolase (FAAH) and
monacylglycerol lipase (MAGL), respectively.
Although CB1Rs and CB2Rs are considered the accepted cannabinoid receptors and AEA
and 2-AG are the accepted ligands, there is evidence to support a growing number of receptors
and ligands that could be considered part of the endogenous cannabinoid system. GPR55 has
been considered a putative cannabinoid binding receptor (Ross et al., 2012) while noladin ether
(Fezza et al., 2002) and N-arachidonoyldopamine (Bisogno et al., 2000) have been suggested as
putative endogenous ligands. Further, AEA has been suggested to be an agonist at the vanilloid
type 1 (TRPV1) receptor (Di Marzo et al., 2001). More recently, studies in our laboratory have
determined that WIN55,212-2 shows brain region-dependent activation of other receptors (Non
CB1R/CB2R/GPR55) while CP55,940 appears to be specific for the CB1Rs in all brain regions
(Nguyen et al., 2010).

7

Figure 0.3 Location of CB1Rs in forebrain and midbrain regions of the mesocorticolimbic
dopaminergic system. From (Fitzgerald et al., 2012)
0.4 Neuroanatomical localization of CB1Rs and in vivo effects
CB1Rs are expressed heterogeneously throughout the CNS and are one of the most
abundant G-protein coupled receptors (GPCRs) in the brain (Howlett et al., 2002) (Figure 0.3).
Very high expression of CB1Rs is found in the globus pallidus, substantia nigra pars reticulata
and molecular layer of the cerebellum. Moderate expression in the hippocampus, striatum
(caudate-putamen and nucleus accumbens) and lower expression occurs in the hypothalamus,
periaqueductal gray (PAG), basolateral amygdala, ventral tegmental area and cortex
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(Herkenham, 1991). In the human CNS, the distribution of CB1Rs is very similar even
throughout development where CB1R densities are higher in earlier developmental stages (Glass
et al., 1997). Studies utilizing CB1R knockout mice and the CB1R-specific inverse agonist,
SR171614A, have demonstrated that these receptors mediate many of the behavioral effects of
THC (Rinaldi-Carmona et al., 1994; Zimmer et al., 1999). Corresponding to the regional
expression of CB1Rs, cannabinoid agonists produce effects in rodents that include motor
impairment, memory impairment, hypothermia, antinociception, anxiety-like behaviors and
hyperreflexia (Compton et al., 1993; Dewey, 1986). In preclinical studies, behaviors attributed
to marijuana use in humans are attributed to CB1R activation including: increased feeding
(Beardsley et al., 1986; Chambers et al., 2007), reduced emesis and nausea (Darmani, 2001a, b),
a wide range of analgesia/antinociception or reductions in pain hypersensitivity (Lichtman and
Martin, 1991; Martin et al., 1999). There are also impairments in several aspects of memory
(Lichtman and Martin, 1996; Niyuhire et al., 2007) and reduced pressure in the aqueous humor
in the eye (Chien et al., 2003; Green and Pederson, 1973); however, only some behaviors like
“subjective high” and tachycardia have been verified to be CB1Rs-dependent in humans (Huestis
et al., 2001). THC has been found to increase dopamine release in the nucleus accumbens and
increase activation of ventral tegmental area neurons like other drugs of abuse; however, it is not
certain that acute THC is rewarding (Gardner, 2005b). THC also increases dopamine release in
the human striatum (Bossong et al., 2009). In mice, place preference has been shown with low
doses of THC (Lepore et al., 1995) or after priming the mouse with a single dose of THC and
testing the animal after 24 hours with another single dose of THC (Valjent and Maldonado,
2000). Mice (Martellotta et al., 1998), rats (Fattore et al., 2001) and squirrel monkeys (Tanda et
al., 2000) self-administer THC or WIN55,212-2, and THC microinjections into the nucleus
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accumbens and ventral tegmental area of rats (Zangen et al., 2006) increase lever pressing.
Intracranial self-stimulation (ICSS) paradigms with synthetic cannabinoid agonists such as
WIN55,212-2 show rightward shifts in rats suggesting aversion (Vlachou et al., 2005), but other
studies with THC show leftward shifts in rats suggesting reward (Gardner et al., 1988; Lepore et
al., 1996). In humans, THC is reported to have both rewarding and aversive aspects and those
who smoke marijuana often report that the positive effects remain stable while certain negative
effects like dry mouth and lightheadedness are reduced with repeated use (Green et al., 2003).
This might suggest that less tolerance develops in those brain regions involved with reward.
CB1Rs also appear to be important for mediating the rewarding properties of other drugs of
abuse as CB1R knockout mice fail to demonstrate elevated dopamine release in nucleus
accumbens or substantial intake by ethanol or morphine (Hungund et al., 2003; Mascia et al.,
1999).
Neocortex
The neocortex is involved with higher order functions that involve the processing of
sensory stimuli (olfactory, somatosensory, visual, auditory, associational), the execution of
complex movements (primary and motor cortices) and executive control/working memory
(prefrontal cortex and anterior cingulate cortex). The prefrontal cortex is responsible for the
planning of movements, plays a role in the consolidation of memories and may be involved with
reward. CB1 receptors are located on axon terminals of corticostriatal projections, which may
contribute to the locomotor suppressant effects of Δ9 -THC. CB1Rs are expressed throughout the
neocortex with the highest expression in layers I and VI and lower levels expressed throughout
layers II-V (Herkenham, 1991). The neocortex is comprised of large, glutamate-containing
pyramidal neurons that are expressed in deep layer III and layer V and serve as the main
10

projections of the cortex to subcortical brain regions and throughout the body. Much smaller
pyramidal neurons contained in layers II and III project to other cortical areas while layer VI
pyramidal neurons that have axon collaterals throughout the neocortex and thalamus. The cortex
is also comprised of several different GABAergic interneurons, which heavily populate layer IV
(the main destination of thalamic projections to cortex), that are classified by their morphology,
peptides (i.e., cholecystokinin (CCK), parvalbumin, neuropeptide Y, calretinin) and their
electrophysiological characteristics (Butt et al., 2005). CB1Rs are expressed in cholecystokinin
(CCK)-positive GABAergic interneurons (Tsou et al., 1998), non-CCK GABAergic interneurons
(Hill et al., 2007) and in some glutamatergic pyramidal neurons throughout the neocortex (Hill et
al., 2007; Monory et al., 2006); however, they have not been found on parvalbumin interneurons
(Bodor et al., 2005). In the prefrontal cortex, CB1Rs are known to exist on adrenergic afferents
(axonal projections) whose cell bodies most likely originate in the locus coeruleus (Oropeza et
al., 2007). No studies to date have reported expression of CB1Rs on dopaminergic afferents
(Miner et al., 2003).
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Figure 0.4 Example of direct (D1R) and indirect (D2R) signaling pathways of the caudateputamen in the CNS. MSNs of the D1R/direct pathway project primarily to the substantia nigra
pars reticulata (SNr) and entopeduncular nucleus (represented here as GPi) while MSNs of the
D2R/indirect pathway project to the globus pallidus (GPe). Note that CB1Rs are found in both
populations. The primary dopaminergic innervation to the caudate-putamen is the substantia
nigra pars compacta (SNc). The primary glutamatergic innervation to the caudate-putamen is
from the cortex. Both pathways feed-back on the cortex through the thalamus. From
(Benarroch, 2007).
Basal Ganglia
The highest expression of CB1Rs in the CNS are found in the output regions of the
caudate-putamen: substantia nigra pars reticulata, entopeduncular nucleus and globus pallidus
(Herkenham, 1991) (Figure 0.4). Moderate expression is also found in the caudate-putamen and
subthalamic nucleus (Herkenham, 1991). The predominate neurons in the caudate-putamen are
GABAergic medium spiny neurons (MSNs), which comprise 95% of the total neuronal
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population (Kemp and Powell, 1971). Remaining neurons are interneurons that are subdivided
by morphology, neuropeptide/ acetylcholinergic production and based on electrophysiological
properties (Kawaguchi et al., 1995). CB1Rs are expressed in the MSN population, as well as
interneurons that primarily express parvalbumin (Fusco et al., 2004). The MSN population is
further subdivided into two populations: those containing dopamine type 1 (D1 and D5) receptors
(D1Rs)/substance P/dynorphin and those containing dopamine type 2 (D 2-4) receptors/enkephalin
(D2R)(Gerfen, 1992; Gerfen et al., 1990; Le Moine et al., 1995). CB1Rs are located in both
populations (Hohmann and Herkenham, 2000). These subpopulations also have specific axonal
projection. The D1R/dynorphin MSN population projects primarily to substantia nigra pars
reticulata (the direct pathway) and the D2R/enkephalin MSN population projects primarily to the
globus pallidus (the indirect pathway) (Gerfen, 1988). In regards to motor control by caudateputamen, these specific projections produce an opponent process system that produces increases
in locomotor activity following dopamine release. Dopamine increases activity in
D1R/dynorphin MSNs and suppresses activity in D2R/enkephalin MSNs. This is achieved
through the differences in coupling of these receptors to specific G-proteins and control of ACS
activity. D1Rs couple primarily to Gαs/olf (Drinnan et al., 1991) and stimulate ACS (Kebabian et
al., 1984; Kebabian et al., 1972) and D2Rs couple primarily to Gαi/o (Kebabian et al., 1984;
Senogles et al., 1990) and inhibit ACS (Stoof and Kebabian, 1981). Therefore, dopamine release
differentially activates the neurons in which these receptors are located. As further illustration,
direct injection of GABAA receptor agonists (which suppress neuronal activity, e.g. muscimol)
into these regions produce opposing effects. Injection of muscimol into the globus pallidus
produces locomotor suppression while injection of muscimol into substantia nigra produces
locomotor activity (Amalric and Koob, 1989). More recent optogenetic studies have found that
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selective activation of D1R MSNs in the caudate-putamen increased ambulation while selective
activation of D2R MSNs reduced ambulation, further providing evidence for the opponent
process system (Kravitz et al., 2010).
Although the projections of these neurons primarily terminate in their respective output
nuclei, axon collaterals from the D1R/dynorphin MSNs also project to the globus pallidus
(Lindvall and Bjorklund, 1979) and there are GABAergic axonal projections from the globus
pallidus that terminate in the substantia nigra pars reticulata (Bolam et al., 1993). The
preponderance of CB1Rs that are located in the substantia nigra pars reticulata, entopeduncular
nucleus and globus pallidus originate from cell bodies in the caudate-putamen because lesion of
the caudate-putamen abolishes the expression of CB1Rs in these areas (Herkenham et al., 1991a).
This study also found that lesion of the medial forebrain bundle did not affect CB1R levels in the
caudate-putamen of the lesioned side, suggesting that CB1Rs found in the caudate-putamen do
not arise from the dopaminergic axonal projections of the medial forebrain bundle. More recent
studies using detailed electron microscopy corroborate the finding that CB1Rs are not expressed
in axons containing dopamine in the caudate-putamen (Fitzgerald et al., 2012). CB1Rs are found
on glutamatergic and GABAergic axon terminals in the caudate-putamen (Rodriguez et al.,
2001). The glutamatergic axons arise from neocortical projections, primarily motor cortices,
which also contain D2R autoreceptors (Wang and Pickel, 2002). The GABAergic axons are
primarily derived from local MSNs as well as GABAergic interneurons, which contain both
CB1Rs and D2Rs (Bennett and Bolam, 1994). There are also glutamatergic axonal projections
from the amygdala and hippocampus that terminate in the caudate-putamen (Gerfen, 1984), but it
is not clear if these projections also contain CB1Rs.
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Systemic administration of THC produces primarily locomotor suppression and catalepsy
(Dewey, 1986) and suppresses total neuronal activity in all regions of the basal ganglia (Shi et
al., 2005). Several studies have attempted to dissect which brain regions are responsible for
these effects, but the results are inconclusive. Early studies compared the effect of cannabinoids
on unilateral injection of muscimol into the globus pallidus and substantia nigra. Injection of
muscimol into the globus pallidus produces catalepsy while injection of THC enhances the
muscimol effect, suggesting that globus pallidus could play a role in THC-mediated catalepsy
(Wickens and Pertwee, 1993). Unilateral injection of muscimol into the substantia nigra produce
contralateral circling, a measure of hyperactivity, and 1 µg of THC enhanced this effect while 10
µg of THC abolished this effect (Wickens and Pertwee, 1995), suggesting a dose-response.
Intranigral injection of CP55,940 alone also produces contralateral turning (Sanudo-Pena et al.,
1996). Intrastriatal injections also produce contralateral turning, which is blocked by the D2R
agonist quinpirole (Sanudo-Pena et al., 1998). More recently, studies using mice with genetic
deletion of CB1Rs in either glutamate-, GABA- or D1R-containing forebrain neurons determined
that cannabinoid-mediated locomotor suppression was reduced only in mice that had genetic
deletion of CB1Rs in glutamate-containing neurons (Monory et al., 2007). This study also
determined that catalepsy was abolished in mice that had genetic deletion of CB1Rs in D1Rcontaining neurons. The source of glutamate-containing neurons that modulate THC-mediated
locomotor suppression is not clear; however, the subthalamic nucleus, which is part of the basal
ganglia, may play a part. The subthalamic nucleus receives GABAergic projections from the
globus pallidus and sends glutamatergic projections to substantia nigra and globus pallidus
(Deniau et al., 1978). Direct injection of CP55,940 into the subthalamic nucleus produces
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locomotor suppression, suggesting the importance of this region in cannabinoid-mediated
locomotor suppression (Miller et al., 1998).
Nucleus accumbens
The nucleus accumbens (ventral striatum) is similar to the caudate-putamen in that it
contains D1R/dynorphin and D2R/enkephalin MSN populations (Curran and Watson, 1995) that
project to the ventral tegmental area and ventral pallidum, respectively. There is some evidence
that D1R/dynorphin MSNs also express the D3, D2R subtype (Ridray et al., 1998). The nucleus
accumbens is subdivided into the core and shell areas, which are differentiated mainly by
calbindin staining that is strongly stained in the core but much lighter in the shell (Groenewegen
et al., 1999). Functionally, the nucleus accumbens shell may play a more important role in drug
reward because cocaine, morphine and amphetamine generally increase dopamine in the shell
but not the core (Pontieri et al., 1995), and several drugs of abuse are self-administered when
injected directly into the shell but not the core (Di Chiara et al., 2004). CB1Rs are located
predominantly on axon terminals in the shell, and are also found on both D1R and D2R MSNs
(Pickel et al., 2004). Despite the location of CB1Rs in nucleus accumbens and their regulation of
dopamine release (Wu and French, 2000), preclinical measures of reward-related behavior,
especially in rodents, have failed to provide clear results regarding THC or other cannabinoids in
regards to their reward profile (Tanda and Goldberg, 2003).
Other regions
CB1Rs are primarily expressed by GABAergic CCK-containing basket cells of both the
hippocampus (Freund and Hajos, 2003; Mackie, 2005) and amygdala (Katona et al., 2001;
Marsicano and Lutz, 1999; Tsou et al., 1998). The hippocampus contributes to learning behavior
and cannabinoids are known to disrupt tasks such as the delayed nonmatch-to-sample task and
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Morris water maze task, which involve this region (Hampson and Deadwyler, 1998; Varvel and
Lichtman, 2002). The amygdala contributes to anxiety- and fear-related behaviors and the
ventral hippocampus can contribute to anxiety-related behaviors (Rubino et al., 2008). Focal
injection of cannabinoids into the amygdala produces anxiety-related behaviors while focal
injection into ventral hippocampus produces anxiolytic-related behaviors (Rubino et al., 2008).
Systemic injection of cannabinoids produces anxiolytic-related behaviors at low doses and
anxiogenic-related behaviors at higher doses (Parolaro et al., 2010). In amygdala, dopamine is
actually increased during stress and enhances amygdala-related behavior (Inglis and
Moghaddam, 1999; Rosenkranz and Grace, 1999). Further, the amygdala has been implicated in
drug reinstatement, as shown by its involvement in consolidation of drug-paired cues (e.g.
associated with conditioned place preference paradigms) (Fuchs and See, 2002; Luo et al., 2013).
The hypothalamus regulates mostly autonomic, metabolic and circadian rhythm
functions. The medial preoptic area controls thermoregulation and direct injection of
WIN55,212-2 into this region produces hypothermia (Rawls et al., 2002); however, THCmediated hypothermia is still present in rats with lesions to this area (Schmeling and Hosko,
1976). The hypothalamus receives inputs from the limbic system and midbrain. The thalamus is
a gateway between the cortex and the rest of the CNS and mediates sensory perception as well as
motor function. Although CB1R expression and G-protein signaling is low in thalamus, there is
high CB1R expression in the lateral habenula (Tsou et al., 1998). There is low expression of
CB1Rs in periaqueductal gray and this region is partly responsible for the antinociceptive
properties of cannabinoids (Herkenham, 1991; Lichtman and Martin, 1991). The spinal cord is
also involved in the antinociceptive properties of cannabinoids where CB1Rs are found in the
dorsal root ganglia nociceptive neurons. Finally, very high expression of CB1Rs is found in the

17

molecular layer of cerebellum, a region that is important for motor coordination. Further, some
evidence suggests that cerebellum is involved in the withdrawal signs (Tzavara et al., 2000)
following cannabinoid abstinence and for the hyperreflexia observed after cannabinoid
administration (Patel and Hillard, 2001).
0.5 CB1R signaling
CB1Rs belong to the rhodopsin-like class A family of G-protein coupled receptors
(GPCRs), which contain seven transmembrane domains with an extracellular glycosylated amino
terminus and an intracellular carboxyl-terminus. G-proteins are composed of three separate
subunits: Gα, Gβ and Gγ.

In the inactive confirmation, guanosine diphosphate (GDP) binds to

the α subunit, which forms a heterotrimeric complex with the βγ dimer that binds. Agonist
binding to the receptor results in the exchange of guanosine triphosphate (GTP) with GDP. In
this active state, the βγ dimer dissociates from the α subunit providing two distinct signaling
mechanisms (Childers et al., 1993). The GPCR acts as a catalyst for this exchange and allows
for the activation of several G-proteins, which amplifies signaling (Breivogel et al., 1997).
CB1Rs typically couple to Gαi/o subunits, although some research suggests CB1R coupling to Gαs
(Bonhaus et al., 1998; Glass and Felder, 1997) and Gαq/11 (De Petrocellis et al., 2007; Lauckner
et al., 2005). G-protein coupling can occur at the intracellular loops (Abadji et al., 1999) and the
c-terminus (Howlett et al., 1998; Mukhopadhyay et al., 1999) of CB1Rs. The activation of Gαi
subunits typically leads to an inhibition of ACS and a decrease in accumulation of cAMP
(Smigel et al., 1984); however, it should be noted that co-expression of CB1Rs and ACS
isoforms I, III, V, VI or VIII decreases the accumulation of cAMP whereas cAMP accumulation
increases when CB1Rs are co-expressed with AC isoforms II, IV, and VII (Rhee et al., 1998).
CB1Rs modulate multiple downstream signaling events via activation of Gαi/o and Gβγ subunits,
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including phosphorylation of p42/p44 mitogen activated protein kinases (MAPK), which are also
known as extracellular signal-regulated kinases (ERK1/2) (Bouaboula et al., 1995; Derkinderen
et al., 2001; Galve-Roperh et al., 2002), inhibition of N-type and P/Q type voltage dependent
Ca+2 channels (Pan et al., 1996; Twitchell et al., 1997) and stimulation of inward rectifying K+
channels (Mackie et al., 1995; Vasquez et al., 2003). CB1Rs can also inhibit Na+ channels
(Nicholson et al., 2003), stimulate phospholipases C and A2 (PLC, PLA2) (Hunter et al., 1986),
activate c-Jun N-terminal kinase (JNK) 1 and 2 (Rueda et al., 2000b), p38 MAPK (Rueda et al.,
2000a), nitric oxide (Prevot et al., 1998) and protein kinase B (also known as thymoma viral
proto-oncogene (AKT) (Gomez et al., 2011). CB1Rs can also activate the factor associated with
neutral sphingomyelinase (FAN), which increases ceramide production in a pertussis toxin
independent manner (Sanchez et al., 2001).
GPCRs can also signal through the recruitment of scaffolding proteins, such as arrestins.
Studies using channel rhodopsin led to the discovery of a 48 kDa protein that bound to
phosphorylated rhodopsin that is now known as arrestin1 or visual arrestin (Wilden et al., 1986).
In 1990, a similar molecule was found to inhibit function of the β2-adrenergic receptor (Lohse et
al., 1990) and was termed β-arrestin1. Soon after, β-arrestin2 was discovered and shown to
interact with the β2-adrenergic receptor (Attramadal et al., 1992). The discovery of the arrestins
was in part due to the isolation and purification of the G-protein receptor kinase 2 (GRK2,
referred to β adrenergic receptor kinase at the time) (Benovic et al., 1987). Arrestins were
initially identified as accessory proteins that promote desensitization (a reduction in G-protein
activation) of GPCRs. However, more recent studies have determined that βarrestins can recruit
c-Src, a nonreceptor tyrosine kinase that activates ERK 1/2, (DeFea et al., 2000; Luttrell et al.,
1999) through a βarrestin2, v-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1), mitogen
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activated protein kinase kinase 1 (MEK1) and ERK1/2 scaffolding complex (Luttrell et al.,
2001). βarrestins can also recruit JNK3 into a scaffolding complex (McDonald et al., 2000) and
activate PI3K through an AKT scaffolding complex (Povsic et al., 2003) that can also recruit
protein phosphatase 2A (PP2A) in the brain (Beaulieu et al., 2005). CB1Rs are desensitized by
mechanisms that involve GRK3 and βarrestin2 (Jin et al., 1999), therefore CB1Rs might also
activate these signaling proteins through βarrestin scaffolding, as shown for the β2-adrenergic
receptor.
Homo- and hetero-dimerization of GPCRs also provides a novel mechanism of GPCR
signaling. Evidence for GPCR dimerization was initially provided by studies showing that
GABAB receptors form obligatory homodimers (Kubo and Tateyama, 2005). Histological
techniques, such as electron microscopy and fluorescence resonance energy transfer (FRET),
showed that the CB1Rs form homodimers and heterodimers with mu, kappa, and delta-opioid
receptors (MOR, KOR, DOR), orexin 1, adenosine type 2A (A2A), β2-adrenergic receptors and
D2Rs (Hudson et al., 2010; Wager-Miller et al., 2002). Electron microscopy studies have
supported dimerization between CB1Rs and MORs in the nucleus accumbens (Pickel et al.,
2004). Likewise, functional studies conducted in striatal cell membrane homogenates showed
that the MOR-selective agonist DAMGO reduced WIN55,212-2 stimulated [35S]GTPγS
activation (Rios et al., 2006). In contrast, a study using transfected Xenopus oocytes showed a
cooperative effect between CB1Rs and MORs (Hojo et al., 2008). Heterodimerization of D2Rs
and CB1Rs has been shown functionally in cell culture and in vitro with striatal cultures (Glass
and Felder, 1997; Jarrahian et al., 2004; Kearn et al., 2005; Marcellino et al., 2008), in which
agonist stimulation of CB1Rs increased AC activity, perhaps through Gαs/olf activation. CB1R
and D2R agonists alone inhibited cAMP production but simultaneous introduction of agonists for
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both receptors led to cAMP accumulation. A similar study showed that A2A receptors colocalized with CB1 Rs in vitro and that A2A receptor antagonist administration in rats abolished
the inhibitory motor effects of WIN55,212-2 (Carriba et al., 2007). Indirect evidence has also
shown that that D2R and A2A receptors promote cannabinoid-mediated increases in AC activity
in the striatum. Administration of CP55,940 in mice with genetic deletion of either D2R or A2A
receptors abolished phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of
Mr32 kDA (DARPP-32) at threonine 34 (Andersson et al., 2005) (Figure 0.5). Phosphorylation
of DARPP-32 at this site was also abolished in A2A knockout mice following THC
administration (Borgkvist et al., 2008). DARPP-32 (Hemmings et al., 1984b; Ouimet et al.,
1984; Walaas et al., 1983; Walaas and Greengard, 1984) is highly expressed in dopaminoceptive
neurons of striatum and is expressed in all neuronal compartments. DARPP-32 is
phosphorylated by protein kinase A (PKA) at threonine 34 and becomes an inhibitor of protein
phosphatase 1 (PP1) (Hemmings et al., 1984a; Huang et al., 1999). Therefore, it is possible that
dimerization of CB1Rs with either D2Rs or A2A receptors increases ACS activity, which
increases PKA activity (Walsh et al., 1968) and leads to phosphorylation of DARPP-32 at
threonine 34.
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Figure 0.5 Regulation of DARPP-32 by both glutamate and dopamine in the striatum. From
(Nishi et al., 2002).
DSI and DSE
CB1Rs are predominantly expressed presynaptically and inhibit neurotransmitter release
(Ishac et al., 1996; Kathmann et al., 1999; Nakazi et al., 2000; Shen et al., 1996; Szabo et al.,
1999). Studies on the subcellular localization of CB1Rs revealed that they are highly expressed
on axon terminals and preterminal segments (Hajos et al., 2000; Katona et al., 2001).
CB1Rs play a role in refining neurotransmission by reducing presynaptic release of
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neurotransmitters through the signaling systems described above. Unlike neurotransmitters,
CB1Rs are produced on demand and inhibit presynaptic neurotransmitter release through
retrograde transmission primarily via release of 2-AG (Marsicano et al., 2003). In the
hippocampus, excitation of CA1 pyramidal neurons leads to an influx of calcium, which
promotes 2-AG synthesis in the neuron and 2-AG is released retrogradely and inhibits GABA
release from nearby interneurons (Kano et al., 2009). This process is referred to as
depolarization-induced depression of inhibition (DSI). Suppression of glutamate release on the
projection neuron can also occur through the same process of retrograde signaling by 2-AG and
is referred to as depolarization-induced depression of excitation (DSE). DSI and DSE were
discovered to be mediated by CB1Rs in both the cerebellum and hippocampus (Kreitzer and
Regehr, 2001; Ohno-Shosaku et al., 2001; Ohno-Shosaku et al., 2012). The necessity of CB1Rs
in producing DSI and DSE is demonstrated by the loss of these processes in mice with genetic
deletion of CB1Rs. 2-AG is also necessary because these processes are lost in mice with genetic
deletion of DAGL (Gao et al., 2010; Uchigashima et al., 2007). The duration of DSI/DSE is also
dependent on the catabolism of 2-AG by DAGL (Hashimotodani et al., 2008) and breakdown of
2-AG by presynaptic MAGL (Hashimotodani et al., 2007).
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Figure 0.6 Schematic representation of CB1R desensitization and downregulation following
repeated cannabinoid administration. When an agonist binds, it causes dissociation of the Gα,
subunit which leads to the phosphorylation of the receptor by GRK. β-arrestins bind to the
phosphorylated receptor, which leads to internalization of the receptor. The receptor is either
recycled back to the membrane or degraded in endosomes, which is mediated by GASP. From
(Smith et al., 2010).
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0.6 Tolerance, Desensitization and Downregulation following repeated THC administration
Tolerance develops to the in vivo effects of THC following repeated administration.
Tolerance is a reduction in the effect of a drug following repeated administration of that drug.
Repeated administration of THC, synthetic cannabinoid agonists and inhibition of 2-AG
degradation in rodents produce tolerance to cannabinoid-mediated antinociception, hypothermia,
catalepsy, and locomotor suppression (Carlini, 1968; Gonzalez et al., 2005; Pertwee et al., 1993;
Schlosburg et al., 2010), and cross-tolerance develops among the different cannabinoid drugs
(Fan et al., 1994). Surprisingly, tolerance does not develop to THC-mediated mouse killing
(Miczek, 1979) and for some of the memory impairing effects of cannabinoids (Barna et al.,
2007; Boucher et al., 2009; Ferraro and Grilly, 1974) but tolerance has been reported for the
delayed match to sample performance test (Deadwyler, 1995). Studies in humans have
demonstrated that tolerance develops to the cardiovascular (Benowitz and Jones, 1975) and
memory/cognitive impairing (D'Souza et al., 2008) effects of cannabinoids whereas little
tolerance develops to the motoric or “subjective high” effects (D'Souza et al., 2008; Haney et al.,
1999a, b). Adaptation to chronic administration of cannabinoids is minimally represented by
pharmacokinetic changes (Dewey et al., 1973; Martin et al., 1976), but relies more on
pharmacodynamic changes, which include CB1R desensitization and downregulation (SimSelley, 2003).
The mechanisms underlying G-protein coupled receptor (GPCR) desensitization and
downregulation were initially determined using heterologously expressed β-adrenergic receptors
(Gainetdinov et al., 2004; Inglese et al., 1993; Lefkowitz, 1998). Desensitization involves the
phosphorylation of specific residues on the C-terminus of the receptor that causes a
conformational change in the receptor (Lefkowitz, 1998). This process can occur through either
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a heterologous or homologous pathway. Heterologous phosphorylation involves promiscuous
protein kinases like PKA and PKC that phosphorylate either the active or inactive state of the
receptor, typically through activation of other receptors (Chu et al., 2010). Homologous
desensitization is more conservative and leads to phosphorylation of only activated receptors.
This latter form of desensitization occurs in response to phosphorylation by G-protein receptor
kinases (GRKs). The recruitment of GRKs to agonist-activated receptors occurs through Gβγ
sequestration of GRKs to receptors (Daaka et al., 1997). Phosphorylation of specific residues on
GPCRs facilitates the binding of arrestin molecules that reduce both G-protein coupling and
initiate the internalization of receptors, and, as discussed previously, can lead to other signaling
events. Specific residues of the CB1R have been associated with receptor adaptions. The cterminus of CB1Rs is important for desensitization and requires mutation of four separate
phosphorylation sites to suppress internalization (Daigle et al., 2008a), and residues between
V459 and V464 are necessary for internalization (Hsieh et al., 1999). S425 and S429 are
required for desensitization, but not endocytosis (Hsieh et al., 1999). L404F mutation can
enhance agonist-induced trafficking (Anavi-Goffer et al., 2007). Truncation of the receptor at
residue 417 attenuates desensitization (Jin et al., 1999). Mutation of CB1R residues 425 and 429
does not alter β-arrestin recruitment or internalization, but attenuate ERK 1/2 phosphorylation
(Daigle et al., 2008b) and GIRK channel activation (Jin et al., 1999). Class A GPCRs
preferentially bind to β-arrestin 2 (Oakley et al., 2000); however, CB1Rs can also interact with βarrestin1 (Bakshi et al., 2007). In the brain, the major β-arrestin isoforms are β-arrestin1 and βarrestin2, each of which is uniquely distributed in the CNS (Gurevich et al., 2002) (Figure 0.6).
CB1R adaptation in response to repeated cannabinoid treatment has been investigated
using both cell and animal models. There are seven known mammalian GRK isotypes whose
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expression differs by brain region in the CNS. GRK2 and GRK3 are the most highly expressed
in the CNS, although GRK4 is also expressed (Arriza et al., 1992). The role of GRK and βarrestin in mediating CB1R desensitization has been demonstrated in the Xenopus oocyte
expression system (Jin et al., 1999). Repeated THC administration changes the expression of
both GRKs and β-arrestins in a region-dependent manner (Rubino et al., 2006). However, it is
unclear how these regional differences affect desensitization. The rate of internalization
correlates with the relative efficacy of cannabinoid agonists to activate G-proteins. Lower
efficacy agonists, like THC, produce a greater magnitude of internalization/desensitization (Wu
et al., 2008). CB1Rs are internalized through clathrin-coated pits into early endosomes (Hsieh et
al., 1999). At the molecular level, repeated cannabinoid exposure results in the functional
uncoupling of CB1Rs from G-proteins (desensitization) (Sim et al., 1996) and agonist-promoted
internalization (Jin et al., 1999); followed by either receptor degradation in lysosomes
(downregulation) or recycling to the cell membrane (resensitization) (Tappe-Theodor et al.,
2007). Downregulation involves targeting of CB1 Rs for degradation, which appears to require
G-protein-associated sorting protein 1 (GASP1), a protein that has been shown to interact with
CB1Rs and was required for agonist-induced downregulation of CB1Rs in spinal neurons (TappeTheodor et al., 2007). Genetic deletion of GASP1 abolishes CB1R downregulation in the spinal
cord and cerebellum of repeated WIN55,212-2-treated mice that is accompanied by a reduction
in tolerance to cannabinoid-mediated antinociception, motor incoordination, and locomotor
suppression (Martini et al., 2010; Tappe-Theodor et al., 2007).
Studies in rodents have determined that the development of desensitization and
downregulation of CB1Rs following repeated THC administration depends on both the dose and
length of cannabinoid administration, while acute doses of CB1R agonists do not produce
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significant desensitization and downregulation in vivo ((Sim-Selley, 2003), Table 0.1). There are
also brain regional differences in the development of desensitization and downregulation when
cannabinoid dose and treatment time are constant ((Sim-Selley, 2003), Table 0.1). Specifically,
regions of the basal ganglia (caudate-putamen, nucleus accumbens, globus pallidus and
substantia nigra) show lower magnitude of desensitization and downregulation compared to
areas like the hippocampus and periaqueductal gray (Sim-Selley, 2003), Table 0.1).
Functionally, cannabinoid-mediated catalepsy and locomotor suppression, behaviors associated
with the basal ganglia, exhibit less tolerance when compared to responses such as hypothermia
(medial preoptic area) and antinociception (periaqueductal gray and spinal cord) (Bass and
Martin, 2000; Whitlow et al., 2003). Both post-mortem studies and studies in live subjects using
positron emission topography (PET) have found region-dependent differences in CB1R levels in
brains from marijuana users compared to non-users (Hirvonen et al., 2012; Villares, 2007).
These findings correspond to studies showing that more tolerance develops to the memory
impairing effects of THC, which is associated with hippocampal function compared to the
motoric or “subjective high” effects of THC, which is associated with basal ganglia function
(D'Souza et al., 2008). PET studies also showed differences in recovery of CB1Rs after cessation
of marijuana treatment (Hirvonen et al., 2012), which agreed with previous studies in rodents
(Sim-Selley et al., 2006). In both studies, basal ganglia regions recovered faster than areas like
the hippocampus.
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TABLE 0.1 Summary of studies that have examined the effect of chronic cannabinoid
treatment on several parameters of CB1R function. Data from time course studies is not
included because results vary based on duration of treatment. Adapted from (Sim-Selley,
2003)
Treatment
THC (10 mg/kg)
2X/day for 6.5 days
Mice
THC (10 mg/kg)
2 weeks, rat
CP (1,3,10 mg/kg)
2 weeks rat
THC (6.4 mg/kg)
7 days, rat
CP (0.4 mg/kg)
11 days, rat
THC (10 mg/kg)
11 days rat

Tolerance
SA

Receptor Binding
No change whole
brain

Open field

Dec: CPu

Open field

Dec. str

SA

Dec str

SA,
analgesia

Anandamide
(3mg/kg)
5 days, rat
CP (2 mg/kg)
2X/day for 6.5 days

Inc cblm, hip
No chg str
Hypomot
Hypotherm
immobil

Dec cblm

Inc cblm

No chg in
CBinhibited in
cblm
Dec Cpu, GP,
ctx, hip, cblm

SA

THC (10 mg/kg)
5 days, rat

CP (0.4 mg/kg)
2X/day for 6.5.days
rat
THC (10-160
mg/kg)
15 days, mice

cAMP/PKA

Dec Cpu
No chg others
Dec str
Inc hip, cblm

R-methanandamide
(10 mg/kg)
5 days, rats
Anandamide (20
mg/kg)
15 days, rat
THC (15 mg/kg)
2X/day for 15 days,
rat

[35S]GTPγS

Dec Cpu
No chg others

THC (3 mg/kg)
5 days, rat

THC (10 mg/kg)
21 days, rat
THC (10 mg/kg)
5 days, rat

CB1 mRNA
No change whole
brain

Dec Cpu ctx, hip,
cblm
No chg GP
Dec cblm, CPu, ctx
No chg GP

Inc str
No chg hip, cblm

Dec lCPu, cblm
No chg hip, ctx, GP
tetrad

No chg str, hip, ctx,
cblm

analgesia

Dec str, hip, ctx,
cblm
Dec str, ctx, hip, GP,
cblm

SA,
hypotherm
SA,

Dec Cpu, GP, ctx,
hip, cblm
Dec Cpu, GP, ctx,
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Dec CPu
No chg cblm,
ctx, GP
Dec CPu, hip
No chg hip, ctx

No chg Cpu,
GP
No chg lCPu,
ctx, hip
Dec str, ctx,
hip, cblm

Dec str, ctx,
hip
No chg cblm
Dec Cpu, GP,
ctx, hip, cblm
Dec Cpu, GP,

No chg str,
ctx, cblm
Basal
cAMP/PKA
Inc cblm,
str, ctx
No chg str,
ctx, hip,
cblm

WIN (3-48 mg/kg)
15 days, mice

hypotherm

hip, cblm

ctx, hip, cblm

0.7 Signaling pathways known to modulate CB1R desensitization and downregulation
The signaling mechanisms that underlie these brain-region dependent differences in
desensitization and downregulation are not known, but studies have suggested a role for ERK
and β-arrestin2. The role that ERK activation might play in CB1R adaptation following repeated
THC administration was further studied by Rubino et al. (2005). ERK activity was not increased
following acute THC treatment in mice treated with SL327 (a MEK inhibitor) or Ras-GRF1
knockout mice (Rubino et al., 2005). Furthermore, tolerance to THC-mediated locomotor
suppression was prevented in these mice after treatment with 10 mg/kg THC b.i.d for 4.5 days.
In agreement with these findings, autoradiographic studies using [ 3H]CP55,940 binding
determined that CB1Rs were not significantly decreased in the caudate-putamen or cerebellum,
but were decreased in the hippocampus of mice that received SL327 treatment and in Ras-GRF1
knockout mice. Interestingly, Ras-GRF1 knockout mice had reduced CB1R binding in the
prefrontal cortex compared to wild type controls. This result was not seen with SL327 treated
mice, suggesting that the loss of Ras-GRF1 affected CB1R levels through a different mechanism
than MEK inhibition alone. CP55,940-stimulated [35S]GTPγS binding was not reduced in the
caudate-putamen or hippocampus following repeated THC administration in Ras-GRF1 mice
compared to controls, which agrees with the in vivo data. CP55,940-stimulated [35S]GTPγS
binding was reduced in Ras-GRF1 knockout compared to wild type mice in the prefrontal cortex
and cerebellum. Inhibition of MEK using SL327 prevented CB1R desensitization in the
prefrontal cortex, caudate-putamen and cerebellum, but not in the hippocampus. Overall, these
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data suggest that ERK plays a role in modulated CB1R adaptations in a brain region-dependent
way.
Our laboratory has reported that β-arrestin2 contributes to brain-region dependent
differences in CB1R desensitization and downregulation and in the development of tolerance to
THC-mediated in vivo effects by using β-arrestin2 knockout mice (Nguyen et al., 2012).
Vehicle-treated β-arrestin2 knockout mice had enhanced THC-mediated antinociception and
hypothermia and increased [35S]GTPγS binding in the piriform cortex, auditory and visual
cortices and caudal hippocampus. After receiving twice-daily injections of 10 mg/kg THC for
6.5 days, β-arrestin2 knockout mice exhibited significantly greater tolerance to THC-mediated
catalepsy and attenuated tolerance to antinociception. At the receptor level, β-arrestin2 knockout
mice exhibited greater desensitization in the piriform cortex, auditory and visual cortex,
somatosensory cortex, globus pallidus, hypothalamus and substantia nigra and attenuated
desensitization and downregulation in the cerebellum, caudal periaqueductal gray and spinal cord
(Nguyen et al., 2012). These results suggest that although ERK and β-arrestin2 might contribute
to brain region-dependent differences in CB1R adaptations, other factors must be involved.

0.8 Induction of transcription factors by cannabinoids
Transcription factors might also contribute to regional differences in CB1R adaptions.
Similar to the development of desensitization and downregulation, regional difference exist in
the CNS regarding the induction of transcription factors by cannabinoid agonists. The regulation
of gene expression by CB1 Rs is likely to begin with the activation of immediate early genes
(IEGs), which are transcription factors that regulate the expression of downstream target genes.
Immediate early genes can be constitutively expressed or induced by stimuli. For cannabinoids,
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zif268 (or krox24), cAMP response element binding protein (CREB) and the Fos and Jun
families of IEGS have been investigated most extensively. CREB is constitutively expressed and
its binding to DNA is regulated by phosphorylation by upstream kinases. Inducible IEGs include
zif268, the Fos (c-Fos, FosB, Fos-related antigen 1 (Fra-1), Fra-2 and ΔFosB) and Jun (c-Jun,
JunB and JunD) families of transcription factors, which form AP-1 complexes that bind to AP-1
consensus sites on target genes. Inducible transcription factors are basally expressed in the brain
and exhibit species-specific regional differences in basal expression (Herdegen and Leah, 1998).
Transcriptional repressors also exist, such as cAMP response-element modulator (CREM), which
reduces CREB transcription, and Fos-related antigen 1 (Fra1), which reduces the transcriptional
ability of AP-1 complexes (Foulkes and Sassone-Corsi, 1992; Yoshioka et al., 1995). IEGs can
also induce or repress the expression of other IEGs. For example, CREB can induce c-fos
mRNA (Sheng et al., 1991), whereas ΔFosB, a truncated splice variant of FosB, can repress c-fos
mRNA expression through epigenetic regulation by recruitment of histone deacetylase 1
(HDAC1) (Renthal et al., 2008). Co-regulation adds to the complexity of understanding
interactions among IEGs and provides multiple points for interactions between these signaling
pathways. Interpretation of results with cannabinoids is further complicated by differences in the
particular drugs and doses administered, temporal paradigm and species examined. The role of
specific IEGs in directly modulating the CB1R gene, CNR1, has not been fully characterized, but
a recent study in a mouse model of Huntington’s disease suggests that the repressor element 1
silence transcription factor (REST) can regulate transcription of CB1Rs (Blazquez et al., 2011).
Although there are numerous transcription factors found in mammalian cells, the majority
of research has focused on the induction of zif268 (also known as Krox-24), CREB the Fos
family of transcription factors (c-Fos, Fosb, ΔFosB, Fra-1 and Fra-2) and the Jun family of
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transcription factors (c-Jun, JunB and junD) (Lazenka et al., 2013). Mailleux et al. (1994) first
reported that zif268 mRNA increased in the cingulate cortex, fronto-parietal cortex and caudateputamen of rats 20 minutes after acute THC (5 mg/kg) injection. Separate studies in the caudateputamen showed that zif268-immunoreactive (-ir) cells were restricted to striosomes when
assessed 2 hours after injection of CP55,940 (2.5 mg/kg) (Glass and Dragunow, 1995). Studies
in the hippocampus showed that acute THC (1 mg/kg) increased zif268 mRNA in CA1 and CA3,
but not dentate gyrus, in CD1 mice (Derkinderen et al., 2003). Zif268 is increased in the
hippocampus of C57Bl/6J mice during learning tasks such as the Morris Water Maze task, but
repeated administration of THC (1 mg/kg, 11 days) was shown to reduce zif268 in the
hippocampus, suggesting zif268 could contribute to the memory impairing effects of THC
(Boucher et al., 2009). This group also found a decrease in zif268 in caudate-putamen of these
mice. The effects of THC have also been tested in zif268 knockout mice, but no genotypespecific differences were found for cannabinoid-induced analgesia or spontaneous withdrawal
(Tzavara et al., 2001).
CREB has been proposed to be an important mediator of the effects of drugs of abuse
(Nestler, 2004). Initial studies showed no changes in CREB bound to DNA in the caudateputamen or cerebellum of rats that received THC (5-40 mg/kg b.i.d) for 5 days with brain
collection 21 days after the last injection (Rubino et al., 2003). Subsequent studies using acute
THC (15 mg/kg) administration found increased pCREB levels in the caudate-putamen,
hippocampus and cerebellum, but not prefrontal cortex, of rats when measured 30 minutes
following injection (Rubino et al., 2004). A different regional pattern emerged following
repeated THC administration (15 mg/kg, b.i.d., 6.5 days), whereby pCREB was only increased in
the prefrontal cortex of THC-treated rats. This finding could indicate that tolerance developed to
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THC-induced activation of CREB in the other regions. A separate study examined CREB in the
granule cell layer of the rat cerebellum. Results showed an increase in pCREB-ir cells in the
granule cell layer following acute administration of 5 or 10 mg/kg THC, whereas repeated THC
(10 mg/kg q.d., 4 weeks) administration produced a decrease in pCREB-ir that persisted for 3
weeks (Casu et al., 2005). This finding highlights the temporal nature of CREB activation, and
suggests that alterations in CREB activity can persist after cessation of drug treatment.
Measurement of CREB in the hippocampus following repeated THC administration has provided
varying results. In one study, CREB and pCREB were decreased in the hippocampus in C57BL6
mice administered THC (10 mg/kg q.d.) for 7 days with levels assessed 24 hours after the last
administration (Fan et al., 2010). Another group reported that repeated THC (10 mg/kg, b.i.d.)
administration in rats for 4.5 days increased pCREB when tested 30 minutes after the final
administration (Rubino et al., 2006). Differences in results could reflect methodological
differences between the studies, most notably the survival time following final THC injection.
Fos (c-Fos, FosB, fos-related antigen 1 (Fra-1), Fra-2 and ΔFosB) and Jun (c-Jun, JunB
and junD) families of transcription factors form AP-1 complexes that bind to AP-1 consensus
sites on target genes. Mailleux et al. (1994) showed that c-Fos-ir and c-Jun-ir cells increased in
the cingulate cortex when measured 20 minutes after THC (5 mg/kg) injection, whereas only cFos-ir cells increased in the fronto-parietal cortex and caudate-putamen. Subsequent studies
showed an increase in c-Fos-ir cells in the caudate-putamen and nucleus accumbens of rats when
measured 2 hours after THC injection (10 mg/kg) (Miyamoto et al., 1996). In this same study,
pretreatment with a dopamine D1 receptor (D1R) antagonist (SCH-23390, 0.32 mg/kg), but not a
D2 receptor (D2R) antagonist ((-)-sulpiride,100 mg/kg, i.p.), significantly attenuated c-Fos
induction in these regions, suggesting that c-Fos induction was due to CB1R-mediated dopamine
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release and not through direct CB1R signaling. The same group measured c-Fos-ir following
repeated THC administration (10 mg/kg, q.d., 4 days) at 2 hours after final injection and
compared the results to acute induction (Miyamoto et al., 1997). Repeated THC administration
induced fewer c-Fos-ir cells as compared to acute administration, suggesting the development of
tolerance. A similar study also suggested that tolerance developed to the induction of c-Fos in
the prefrontal cortex and cerebellum following repeated, but not acute, THC (15 mg/kg)
administration (Rubino et al., 2004).
Fewer studies have assessed FosB and its truncated isoforms (ΔFosB, Fra-1 and Fra-2)
following cannabinoid treatment. Fos antigens are generally induced rapidly and transiently
after acute drug administration (e.g. c-Fos). However, ∆FosB, a C-terminally truncated splice
variant of FosB, is stable and accumulates with repeated induction over time (e.g. during
repeated drug treatment), and can be detected in neurons for several weeks after cessation of
drug treatment (Chen et al., 1997; Perrotti et al., 2005; Ulery et al., 2006). ΔFosB could
therefore be important in regulating the long-term effects of repeated cannabinoid administration.
THC administration increased Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) and AP-1
DNA binding in the nucleus accumbens when measured one hour following administration of 10
or 15, but not 5, mg/kg of THC in rats (Porcella et al., 1998). AP-1 binding in the cingulate
cortex and caudate-putamen was increased only after the highest dose of THC. In the cingulate
cortex, this occurred in conjunction with increased c-Fos FosB, Fra-1 and Fra-2, whereas in the
caudate-putamen, only c-Fos and FosB were significantly induced. ΔFosB was not significantly
induced in any region examined, which is consistent with its low level of induction after a single
drug injection. Induction of c-Fos, FosB, Fra-1 and Fra-2 was CB1R-mediated because it was
blocked by pretreatment with the antagonist SR141716A (Rimonabant) (Porcella et al., 1998).
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Regional assessment of FosB following acute and repeated THC administration showed
increased FosB in prefrontal cortex and hippocampus only after repeated THC administration
(Rubino et al., 2004). The regional induction of ∆FosB following repeated THC administration
has only been recently tested. Repeated THC administration significantly increased the number
of FosB/ΔFosB-ir cells in the nucleus accumbens core with trends toward increases in the
nucleus accumbens shell and caudate-putamen (Perrotti et al., 2008).
TABLE 0.2 Summary of brain region-dependent changes in immediate early gene (IEG)
expression following acute or repeated THC administration. Adapted from (Lazenka et al.,
2013)
Treatment
Transcription factor (time after last
injection)

Increase in brain region

Decrease in brain region

Measure

Zif268
Acute

5 mg/kg THC
(20 min)

Cingulate cortex, fronto-parietal
and caudate-putamen

mRNA
immunohistochemistry

Acute

2.5 mg/kg
CP55,940 (2 h)

Striosome of caudate-putamen

mRNA
immunohistochemistry

Acute

1 mg/ml THC
(60 min)

Hippocampus
CA1 and CA3

mRNA
immunohistochemistry

Repeated
CREB
Acute

1 mg/kg THC
Prefrontal cortex, caudateProtein
immunohistochemistry
q.d. for 11 days
putamen and CA3
(90 min after
(compared to vehicle
pCREB protein bound to
15 mg/kg
last
probe THC
trial) Caudate-putamen, hippocampus
controls)
DNA
(30 min)
and cerebellum
ELISA

Acute

5 or 10 mg/kg
THC (90 min)

Cerebellum

pCREB protein
immunohistochemistry

Acute

1 μg, 5 μg or
10 μg THC
microinjection
(immediately
after elevated
plus maze)

Prefrontal cortex (10 μg) and
ventral hippocampus (5 μg)
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Basolateral amygdala
(1 μg)

(pCREB) immunoblot

Repeated

15 mg/kg THC
b.i.d. for
6.5 days
(30 min)

Repeated

10 mg/kg THC
q.d. for 4 weeks
(24 h or
3 weeks)

Repeated

10 mg/kg THC
4.5 days
(30 min)

Repeated
c-Fos

pCREB protein bound to
DNA
ELISA

Prefrontal cortex

Cerebellum

Hippocampus

pCREB protein
immunohistochemistry

pCREB bound to DNA

Hippocampus

10 mg/kg THC
7 days (24 h)

pCREB and total CREB
protein immunoblot

Acute

5 mg/kg THC
(20 min)

Cingulate cortex, fronto-parietal
and caudate-putamen

mRNA
immunohistochemistry

Acute

10 mg/kg THC
(2 h)

Caudate-putamen and nucleus
accumbens

Protein
immunohistochemistry

Acute

Acute

25 mg/kg THC
(1 h)

Lateral septum, paraventricular
nucleus, caudate-putamen,
nucleus accumbens
and
Prefrontal
cortex, nucleus
5 mg/kg THC
mediodorsal
thalamus
accumbens, caudate-putamen and
(1 h)
hippocampus

Prefrontal cortex and
cerebellum

mRNA
immunohistochemistry
mRNA
RT-PCR

15 mg/kg THC
b.i.d. for
Prefrontal cortex and cerebellum
6.5 days
(30 min)

c-Fos protein bound to
DNA
ELISA

Acute

10 mg/kg and
15 mg/kg THC
(1 h)

Nucleus accumbens

FosB, Fra-1 and Fra-2
protein immunoblot

Acute

15 mg/kg THC
(1 h)

Caudate-putamen

FosB protein immunoblot

Acute

15 mg/kg THC
(1 h)

Cingulate cortex

FosB, Fra-1 and Fra-2
protein immunoblot

Prefrontal cortex and
hippocampus

FosB protein bound to
DNA
ELISA

Repeated

FosB

Repeated

15 mg/kg THC
b.i.d. for
6.5 days
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(30 min)
ΔFosB

Repeated

10–150 mg/kg
q.d. for
14.5 days
(24 h)

Repeated

10 mg/kg q.d.
Prefrontal cortex, caudatefor 13.5 days putamen, nucleus accumbens and
(24 h)
cerebellum

Protein
immunohistochemistry

Nucleus accumbens core

Protein immunoblot

Figure 0.7. Representative figure of the FosB/ΔFosB mRNA transcript. ΔFosB is an isoform of
FosB and the splicing out of region IVb reduces protesomal degradation of ΔFosB. Adapted
from (Alibhai et al., 2007).
0.9 Transcriptional regulation by ΔFosB
ΔFosB is a member of the Fos family of transcription factors and is a truncated form of
FosB (Figure 0.7). Early research into ΔFosB transcriptional regulation determined that it
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repressed AP-1 activation when transiently transfected with various Fos and Jun family members
(Nakabeppu and Nathans, 1991); however, another study determined that ΔFosB could
activate transcription of an AP-1 reporter in a stably transfected cell line (Dobrazanski et al.,
1991). In order to understand the overall pattern of ΔFosB-regulated gene expression in vivo,
microarray studies were performed (McClung and Nestler, 2003). Gene expression changes in
the nucleus accumbens were characterized following ΔFosB induction following repeated
cocaine administration. These changes were compared to changes produced by overexpression
of ΔFosB using bitransgenic mice and overexpression of ΔcJun, a dominant negative inhibitor of
ΔFosB transcriptional regulation, in bitransgenic mice. These studies determined that initial
overexpression/induction of ΔFosB produced similar effects as ΔcJun, meaning ΔFosB acted
primarily as an AP-1 repressor. However, long-term overexpression/induction of ΔFosB had
mostly opposing effects compared to ΔcJun, meaning ΔFosB acted as an AP-1 activator. At the
behavioral level, differences also exist following short-term and long-term ΔFosB induction.
Short term-ΔFosB induction and ΔcJun both reduce preference for cocaine, while long-term
induction of ΔFosB increases preference for cocaine (McClung and Nestler, 2003).
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Figure 0.8 ΔFosB, due to its stability, accumulates following repeated drug administration.
Adapted from (Nestler et al., 2001).

0.10 Genes targeted by ΔFosB
Unlike FosB, ΔFosB is minimally induced with acute drug administration but
accumulates in cells due to its stability (Figure 0.8). ΔFosB regulates the N-methyl-D-aspartate
(GluR2), as has been shown in the cerebral cortex following electroconvulsive seizures (Hiroi et
al., 1998). The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA)
glutamate receptor subunit 2 is also a ΔFosB target gene (Kelz et al., 1999). Overexpression of
ΔFosB in bitransgenic mice increases GluR2 expression by over 50% in the nucleus accumbens,
but no effect is seen on any other AMPA receptor subunit (Kelz et al., 1999). GluR2 is also upregulated by cocaine, an effect ablated by overexpression of ΔcJun (Peakman et al., 2003) while
ΔFosB binds the AP-1 consensus sequence at the GluR2 promoter region. Cyclin-dependent
kinase 5 (CDK5) and its activating cofactor, p35, were identified as a ΔFosB target gene in the
hippocampus and striatum by use of DNA microarrays (Bibb et al., 2001a; Chen et al., 2000b).
CDK5 mRNA, protein, and activity are up-regulated in response to ΔFosB overexpression or
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chronic cocaine treatment (Bibb et al., 2001a; Chen et al., 2000a) and this effect is blocked by
overexpression of ΔcJun (Peakman et al., 2003). In addition, chromatin immunoprecipitation
assays demonstrated that ΔFosB is selectively associated with the CDK5 promoter following
chronic, but not acute, cocaine administration (Kumar et al., 2005). CDK5 is involved in the
regulation of cocaine-induced changes in dendritic spine density (Norrholm et al., 2003). CDK5
also increases the phosphorylation of DARPP-32 at threonine 75, which inhibits PKA activity
(Bibb et al., 1999). Dynorphin appears to be another target for ΔFosB (Andersson et al., 2003),
and is an example of a gene repressed by the transcription factor (Zachariou et al., 2006a).
Finally, ΔFosB can recruit histone deacetylases (HDAC) to gene promoters, perhaps regulating
gene expression through epigenetic mechanisms (Renthal et al., 2008). ΔFosB is known to
repress cFos expression following repeated amphetamine administration through recruitment of
HDAC1, which deacetylates histones at the promoter site, causes DNA to condense, and
represses transcription.
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Rationale and Hypothesis
CB1Rs belong to the superfamily of GPCRs and are one of the most abundantly
expressed GPCRs in the mammalian central nervous system. These receptors mediate the
psychoactive and therapeutic effects of THC, the main psychoactive constituent of marijuana.
Repeated administration of THC is known to produce brain region-dependent differences in
CB1R desensitization and downregulation and induction of transcription factors, suggesting a
role for transcription factors in modulating these CB1R adaptations. One transcription factor,
ΔFosB, is induced primarily in striatal regions following repeated THC administration, and these
regions are also known to be more resistant to CB1R adaptations. As an overall hypothesis for
this thesis, studies were performed to determine if THC-mediated induction of ΔFosB is
regulated through interactions between cannabinoid and dopamine systems and that brain regiondependent differences in ΔFosB transcriptional regulation could explain some aspects of longterm CB1R signaling and CB1R adaptations.
In Chapter 1, studies were performed to determine the brain regional relationship
between the THC-mediated induction of ΔFosB and CB1R desensitization and downregulation. I
hypothesize that regions with induction of ΔFosB will have less CB1R desensitization than
regions where ΔFosB is not induced. Further, I predict that CB1Rs are expressed in those cells
where ΔFosB is induced, and that THC-mediated induction of ΔFosB is CB1R-dependent. If
ΔFosB regulates CB1R signaling, then it would require that ΔFosB and CB1Rs are co-expressed.
Chapter 2 addresses the overall hypothesis by determining if ΔFosB can modulate CB1R
desensitization. To test this, bitransgenic mice with overexpression of ΔFosB or ΔcJun (a
dominant negative inhibitor of ΔFosB transcription) in specific neuronal populations will be used
to determine the effect of overexpression of these transcription factors on CB1R desensitization.
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This approach allowed direct testing of whether expression of ΔFosB would affect CB1R
adaptation in distinct brain regions. ΔFosB is overexpressed in the D1R/dynorphin MSN
population of the caudate-putamen and nucleus accumbens, as well as in the hippocampus and
parietal cortex. ΔcJun is overexpressed in both the D1R/dynorphin and D2R/enkephalin MSN
population, as well as in the hippocampus and parietal cortex. The specific overexpression of
ΔFosB in the D1R/dynorphin MSN population is functionally relevant since several drugs of
abuse specifically induce ΔFosB in this neuronal population. THC-medited in vivo effects were
also tested in these mice to determine if any ∆FosB-mediated changes in CB1R desensitization
were associated with altered tolerance following repeated THC administration. To address this
possibility, tolerance to THC-mediated antinociception, hypothermia, locomotor suppression and
catalepsy was assessed. It is hypothesized that ΔFosB overexpression will reduce CB1R
desensitization in the caudate-putamen, substantia nigra and nucleus accumbens, but have no
effect in the hippocampus. Overexpression of ΔcJun is predicted to enhance desensitization in
the caudate-putamen, nucleus accumbens, globus pallidus and substantia nigra by blocking
∆FosB-mediated transcription, but have no effect in the hippocampus. Further, less tolerance is
expected to develop to the locomotor suppressing effects of THC in mice overexpressing ΔFosB
while enhancing tolerance is expected in the ΔcJun overexpressing mice, because these brain
contribute to THC-mediated locomotor suppression.
CB1Rs are found primarily on axon terminals, suggesting that THC-mediated ΔFosB
induction could be mediated indirectly by trans-synaptic events involving other receptors as
opposed to directly by CB1Rs in a cell autonomous manner. It is hypothesized that CB1Rmediated ΔFosB induction can be indirectly mediated by CB1R-mediated release of dopamine
and the activation of D1Rs. Other studies with drugs of abuse that produce dopamine release in
43

striatal regions have found that antagonism of D1Rs can abolish the induction of ΔFosB in these
regions. In chapter 3, this question was addressed pharmacologically by administering D1R
antagonists (SCH23390 and SCH39166) to determine if antagonism of D1Rs blocks THCmediated induction of ΔFosB. If THC-mediated induction of ΔFosB is dependent on D1Rs, it is
hypothesized that ΔFosB will be specifically induced in D1R/dynorphin MSNs. To address this
possibility, dual staining studies were conducted using antibodies directed against dynorphin and
FosB/ΔFosB. This question is important since cocaine and natural rewards are known to
increase ΔFosB expression specifically in this neuronal population. Activation of D1Rs is known
to alter the activity of DARPP-32 via phosphorylation at threonine-34 and genetic deletion of
both DARPP-32 and mutation of the threonine-34 site attenuates cocaine-mediated induction of
ΔFosB in striatal regions. Therefore, it is hypothesized that genetic deletion of DARPP-32 will
attenuate THC-mediated induction of ΔFosB. If striatal ΔFosB induction is attenuated in
DARPP-32 knockout mice, it is hypothesized that greater tolerance will develop to THCmediated locomotor suppression, as predicted after inhibition of ΔFosB.
Finally, if ΔFosB regulates CB1R desensitization, it is likely occurring through regulation
of transcription and changes in the expression of known targets. It is hypothesized that
expression of CDK5 and p35, two known transcriptional targets of ΔFosB, will be increased in
regions where ΔFosB is induced following repeated THC administration. I also predict that
repeated THC administration will increase the phosphorylation state of DARPP-32 at threonine
75 since CDK5, when dimerized with p35, phosphorylates DARPP-32 at this site.
Understanding the signaling mechanisms that underlie CB1R adaptation will provide insights
into the development of possible therapeutic targets that can then selectively enhance or reduce
CB1R adaptation.
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Figure 0.9 Hypothesized mechanism of THC-mediated ΔFosB induction in striatum. THC
promotes release of dopamine through inhibition of GABA release from GABAergic MSN
terminals. Dopamine activates D1Rs on D1R/dynorphin MSNs, which activates AC, increases
cAMP and subsequently activates PKA. PKA then phosphorylates DARPP-32 at threonine 34,
which indirectly increases phosphorylation of ERK through increased phosphorylation of
striatal-enriched protein tyrosine phosphatase (STEP, not shown), which inactivates ERK. PKA
and ERK (through ETS domain-containing protein 1, ELK-1) phosphorylate CREB, which
regulates expression of ΔFosB when dimerized with serum response factor (SRF). ΔFosB can
increase CDK5 and p35/p25 expression, which would feed back on the DARPP-32 pathway,
providing one mechanism through which ΔFosB could regulate CB1R desensitization. CB1Rs
could also increase ERK phosphorylation through the recruitment of βarrestin.
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Chapter 1: ΔFosB induction correlates inversely with CB 1 receptor desensitization in a
brain region- dependent manner following repeated Δ9-THC administration
1.1 Introduction
Marijuana is the most widely used illicit drug in the United States and its repeated use
leads to the development of both tolerance and withdrawal symptoms, which are included in the
DSM-IV criteria for cannabis use disorder (American Psychiatric Association, 2000; SAMHSA,
2010). THC is the main psychoactive constituent of marijuana and produces its behavioral
effects via CB1Rs, which are G-protein-coupled receptors that are widely distributed in the brain
(Howlett et al., 2002). Cannabinoid-mediated effects in rodents include antinociception,
hypothermia, catalepsy, hypolocomotion and memory impairment (Howlett et al., 2002; Varvel
and Lichtman, 2002). Repeated THC administration produces tolerance to these effects and
withdrawal occurs upon cessation of treatment or antagonist administration (Lichtman and
Martin, 2005). Studies have revealed alterations in CB1R signaling following repeated
cannabinoid treatment, but the relationship between these molecular adaptations and tolerance
and dependence are not well understood. Repeated THC administration decreases both CB1R
levels (downregulation) and CB1R-mediated G-protein and effector activity (desensitization) in
rodent brain (Sim-Selley, 2003). Several studies have demonstrated that there are differences
among brain regions in the magnitude and temporal properties of CB1R desensitization and
downregulation. Specifically, CB1R desensitization and downregulation occur at lower agonist
doses and develop more rapidly in the hippocampus than in the striatum (caudate-putamen and
nucleus accumbens) (Breivogel et al., 1999; McKinney et al., 2008). These findings appear to
translate to human cannabis users. CB1R levels were lower in the brains of marijuana users
compared to non-users, and the magnitude of apparent downregulation exhibited a similar
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regional pattern as seen in rodents (Villares, 2007). Region-specific reductions in CB1R binding
have also been reported using in vivo imaging in subjects that were marijuana users (Hirvonen et
al., 2012). The recovery of CB1R levels and activity after cessation of cannabinoid treatment
was slower in the hippocampus than striatum in rodents (Sim-Selley et al., 2006). Similarly,
reduced CB1R binding in human brain persisted in the hippocampus after ~4 weeks of abstinence
from marijuana, whereas binding in other regions appeared similar to pre-drug levels at this time
point (Hirvonen et al., 2012). These observations are important because the hippocampus is
associated with cognitive and memory impairing effects of cannabinoids, whereas the striatum
mediates motivational and motor effects of these drugs(Breivogel and Sim-Selley, 2009). In
fact, studies in human marijuana users suggest that greater tolerance develops to memory
impairment compared to motor or subjective measures such as “high” (D'Souza et al., 2008;
Haney et al., 2004; Ramaekers et al., 2009)
The mechanisms underlying regional differences in CB1R adaptations are not known, but
differences in the expression of signaling and regulatory proteins among brain regions, and
changes in their expression following repeated THC administration, could contribute to these
findings. ΔFosB, a truncated splice variant of the transcription factor FosB, is modestly induced
following a single drug injection, but accumulates upon repeated drug administration and is
stable for weeks after cessation of treatment (Chen et al., 1997). Treatment with several drugs of
abuse, including opiates and cocaine, induces ∆FosB in the striatum (Nestler et al., 2001). We
showed that THC significantly increased the number of FosB/∆FosB-immunoreactive (-ir) cells
in the nucleus accumbens core (Perrotti et al., 2008). Semi-quantitative analysis also showed
that THC-induced FosB/∆FosB-ir cells in other forebrain regions, but protein levels could not be
quantified with this technique.
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Bitransgenic mice that overexpress ΔFosB in dopamine D1R/dynorphin containing
striatal MSNs exhibit increased rewarding effects of several drugs of abuse and natural rewards
(Nestler, 2008). These same mice also had increased G-protein signaling and AC inhibition for
mu- and kappa-opioid receptors, respectively, in the nucleus accumbens, suggesting that ΔFosB
modulates signaling at the receptor/effector level (Sim-Selley et al., 2011). The striatum and its
projection regions appear resistant to CB1R desensitization and downregulation (Sim-Selley,
2003) and the striatum is involved in the rewarding effects of drugs of abuse (Koob, 1999; Koob
and Volkow, 2010). Taken together, these findings suggest that ΔFosB might modulate CB1Rs
after repeated drug administration, but the regional expression pattern of ΔFosB and CB1R
desensitization and downregulation has not been directly compared in brains from animals that
received the same THC administration paradigm. Therefore, this study investigated the brain
regional relationship between ΔFosB induction and CB1R desensitization and downregulation
after repeated THC treatment. Studies were also conducted to determine the neuroanatomical
relationship between CB1Rs and ∆FosB positive cells in the striatum. Finally, the role of CB1Rs
in THC-mediated ∆FosB induction was assessed in CB1R knockout mice. Results showed an
inverse regional relationship between CB1R desensitization and ∆FosB induction and
neuroanatomical results support the possibility of both cell-autonomous and trans-synaptic
interactions.
1.2 Materials and Methods
Materials
THC and [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3hydroxypropyl)cyclohexanol] (CP55,940) were provided by the Drug Supply Program of the
National Institute on Drug Abuse (Rockville, MD). [35S]GTPγS (1250 Ci/mmol) was purchased
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from PerkinElmer Life Sciences (Boston, MA). Bovine serum albumin (BSA) and guanosine
diphosphate (GDP) were purchased from Sigma-Aldrich (St. Louis, MO). Goat anti-rabbit antiFosB antibodies (sc-7203 and sc-48) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Goat anti-CB1R and guinea-pig anti-CB1R antibodies (against residues 401-473 of
the CB1R) (Pickel et al., 2006) were generously provided by Dr. Ken Mackie (Indiana
University, Bloomington, IN). Secondary antibodies were purchased from either LI-COR
(Lincoln, NE) or Invitrogen (Grand Island, NY). ProLong® Gold anti-fade reagent with 4',6diamidino-2-phenylindole (DAPI) was purchased from Invitrogen. All other reagent grade
chemicals were obtained from Sigma Chemical Co. or Fisher Scientific.
Subjects
Male ICR mice (Harlan Laboratories, Indianapolis, IN) weighing 25-30 grams (n=8 per
group) were used to assess CB1R adaptations and ∆FosB induction. THC (10 mg/kg) was
dissolved in a 1:1:18 solution of ethanol, emulphor and saline (vehicle). Mice were injected
subcutaneously with either vehicle or THC at 07:00 and 16:00 h for 13 days. On day 14, mice
received a morning injection only, and 24 hours later mice were sacrificed by decapitation and
brains were extracted. Brains were then hemisected, with one half dissected for immunoblot
analysis and the other half frozen in isopentane at -30°C for autoradiography and
immunohistochemistry to measure [35S]GTPγS binding and CB1R levels, respectively. Based on
initial results, a second group of ICR mice was treated as described above, and the lateral and
basomedial nuclei of the amygdala were dissected to determine ΔFosB expression.
For immunohistochemical studies to determine whether CB1Rs and ΔFosB are colocalized in striatal neurons, male ICR mice (n=4) were treated with vehicle or a ramping dose of
THC (10-20-30 mg/kg) twice daily for 6.5 days. We have previously determined that this
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treatment paradigm induces a high level of ∆FosB in the striatum (unpublished data). Brains
were collected 24 hours after final drug administration to maximize the detection of ∆FosB,
which is more stable than FosB.
The role of CB1Rs in ∆FosB induction was determined using CB1R knockout mice on a
C57Bl/6J background and littermate controls (Zimmer et al., 1999) (n = 7-8 per group). CB1R
knockout and wild type (WT) mice were treated with THC (10mg/kg) or vehicle for 13.5 days as
described above, and the caudate-putamen and nucleus accumbens were dissected 24 hours after
final treatment. A separate group of C57Bl/6J mice (Jackson Laboratories, Bar Harbor, Maine)
were treated with increasing doses of THC to determine whether results in CB1R knockout mice
were due to an inability of this dose of THC (10 mg/kg) to further induce ∆FosB above levels in
vehicle-treated mice. Mice received vehicle, 10 mg/kg THC or 30 mg/kg THC for 13.5 days as
described above and the caudate-putamen was dissected 24 hours after the final injection.
Mice were housed four to six per cage and maintained on a 12-hr light/dark cycle in a
temperature controlled environment (20-22°C) with food and water available ad libitum. All
experiments were performed with the approval of the Institutional Animal Care and Use
Committee at Virginia Commonwealth University in accordance with the National Institutes of
Health guide for the care and use of Laboratory animals 7 th edition.

Dissections
Brain regions of interest were dissected from hemisected or whole fresh brains. The
prefrontal cortex was dissected by making a cut at the posterior extent of the anterior olfactory
nucleus after which the olfactory nuclei were removed. This sample included frontal association,
primary and secondary motor, anterior cingulate, prelimbic and orbital frontal cortices. The next
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cut was made anterior to the optic chiasm to produce a thick coronal section. The nucleus
accumbens was dissected by removing the cortex ventrally and the septum and nucleus of the
horizontal limb of the diagonal band medially and then collecting the tissue surrounding the
anterior commissure. The caudate-putamen was dissected by removing the cortex and then
collecting the caudate-putamen that remained after removal of the nucleus accumbens. The
hippocampus was exposed by removing the cortex from the remaining brain, then dissecting the
whole hippocampus from the surface of the brain. In a separate experiment, the lateral amygdala
(including the ventrolateral, dorsolateral, and anterior and posterior basolateral nuclei) and
basomedial amygdala were dissected. These dissections were made by first cutting caudal to the
optic chiasm, and then making a second cut directly caudal to the median eminence. The
basomedial amygdala was isolated by removing the surrounding ventral amygdaloid regions and
separating dorsally at the ventral extent of the bifurcated corpus callosum. The lateral amygdala
was isolated by removing the tissue found within the bifurcated corpus callosum.
Agonist stimulated [35S]GTPγS autoradiography
Assays were conducted as previously published from our laboratory (Nguyen et al., 2010;
Sim et al., 1995). Briefly, coronal sections (20 µm) were cut on a cryostat maintained at -20°C,
thaw-mounted onto gelatin-coated slides and stored desiccated at 4°C overnight. Sections were
collected at 3 levels to include 1) prefrontal cortex, 2) nucleus accumbens and caudate-putamen,
and 3) hippocampus, lateral amygdala and basomedial amygdala. Slides were stored desiccated
at -80°C until use. For assays, slides were brought to room temperature, and then rinsed in 50
mM Tris-HCl buffer (pH 7.4) with 3 mM MgCl2, 0.2 mM ethylene glycol tetraacetic acid
(EGTA) and 100 mM NaCl (Assay Buffer) for 10 min at 25°C. Next, slides were transferred to
Assay Buffer + 0.5% BSA, with 2 mM GDP and 10 mU/ml adenosine deaminase for 15 min at
51

25°C. Slides were then incubated in Assay Buffer + 0.5% BSA containing 0.04 nM [35S]GTPγS
with 3 µM CP55,940 or vehicle (basal) for 2 hours at 25°C. CP55,940 was used because we
have previously shown that it does not stimulate [35S]GTPγS binding in autoradiography of
CB1R knockout mouse brains (Nguyen et al., 2010). The maximally effective concentration of
CP55,940 was previously determined in cerebellar sections and homogenates (Nguyen et al.,
2010). After final incubation, slides were rinsed twice in 50 mM Tris buffer (pH 7.4) at 4°C, and
then in deionized water. Slides were then dried and exposed to Kodak Biomax MR film with
[14C] microscales for 18 hrs. Films were digitized at 8-bits per pixel with a Sony XC-77 video
camera. Brain regions of interest (ROIs) were determined using The Mouse Brain Atlas
(Franklin and Paxinos, 2008). Images were analyzed using NIH Image J software as described
previously and resulting values are expressed as nanocuries of [ 35S] per gram of tissue (nCi/g).
Net agonist-stimulated [35S]GTPγS binding was calculated by subtracting basal (without agonist)
binding from agonist-stimulated binding. Values were obtained in quadruplicate sections
collected from eight hemisected brains per group and averaged for statistical analysis.
Immunohistochemistry
CB1R immunofluorescence was used to assess receptor levels in hemisected brains.
Slide-mounted sections were washed in 0.1 M phosphate buffer (pH 7.4) with 0.9% NaCl (PBS)
for 5 minutes and fixed with 4% paraformaldehyde dissolved in 0.05 M phosphate buffer (pH
7.4), 0.9% NaCl, 1% Triton-X100 (PBST) for 30 minutes. Slides were rinsed 3 X 5 minutes in
0.1 M Tris buffer (pH 7.4), with 0.9% NaCl and 0.1% Triton-X100 (TBST), and then blocked in
TBST containing 5% normal donkey serum. Slides were incubated overnight at 4°C in TBST
containing 2.5% normal donkey serum and goat-anti CB1R (1:2000). Slides were then washed 3
X 10 minutes in TBS containing 0.05% Tween-20 and incubated in Alexa 800 donkey anti-goat

52

IgG (1:5000) for 2 hours. After incubation, slides were washed 2 X 10 minutes in TBS
containing 0.05% Tween-20 and 1 X 5 minutes in TBS. Fluorescent immunoreactivity was
detected with the LI-COR Odyssey scanner (42 μm resolution, 1 mm offset with highest quality,
channel sensitivity set at 4.0) and LI-COR software v 2.1 was used to measure the average
intensity of ROIs (Franklin and Paxinos, 2008) with the free form shape tool. Average intensity
values were used to account for differences in the size of ROIs between slices because this is not
corrected using integrated intensity.
CB1R and ΔFosB/FosB dual staining was assessed in coronal sections of the striatum to
determine the anatomical relationship between these two proteins. Slide-mounted sections (20
µm) were washed in 0.1 M phosphate buffer (pH 7.4) with 0.9% NaCl (PBS) for 5 minutes and
fixed with 4% paraformaldehyde (30 minutes) dissolved in 0.05 M PBS. Slides were washed 3
X 5 minutes in PBS and incubated in PBS containing 1% Triton-X100 for 15 minutes. Slides
were then washed 3 X 5 minutes in PBS and incubated in PBS containing 5% normal goat serum
for 1 hour. Slides were incubated overnight at 4°C in PBS containing 2.5% normal donkey
serum and antibodies against CB1R (1:1000; guinea-pig) and FosB (1:500; sc-48/rabbit). Slides
were then washed 3 X 5 minutes in PBS containing Alexa Fluor® 488 goat anti-guinea pig IgG
(1:500) and Alexa Fluor® 594 goat anti-rabbit IgG for 2 hours. After incubation, slides were
washed 3 X 10 minutes in PBS and once for 5 minutes in double-distilled water. Slides were
coverslipped using ProLong® Gold anti-fade reagent with DAPI. Images were captured on a
Zeiss 700 laser scanning confocal microscope utilizing the ZEN 2011 software. Pinhole diameter
was set to 1 Airy unit for the 488 wavelength to which the optical slice thicknesses were matched
for the 405 and 594 detectors. Scan resolution was optimized to meet Nyquist sampling criteria
in the X and Y dimensions. Signal crosstalk was eliminated by separating each wavelength into
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individual tracks and scanning sequentially. Scanning line-by-line, averaging four passes in a
single direction, then yielded an image at a 16 bit depth. All images were taken under a Zeiss
Plan-Apochromat 40x/1.3 Oil objective.
Immunoblots
Immunoblotting was performed as previously described (Sim-Selley et al., 2006;
Zachariou et al., 2003). Tissue was homogenized in 20 mM HEPES buffer (pH 7.8) with 0.4 M
NaCl, 20.0% glycerol, 5.0 mM MgCl2, 0.5 mM ethylenediaminetetraacetic acid, 0.1 mM EGTA
and 1% NP-40 (EMSA buffer) containing 0.5 mM phenylmethanesulfonylfluoride, 10 µg/ml
leupepsin, 100 µg/ml benazamide, 2 µg/ml aprotinin, 500 µM dithiothreitol and Halt™ protease
inhibitor cocktail. Samples (50 µg protein) were loaded in 10% Tris-HCl gels and separated by
electrophoresis. Gels were transferred onto nitrocellulose paper, blocked in 0.1 M TBS with 5%
Carnation™ instant nonfat dry milk for 1 hour, incubated in antibodies against α-tubulin
(1:1000) and FosB (1:500) in 0.1 M TBS containing 0.1% Tween-20 (TBST) with 5% nonfat dry
milk. Blots were washed 3 X 10 minutes in TBST and incubated with Alexa 680 goat anti-rabbit
IgG (1:12000) and Alexa 800 goat anti-mouse IgG (1:12000) in TBST for 45 minutes.
Fluorescent intensity was visualized using the Odyssey LI-COR infrared scanner. LI-COR
software v 2.1 was used to measure integrated intensity between treatments for the band of
interest, with subtraction of the background (average of intensities 3 border widths above and
below the band). In order to verify that bands for the α-tubulin loading control were not
saturated and ensure the accuracy of results, an experiment was conducted in which varying
concentrations of protein (25-100 µg) were loaded onto the gel and intensity was measured using
the LI-COR system. Linear regression analysis showed that these data fitted at r2 = 0.9978,
thereby confirming that the signal was not saturated at 50 µg, the amount of protein used in these
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studies.
Data Analysis
For all experiments, data were analyzed with Prism® version X (GraphPad Software, San
Diego, CA). For desensitization and downregulation studies and immunoblots comparing only
vehicle and 10 mg/kg THC, student t-tests were used to compare means of repeated THC and
vehicle groups based on planned comparisons by region. For studies in CB1R knockout and wild
type mice, data were analyzed by two-way ANOVA and Bonferroni post-hoc test and one-way
ANOVA with Dunnett’s post-hoc test in instances where an interaction was found. For all other
studies, one-way ANOVAs were performed with Bonferroni post-hoc test. To determine whether
∆FosB induction correlated with CB1R desensitization, linear regression analysis was performed
and the significance of correlations was determined with F-tests to determine whether the slope
of the line was significantly non-zero. Significance was determined with p < 0.05.

1.3 Results
Repeated THC administration reduces CP55,940-stimulated [35S]GTPγS binding in a regionspecific manner
CP55,940-stimulated [35S]GTPγS binding was conducted to determine whether 13.5 day
treatment with 10 mg/kg THC (b.i.d.) produced CB1R desensitization in the forebrain. No
differences in basal [35S]GTPγS binding were found between THC- and vehicle-treated mice in
any region examined (data not shown). Densitometric analysis revealed a region-dependent
reduction in CP55,940-stimulated [35S]GTPγS binding in brains from THC- compared to
vehicle-treated mice. THC treatment produced a significant reduction in CP55,940-stimulated
[35S]GTPγS binding in the prefrontal cortex (29% decrease, df=14, p < 0.05) and hippocampus
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(50% decrease, df=14, p < 0.01) compared to vehicle-treated mice (Figure 1.1, Table 1.1). THC
treatment significantly reduced CP55,940-stimulated [35S]GTPγS binding by 27% (df=14, p <
0.05) in both the lateral amygdala (including the lateral and basolateral nuclei) and basomedial
amygdala of THC-compared to vehicle-treated mice. In contrast, there was no significant
difference in CP55,940-stimulated [35S]GTPγS binding in the caudate-putamen or nucleus
accumbens of THC- versus vehicle-treated mice (Figure 1.1, Table 1.1). Therefore, the regional
profile of relative CB1R desensitization was hippocampus >> prefrontal cortex ≥ basomedial
amygdala = lateral amygdala > > caudate-putamen = nucleus accumbens.
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Figure 1.1 (A) Representative autoradiograms showing CP55,940-stimulated [35S]GTPγS
binding in brains from vehicle and THC-treated mice. Prefrontal cortex is shown in row 1,
nucleus accumbens and caudate-putamen in row 2 and hippocampus, lateral amygdala and
basomedial amygdala in row 3. (B) Graph representing differences in net-stimulated [35S]GTPγS
binding expressed as a percent of net-stimulated binding in vehicle-treated mice. Data are means
± SEM with * p < 0.05 and ** p < 0.01 versus vehicle controls, un-paired, two-tailed Student ttest, n = 8 mice per group.
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CB1R-ir is reduced by repeated THC treatment in a subset of brain regions
CB1R-ir was measured using immunohistochemistry in brain sections that were nearadjacent to those used for [35S]GTPγS autoradiography. CB1R-ir in brain sections was analyzed
using the Odyssey LI-COR system, which can scan images with a resolution up to 24 µm,
allowing accurate measurements of differences in fluorescent intensity (Brunet et al., 2009;
Kearn, 2004). CB1R-ir was measured in the same regions as described above for agoniststimulated [35S]GTPγS binding. Decreased CB1R-ir, indicative of downregulation, was found in
many of the same regions as CB1R desensitization, although the magnitude of the decrease was
generally greater for desensitization. CB1R-ir was significantly reduced in the prefrontal cortex
(19% decrease, df=14, p < 0.01), lateral amygdala (15% decrease, p < 0.05) and hippocampus
(22% decrease, df=14, p < 0.05) of THC- compared to vehicle-treated mice (Figure 1.2, Table
1.1). CB1R-ir did not significantly differ between THC- and vehicle-treated mice in the nucleus
accumbens, caudate-putamen or basomedial amygdala. These results demonstrate a similar
regional pattern for CB1R desensitization and downregulation.
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Figure 1.2 (A) Representative images of LI-COR scans for CB1R-ir. Prefrontal cortex is shown
in row 1, nucleus accumbens and caudate-putamen in row 2, and hippocampus, lateral amygdala
and basomedial amygdala in row 3. (B) Graph showing differences in average intensity for
CB1R-ir as a percent of vehicle. Data are means ± SEM with * p < 0.05 versus vehicle controls,
un-paired, two-tailed Student t-test, n = 8 mice per group.
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TABLE 1.1
Net CP55,940-stimulated [35S]GTPγS binding and CB1R-ir measured in brain sections from
vehicle- and THC- treated mice

Region

Net

CB1R-ir

[35S]GTPγS binding

Average intensity

VEHICLE

THC

VEHICLE

THC

Prefrontal cortex

541 ± 35

388 ± 42*

1173 ± 66

946 ± 20*

Nucleus accumbens

286 ± 25

290 ± 32

432 ± 12

417 ± 16

Caudate-putamen

319 ± 14

316 ± 29

1160 ± 34

1134 ± 33

Lateral amygdala

397 ± 21

290 ± 36*

461 ± 18

393 ± 2*

Basomedial amygdala

349 ± 35

253 ± 16*

351 ± 33

365 ± 14

Hippocampus

380 ± 25

188 ± 32**

498 ± 7

392 ± 12**

______________________________________________________________________________
Brain sections were incubated in 0.04 nM [35S]GTPγS, 3 µM CP55,940 and 2 mM GDP for
autoradiography and results are expressed as net CP55,940-stimulated [35S]GTPγS binding
(nCi/g) ± SEM. Near-adjacent sections were processed with an antibody to CB1R for
immunohistochemistry and results are expressed as CB1R-ir average intensity in units of
counts/pixels ± SEM. *p < 0.05 **p < 0.01 different from vehicle by Student’s t-test, n=8 mice
per group.
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∆FosB is induced by THC treatment in specific forebrain regions
Immunoblots were performed to determine the relative expression levels of ΔFosB
between vehicle- and THC-treated mice. Immunoblot results showed region-specific induction of
∆FosB expression by THC. Repeated THC treatment produced significant increases in ∆FosB-ir
in the prefrontal cortex (43% increase, df=14, p < 0.05), caudate-putamen (62% increase, df=14,
p < 0.001), nucleus accumbens (87% increase, df=14, p < 0.001) and lateral amygdala (38%
increase, df=14, p < 0.05) of THC- compared to vehicle-treated mice (Figure 1.3, Table 1.2). In
contrast, ∆FosB-ir in the basomedial amygdala and hippocampus did not significantly differ
between treatment groups. Therefore, the regional profile of THC-mediated ∆FosB induction
was nucleus accumbens > caudate-putamen > prefrontal cortex > lateral amygdala >>
basomedial amygdala = hippocampus.
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Figure 1.3 Immunoblot results for ΔFosB expression in the prefrontal cortex, nucleus
accumbens, caudate-putamen, lateral amygdala, basomedial amygdala and hippocampus of mice
that received repeated vehicle or THC administration. Blots were probed with antibodies
directed against ΔFosB and α-tubulin (loading control). (A) Graph showing densitometric
analysis of brain regions from vehicle- and THC-treated mice expressed as percent vehicle
control. Data are means ± SEM with * p < 0.05 and *** p < 0.001 versus vehicle controls, unpaired, two-tailed student t-test, n = 8 per group. (B) Representative blots showing ∆FosB-ir and
α-tubulin-ir in vehicle- and THC-treated brains for each region examined.
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TABLE 1.2
ΔFosB expression measured by immunoblot in brains from vehicle- and THC-treated mice

ΔFosB-ir
Integrated intensity

Region

THC
VEHICLE

Prefrontal cortex

2.94 ± 0.33

4.20 ± 0.47*

Nucleus accumbens

1.81 ± 0.22

3.39 ± 0.25***

Caudate-putamen

1.56 ± 0.11

2.52 ± 0.12***

Lateral amygdala

2.94 ± 0.11

4.05 ± 0.08*

Basomedial amygdala

1.98 ± 0.11

2.13 ± 0.08

Hippocampus

1.40 ± 0.23

1.20 ± 0.14

______________________________________________________________________________
∆FosB-ir was measured in homogenates prepared from brain regions of interest using an
antibody against FosB that recognizes all FosB isoforms, as described in Methods. The 35-37
kDa band, defined as ΔFosB, was measured for analysis. Results are expressed as integrated
intensity in units of counts-mm2 ± SEM. *p < 0.05 ***p < 0.001 different from vehicle by
Student’s t-test, n=8 mice per group
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CB1R desensitization and ∆FosB expression are inversely correlated
Reductions in CB1R-ir and CB1R-mediated G-protein activity exhibited a similar regional
pattern, whereas THC-mediated ∆FosB induction was most robust in regions with less CB1R
desensitization. In order to determine whether these observations represented significant
correlations, the mean percent changes in [ 35S]GTPγS binding, CB1R-ir and ∆FosB-ir of vehicleversus THC-treated mice were plotted for each region. Desensitization ([ 35S]GTPγS
autoradiography, y-axis) and downregulation (CB1 R-ir, y-axis) were each compared to ∆FosB
expression (immunoblots, x-axis). For the comparison between ∆FosB-ir and downregulation,
the slope of the linear regression line was not determined to be significantly non-zero r (4) =
0.20, p = 0.67. For the comparison between ∆FosB-ir and desensitization, the slope of the linear
regression line was determined to be significantly non-zero r (4) = 0.94, (p < 0.01) (Figure 1.4).
These analyses confirmed initial observations and showed a significant inverse regional
correlation between CB1R desensitization and ∆FosB expression.
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Figure 1.4 Correlation of percent change in measured parameters for THC-compared to vehicletreated mice for the brain regions examined between desensitization (y-axis) and ΔFosB
expression (x-axis). Correlation is presented as percent change from vehicle with corresponding
r-squared values. Data are means ± SEM with ** p < 0.01, F-test, n=8 per group.
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CB1Rs co-localize with and contact ∆FosB/FosB-ir neurons
Immunohistochemistry was performed in order to determine whether the interaction
between CB1Rs and ∆FosB occurs within the same cell or is a trans-synaptic effect. Mice were
treated with a ramping dose of THC (10-20-30mg/kg) that strongly induces ΔFosB expression in
the striatum. The antibody used to assess ∆FosB recognizes FosB/∆FosB, but the 24-hour posttreatment survival time used in this experiment favors detection of ∆FosB (Perrotti et al., 2004).
CB1R-ir was visualized in green and FosB/∆FosB-ir was visualized in red (Figure 1.5). DAPI
(blue) was used to identify cell nuclei. The distribution of CB1R-ir in the caudate-putamen and
nucleus accumbens of both vehicle- and THC-treated mice was similar to that previously
described by (Tsou et al., 1998) (Figure 1.5 A, D). CB1R-ir in both the caudate-putamen and
nucleus accumbens appeared as bright puncta that were distributed in the neuropil and
surrounding cell bodies, as indicated by nuclear markers (Figure 1.5 C, F, G-I). More diffuse
staining was also observed in the caudate-putamen that appeared to represent fiber bundles.
Although most of the CB1R-ir appeared to be on fibers, green fluorescent CB1R-ir cell bodies
were also observed (Figure 1.5 A, C, G and H). FosB/∆FosB-ir nuclei were seen in the caudateputamen and nucleus accumbens of both vehicle- and THC-treated mice (Figure 1.5 B, E), but
fewer FosB/∆FosB-ir nuclei were observed in brain sections from vehicle- compared to THCtreated mice (not shown). Dual staining for DAPI showed that FosB/∆FosB-ir was localized in
cell nuclei (Figure 1.5 C, F, G-I), as previously reported (Perrotti et al., 2008). DAPI stained
nuclei that were immunonegative for FosB/∆FosB were also observed in brains from both groups
of mice (Figure 1.5 C, F, G-I). Examination of dual staining in brains from THC-treated mice
revealed that in many cases CB1R-ir puncta appeared to be surrounding cells that contained
FosB/∆FosB-ir nuclei (Figure 1.5 G-I). Cells were also observed in the caudate-putamen with
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green fluorescence that surrounded DAPI/∆FosB positive nuclei (Figure 1.5 G and H). There
were no instances where CB1R-ir and FosB/∆FosB-ir were dual stained in the nucleus (Figure
1.5 C, F, G-I). Therefore, it appeared that CB1R-ir was both co-localized with FosB/∆FosB-ir in
cells and also in puncta that contacted cells with FosB/∆FosB-ir nuclei.
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Figure 1.5 Representative images showing CB1R-ir (green), FosB/∆FosB-ir (red) and DAPI
(blue) in the caudate-putamen and nucleus accumbens of mice that received repeated THC
treatment. CB1R-ir fibers and puncta were seen in the caudate-putamen (A) and nucleus
accumbens (B) and CB1R-ir cells were occasionally found in the caudate-putamen (A).
FosB/∆FosB-ir was localized to nuclei of cells in the caudate-putamen (B, C) and nucleus
accumbens (E, F). FosB/∆FosB-ir and DAPI were seen in a subset of cell nuclei that were
surrounded by CB1R-ir puncta in the caudate-putamen (C, G, H) and nucleus accumbens (F, I).
CB1R-ir was also seen in cells that contained FosB/∆FosB-ir nuclei in the caudate-putamen
(indicated by arrows in G, H).

ac: anterior commissure

THC-mediated ∆FosB induction is abolished in CB1R knockout mice
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The role of CB1Rs in THC-mediated ∆FosB induction was determined in the nucleus
accumbens and caudate-putamen, regions that showed the highest magnitude of ΔFosB
induction. CB1R knockout and littermate wild type mice were treated with 10 mg/kg THC or
vehicle for 13.5 days (b.i.d.) as described above. ΔFosB expression was significantly increased
in THC- versus vehicle-treated wild-type mice in both the caudate-putamen (39% increase, F1,25,
p < 0.05) and nucleus accumbens (45% increase, F 1,25, p < 0.05) (Figure 6). There was no
significant difference in ∆FosB-ir between vehicle- and THC-treated CB1R knockout mice in
either the caudate-putamen or nucleus accumbens. In the caudate-putamen, two-way ANOVA
determined a significant interaction between the factors of genotype × treatment F1, 25 = 4.86, p<
0.05. One-way ANOVA, followed by Dunnett’s post-hoc test, determined that both vehicle- and
THC-treated CB1R-knockout mice exhibited significantly greater ΔFosB expression (F3,25, p <
0.01) compared to wild type vehicle-treated mice (Figure 6). Because ∆FosB-ir was elevated in
the caudate-putamen of vehicle-treated CB1R knockout compared to wild type mice, it is
possible that further increases in ∆FosB-ir might not be detected in this region after this THC
treatment paradigm, essentially producing a ceiling effect. Therefore, C57Bl/6J mice were
repeatedly administered vehicle, 10 mg/kg and a higher dose (30 mg/kg) of THC twice daily for
13.5 days. Results showed that this 30 mg/kg THC administration paradigm produced a
significantly greater increase in ΔFosB-ir than the 10 mg/kg THC administration paradigm (F2,21,
p < 0.05, Figure 1.7), indicating that the 10 mg/kg paradigm did not induce maximal ΔFosB
expression in this brain region. This result shows that THC-mediated ∆FosB induction is dosedependent and that ∆FosB induction does not occur in CB1R knockout mice.
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Figure 1.6 Immunoblot results for ΔFosB expression in the caudate-putamen and nucleus
accumbens following repeated vehicle or THC administration in wild type and CB1R knockout
mice. Blots were probed with antibodies directed against ΔFosB and α-tubulin (loading control).
(A and B) Graphs showing densitometric analysis of brain regions from vehicle- and THCtreated mice expressed as percent vehicle control. For CPU, data are means ± SEM with ^ p <
0.05 and ^^ p < 0.01 versus wild type vehicle controls, Dunnett’s post-hoc test following a oneway ANOVA, n = 7-8 mice per group. For NAC, data are means ± SEM with * p < 0.05 versus
wild type vehicle controls, Bonferroni post-hoc test following a two-way ANOVA, n = 7-8 mice
per group. (C and D) Representative blots showing ∆FosB-ir and α-tubulin-ir in vehicle- and
THC-treated brains of wild type and CB1R knockout mice for each region examined.
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Figure 1.7 Immunoblots showing ΔFosB-ir in the caudate-putamen of mice that received
vehicle, 10 mg/kg THC or 30 mg/kg THC administration twice daily for 13.5 days. ΔFosB
expression was significantly increased by THC treatment (F2,21 =17.78, p < 0.0001). ∆FosB
levels were 50% ± 11% (p < 0.05) and 104% ± 17% (p < 0.001) above levels in vehicle control
mice following 10 mg/kg and 30 mg/kg THC administration, respectively. ∆FosB-ir was also
significantly greater in mice that received 30 mg/kg THC administration compared to mice
treated with 10 mg/kg THC (p < 0.05). Results are presented as % vehicle control ± SEM with
significance determined following one-way ANOVA with Bonferroni post-hoc test, n = 8 mice
per group.
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1.4 Discussion
This study demonstrated an inverse regional correlation between THC-mediated
induction of ∆FosB and CB1R desensitization in the forebrain. Repeated THC treatment induced
∆FosB in the caudate-putamen and nucleus accumbens, regions that did not exhibit THCinduced CB1R desensitization and downregulation. In contrast, THC treatment did not induce
∆FosB in the hippocampus, which exhibited the highest magnitude of CB1R desensitization and
downregulation. Areas with intermediate levels of CB1R desensitization and downregulation,
such as prefrontal cortex, lateral amygdala and basomedial amygdala, demonstrated either no
change or an intermediate level of ∆FosB induction. Immunohistochemical results showed that
CB1R-ir puncta surrounded cells with FosB/∆FosB-ir nuclei and also that CB1R and
FosB/∆FosB were co-localized in some cells. Previous studies have shown that CB1R are
expressed primarily in GABAergic MSN of the striatum (Hohmann and Herkenham, 2000).
Thus, these results support the idea that ∆FosB could regulate CB1Rs and/or that CB1R signaling
could modulate ∆FosB expression via both direct and trans-synaptic mechanisms. The role of
CB1Rs in THC-mediated ∆FosB induction has not previously been assessed. Studies in CB1R
knockout and wild type mice revealed that ∆FosB induction was CB1R-dependent in the caudateputamen and nucleus accumbens, showing that CB1Rs are required for THC-mediated ∆FosB
induction.
Studies in rodents have established that there are brain region-dependent differences in
the magnitude, rate of development and rate of recovery of CB1R desensitization and
downregulation (McKinney et al., 2008; Sim-Selley, 2003; Sim-Selley et al., 2006). Similar
regional relationships have been found in brains from human marijuana users, where greater
apparent downregulation and slower recovery of ligand binding were found in the hippocampus

72

compared to other brain regions (Hirvonen et al., 2012; Villares, 2007). The similar regional
relationship in CB1R adaptations between rodents and humans suggests that this is a fundamental
property of adaptation of brain CB1Rs to repeated THC exposure. The present study has
extended our previous findings by showing that brain regional specificity also exists for
induction of the stable transcription factor ∆FosB in rodents.
We have previously assessed THC-mediated desensitization and downregulation and
induction of ∆FosB in separate studies using a 15-day ramping-dose THC paradigm (Perrotti et
al., 2008; Sim-Selley and Martin, 2002). This treatment paradigm produced significant CB1R
desensitization and downregulation in almost all regions examined, but the relative magnitude
varied across regions. The hippocampus exhibited a higher magnitude of desensitization and the
caudate-putamen and its projection regions of substantia nigra and globus pallidus exhibited a
lower magnitude of desensitization (Sim-Selley and Martin, 2002). FosB/∆FosB induction was
examined in a separate study by treating mice with this THC ramping dose paradigm and
counting the number of FosB/∆FosB-ir cells (Perrotti et al., 2008). Results showed significant
THC-induced increases in FosB/∆FosB-ir cells in the nucleus accumbens core, with trends
toward increases in the nucleus accumbens shell and caudate-putamen. Semi-quantitative
analysis showed greater numbers of FosB/∆FosB-ir neurons throughout the forebrains of THCcompared to vehicle-treated mice (Perrotti et al., 2008). The current study extends those findings
by using immunoblot analysis, which provides a quantitative measure that distinguishes between
∆FosB and full length FosB and measures total protein expression. Results showed significant
THC-mediated ∆FosB induction in the nucleus accumbens, as well as prefrontal cortex, caudateputamen and lateral amygdala. The finding that THC-mediated ΔFosB induction occurs in these
forebrain regions could have important implications for understanding the mechanisms that
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contribute to the motivational effects of THC. The distribution of THC-induced ∆FosB
expression in the prefrontal cortex, caudate-putamen, nucleus accumbens and lateral amygdala
corresponds to previous findings reported after treatment with other drugs of abuse or exposure
to chronic stress (Perrotti et al., 2004; Perrotti et al., 2008). Neuroplasticity of these brain
regions is critical in the transition from acute to compulsive drug use and has been suggested to
be a neural substrate of addiction (Koob and Volkow, 2010). ∆FosB-mediated regulation of
target genes in these regions could therefore affect behaviors that contribute to the motivational
effects of THC as well as other drugs of abuse. In fact, overexpression of ΔFosB in
D1/dynorphin-containing striatal MSN enhanced the rewarding effects of morphine and cocaine
(Colby et al., 2003; Zachariou et al., 2006a). Moreover, if ∆FosB or its target genes regulate
CB1R desensitization and/or downregulation in these regions, these molecular changes could also
modulate the motivational effects of THC. For example, if ∆FosB or its targets could inhibit
CB1R desensitization, then less tolerance might develop to behaviors mediated by the striatum
versus hippocampus in which ∆FosB is not induced by THC. In fact, studies in humans suggest
that tolerance develops to the memory-impairing effects of THC, whereas subjective criterion,
such as THC-induced “high”, are less susceptible to development of tolerance (D'Souza et al.,
2008; Haney et al., 1997; Haney et al., 2004).
A significant inverse correlation was found between desensitization and ΔFosB induction,
whereas ∆FosB induction did not correlate with CB1R downregulation. One explanation for this
difference is that this THC paradigm did not produce sufficient downregulation to allow a direct
comparison with ∆FosB induction. It is also possible that ΔFosB might directly or indirectly
regulate genes involved in CB1R desensitization, but not downregulation. For example,
desensitization involves phosphorylation of G-protein coupled receptors (GPCRs) by G-protein
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receptor kinases (GRKs), and subsequent recruitment of β-arrestins to the receptor that can
produce desensitization by interfering with receptor-G-protein coupling and initiating
endocytosis (Claing et al., 2002; Jin et al., 1999). β-arrestin-mediated GPCR endocytosis
promotes trafficking to endosomes, which leads to either recycling of the receptor to the plasma
membrane (resensitization) or degradation (downregulation). Trafficking of CB1Rs to lysosomes
for degradation is regulated by G protein-coupled receptor associated sorting protein 1 (GASP1)
(Martini et al., 2007). Thus, a number of regulatory proteins could contribute to the molecular
changes shown in the present study. ΔFosB has not yet been linked to pathways involved in
GPCR trafficking, but this possibility has not been addressed directly.
The gene targets of ∆FosB that could regulate desensitization are not fully known, but
previous studies have identified candidate proteins that regulate CB1R adaptions. Our laboratory
showed that genetic deletion of β-arrestin-2 in mice attenuated CB1R desensitization in the
periaqueductal gray, cerebellum and spinal cord, and enhanced desensitization in the projection
areas of the caudate-putamen (substantia nigra and globus pallidus) following repeated THC
administration (Nguyen et al., 2012). Inhibition of the ERK pathway has also been shown to
modulate CB1R receptor desensitization and downregulation, suggesting that inhibition of
proteins in this pathway could reduce desensitization. Alternative interpretations are also
suggested by the current findings. It is possible that CB1R desensitization in regions such as the
hippocampus inhibits induction of ∆FosB, thus regions in which CB1R desensitization occurs
would show less ∆FosB induction. This mechanism could also explain the inverse regional
relationship identified between CB1R desensitization and ∆FosB induction.
Although the current results support the idea that CB1R desensitization and ∆FosB
induction after repeated THC exposure might be related, it also is possible that the two events

75

could be coincident and not linked. For example, signaling pathways upstream of CB1Rs and
∆FosB might regulate both processes. Studies using rat sarcoma(Ras)-specific guanine
nucleotide exchange factor 1 (GRF1) knockout mice, which blunts ERK activation through this
signaling pathway, showed that the Ras/ERK pathway was necessary for CB1R desensitization
and downregulation in the striatum (Rubino et al., 2005) and was also involved in cocainemediated ΔFosB induction in the striatal neurons (Fasano et al., 2009). These findings provide a
mechanism upstream of ΔFosB induction that could also regulate CB1R desensitization.
However, if ERK was solely responsible for both events, one would predict a positive correlation
between desensitization and ΔFosB induction, whereas results showed a negative correlation in
this study. Thus, it will be important in future studies to determine whether there is indeed a
direct relationship between ∆FosB induction and CB1R desensitization and identify the signaling
processes that regulate these events.
The finding that ΔFosB expression was significantly higher in the caudate-putamen of
CB1R knockout compared to wild type mice suggests that CB1Rs modulate basal ΔFosB
expression in this region. A recent study showed that reduction of CB1R expression in striatal
cells using RNA interference-directed knockdown decreased the levels of D2R mRNA and
protein, as well as D2R-stimulated G-protein activity (Blume et al., 2013). Moreover,
administration of the D2R antagonist, haloperidol, is known to induce ∆FosB expression (Atkins
et al., 1999). Taken together, these findings suggest that loss of striatal CB1Rs in knockout mice
could reduce D2R signaling, which, like haloperidol, would enhance dopamine release. A
potential interaction between CB1Rs and dopamine receptors in dopamine-mediated regulation of
∆FosB could have important implications in understanding the cellular consequences of drugs of
abuse.
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THC has previously been reported to induce ∆FosB, a property common to drugs of
abuse (Perrotti et al., 2008), but we believe that this is the first study to directly assess the
relationship between THC-mediated ∆FosB induction and THC-mediated desensitization and
downregulation in CB1Rs. CB1Rs and ∆FosB were co-localized in a subset of striatal neurons,
demonstrating that adaptations in these pathways following THC exposure could be cell
autonomous. The anatomical proximity of CB1R-ir puncta with cells that express ∆FosB
indicates that CB1Rs might also trans-synaptically regulate ∆FosB. Results suggest several
possible functional interactions between CB1R signaling and ∆FosB in the striatum. The inverse
regional relationship between CB1R desensitization and ∆FosB induction suggests that ∆FosB
induction and subsequent changes in the expression of gene targets might inhibit CB1R
desensitization. A non-mutually-exclusive possibility is that CB1R desensitization impairs a
signaling pathway that normally induces ∆FosB expression, so that CB1R desensitization would
attenuate ∆FosB induction. These possibilities will need to be directly assessed in future studies
to determine the mechanism(s) underlying functional interactions between CB1Rs and ∆FosB
and potential consequences after repeated THC administration.
These results suggest that THC-mediated ∆FosB induction could inhibit CB1R
desensitization or modulate resensitization, and/or that CB1R desensitization could attenuate
THC-mediated ∆FosB induction. Future studies will be required to distinguish among these
mechanisms. The demonstration that CB1Rs are both co-localized with ∆FosB and in puncta that
contact ∆FosB expressing cells indicates that both direct interactions and trans-synaptic effects
could occur. These studies also demonstrate the requirement for CB1Rs in THC-mediated ∆FosB
induction and that induction of ΔFosB is THC dose-dependent. The finding that THC treatment
induces ΔFosB in several regions important for functions related to reward highlights the role
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this transcription factor might play in human marijuana use.
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Chapter 2: ΔFosB modulation of CB1R desensitization and tolerance to cannabinoidmediated effects
2.1 Introduction
THC, the main psychoactive constituent of marijuana (Gaoni, 1964), produces its
behavioral effects by activating CB1Rs in the CNS (Rinaldi-Carmona et al., 1994; Zimmer et al.,
1999). Repeated THC administration produces tolerance to THC-mediated in vivo effects,
including cognitive impairment, locomotor suppression, catalepsy, hypothermia and
antinociception (Lichtman and Martin, 2005). Tolerance occurs concomitantly with CB1R
desensitization (Sim-Selley, 2003), but the mechanism(s) underlying these adaptations are not
well understood. CB1R desensitization varies in magnitude by brain region depending on the
dose and duration of repeated cannabinoid administration and the regional profile of these
adaptations correspond with the development of tolerance to specific cannabinoid-mediated
responses (Sim-Selley, 2003). For example, tolerance to THC-mediated hypothermia develops
more rapidly and at lower doses than tolerance to locomotor suppression and catalepsy
(McKinney et al., 2008; Whitlow et al., 2003) consistent with the lower level of desensitization
observed in structures of the basal ganglia and nucleus accumbens compared to other regions
(Sim-Selley, 2003). In human marijuana users, greater tolerance develops to the memory
impairing effects of THC, which involve hippocampal function, compared to motor impairment
and subjective “high”, which involve striatal circuits (D'Souza et al., 2008; Haney et al., 1999a,
b). Studies in human brain using post-mortem autoradiography or in vivo imaging have revealed
a greater decrease in CB1R levels in the hippocampus compared to the caudate-putamen of
marijuana users compared to non-users (Hirvonen et al., 2012; Villares, 2007). These data agree
with findings in rodent studies and suggest the potential functional relevance of regional
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differences in CB1R adaptation, but the regulatory mechanisms that underlie these regional
differences are not known.
We have proposed that regional differences in the interaction of CB1Rs with specific
signaling and regulatory proteins might contribute to region-specific differences in CB1R
adaptation (Nguyen et al., 2012; Sim-Selley, 2003), and recently suggested that induction of
transcription factors following repeated THC administration might modulate CB1R
desensitization (Lazenka et al., 2013). This idea was based, in part, on the demonstration that an
inverse regional correlation exists between THC-mediated CB1R desensitization and induction of
ΔFosB (Chapter 1). ΔFosB belongs to the Fos family of transcription factors that dimerize with
Jun proteins to produce an AP-1 complex that regulates the transcription of target genes (Chen et
al., 1997; Herdegen and Leah, 1998). ΔFosB, a truncated splice variant of FosB, is a stable
transcription factor that accumulates with repeated drug administration (Nestler et al., 2001).
Transgenic overexpression of ∆FosB in dopamine type 1 receptor (D1R) positive striatal MSNs
enhanced the rewarding effects of drugs of abuse and natural rewards (Nestler, 2008; Werme et
al., 2002). Expression of ∆cJun, which functionally inhibits ∆FosB, reduced cocaine- (Peakman
et al., 2003) and morphine- (Zachariou et al., 2006a) induced condition place preference.
Microarray studies have determined that ΔFosB regulates expression of certain receptors (e.g.,
adenosine A2A receptor) and signaling proteins (G-protein Gαo, protein kinase C and
calcium/calmodulin-dependent protein kinase II) (McClung and Nestler, 2003). Inducible
transgenic overexpression of ∆FosB enhanced mu opioid, but not CB 1, receptor-mediated Gprotein activity in the nucleus accumbens (Sim-Selley et al., 2011), supporting the idea that
∆FosB can regulate GPCR signaling. However, a possible role for ∆FosB in regulating CB1R
desensitization has not been investigated. The current study addressed this question by
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administering repeated THC to transgenic mice that have inducible overexpress ΔFosB or ∆cJun
in the forebrain and assessing CB1R-mediated G-protein activity and THC-mediated in vivo
responses.

2.2 Materials and Methods
Materials
Materials are provided in Chapter 1
Mice and Drug Treatments
Subjects were male, bitransgenic NSE-tTA x TetOp-∆FosB mice (on an FVB/C57BL/6J
background) and NSE-tTA ×TetOp-FLAG-Δc-Jun mice (on an FVB background) with brainregion specific, tetracycline-regulated inducible expression of either ΔFosB or ΔcJun,
respectively (Chen et al., 1998; Peakman et al., 2003). ∆FosB or ∆cJun expression is controlled
by adding doxycycline to the drinking water, which prevents ∆FosB/∆cJun expression.
Omission of doxycycline from the drinking water allows ∆FosB/∆cJun to be expressed. In mice
that overexpress ∆FosB (∆FosB-ON), ΔFosB is expressed in D1R MSNs in the caudate-putamen
and nucleus accumbens, deep layers of cerebral cortex and hippocampus (Chen et al., 1998). In
mice that overexpress ∆cJun (∆cJun-ON), expression occurs in both D1R and dopamine type 2
receptor (D2R) positive MSNs of the caudate-putamen and nucleus accumbens, parietal cortex
and hippocampus (Peakman et al., 2003). ΔcJun is a dominant negative functional inhibitor of
Fos-mediated transcription, thus this model provides a strategy to block the effects of ∆FosB
expression. Mice were housed four to six per cage and maintained on a 12-hr light/dark cycle in
a temperature-controlled environment (20-22°C) with food and water available ad libitum. Mice
were maintained on drinking water that contained doxycycline (100 µg/ml) throughout gestation
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and were either taken off doxycycline for 8 weeks prior to experiments to induce expression of
ΔFosB or ΔcJun or maintained on doxycycline (control). After 8 weeks with/without
doxycycline, mice were treated twice daily (08:00 and 16:00) with vehicle (1:1:18 solution of
ethanol, emulphor and saline) or a ramping dose of THC (10-30-60 mg/kg, subcutaneous
injection) for 6 days, with doses increasing every 2 days (McKinney et al., 2008). On day 7,
mice received only the morning THC injection, and 24 hours later separate groups of mice were
either tested for THC-induced in vivo responses or were sacrificed and brains were collected for
CP55,940-stimulated [35S]GTPγS binding. This THC treatment regimen was employed because
it produces CB1R desensitization throughout the brain, including in the striatum, therefore should
reveal whether ∆FosB expression alters CB1R desensitization. All experiments were performed
with the approval of the Institutional Animal Care and Use Committee at Virginia
Commonwealth University in accordance with the National Institutes of Health guide for the
care and use of Laboratory animals 7th edition.
Agonist-stimulated [35S]GTPγS Autoradiography
Assays were conducted as previously described in Chapter 1. For this study, sections
were collected to include 1) prefrontal cortex, 2) nucleus accumbens, 3) caudate-putamen, 4)
globus pallidus, 5) hippocampus and amygdala (including central, basolateral and basomedial
nuclei), 6) VTA, 7) substantia nigra and 8) cerebellum.
In vivo Assessment
Mice were evaluated 24 hours after the last THC injection to determine whether
overexpression of ΔFosB or ΔcJun affected THC-induced in vivo responses after either repeated
vehicle or THC treatment. ΔFosB-ON and ∆FosB-OFF vehicle-treated mice (n = 8 mice per
group) were initially evaluated for THC-induced hypothermia, antinociception and catalepsy
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using a cumulative dosing procedure to determine whether expression of ∆FosB affected THCmediated responses. Dose-response data were also used to determine the appropriate challenge
dose of THC to administer in subsequent experiments for both ΔFosB and ΔcJun bitransgenic
mice. Baseline measures were first assessed in the absence of THC, and then mice received
intraperitoneal (i.p.) injections of increasing doses (3, 7, 20 and 70 mg/kg) of THC and were
assessed again after each injection. Subjects were evaluated for all measures beginning at 30
minutes after injection of each dose of THC, and the entire dose-response assessment was
completed in less than 3 hours (Falenski et al., 2010; Schlosburg et al., 2010). Catalepsy was
determined in the bar test, antinociception was evaluated in the warm water tail immersion test at
52.0 °C, and body temperature was measured by inserting a thermocouple probe 2.0 cm into the
rectum (Falenski et al., 2010; Long et al., 2009). For locomotor activity, each mouse was placed
in a clear Plexiglas box (42.7 x 21.0 x 20.4 cm) for a 5 min assessment period and Anymaze
software (Stoelting, Wood Dale, Illinois) was used to determine the amount of time spent
immobile (Long et al., 2009). Mice were tested in separate chambers for baseline and THC trials
to avoid habituation. Thigmotaxis was also measured during locomotor activity trials by using
Anymaze to draw a zone in the center of the activity chamber that subtracted the width of a
mouse (~4 cm) from each side of the chamber, thereby by creating two separate zones. The
outside zone represented time spent exhibiting thigmotaxis and the inside zone represented time
spent within the center of the chamber (Simon et al., 1994). Data are presented as: (time spent in
the outside zone/ time spent in the inside zone) x 100. To circumvent the possibility that mice
might acclimate to activity chambers with repeated testing, all remaining experiments tested a
single dose (i.p.) of 100 mg/kg THC for both ΔFosB and ΔcJun bitransgenic mice (n = 8 mice
per group) using the testing procedures described above. Baseline measures were taken, and
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then mice were injected with THC and tested 20 minutes later for locomotor activity. Catalepsy,
antinociception and hypothermia were tested 3 hours after THC injection because initial studies
determined that maximal effects were produced at this time point (data not shown). Because
neither control nor ΔFosB-ON mice that received repeated THC injection exhibited catalepsy at
the 100 mg/kg dose, a separate group of mice was tested at a dose of 200 mg/kg THC.
Analysis
Data were analyzed with Prism® version X (GraphPad Software, San Diego, CA) for all
experiments. For in vivo studies, repeated measures ANOVA were performed with Bonferroni
post-hoc test (cumulative dosing) or two-way ANOVA with Bonferroni post-hoc test (single
injection). For [35S]GTPγS autoradiography, net-stimulated [35S]GTPγS binding was determined
by (CP55,940-stimulated [35S]GTPγS binding – basal [35S]GTPγS binding). Two-way ANOVA
with Bonferroni post-hoc test was used to determine significant differences. Desensitization was
calculated as (net-stimulated [35S]GTPγS binding in THC-treated mice / net-stimulated
[35S]GTPγS binding in vehicle-treated mice), and Student’s t-tests were used based on planned
comparisons by region. Significance was determined with p < 0.05 and all results are presented
as mean ± SEM.

2.3 Results
CB1R desensitization is attenuated in the ventral midbrain and amygdala of mice that
overexpress ΔFosB
CP55,940-stimulated [35S]GTPγS binding was measured in repeated vehicle- and THCtreated ∆FosB-ON and ∆FosB-OFF mice to assess CB1R-mediated G-protein activity and
desensitization. Basal levels of [35S]GTPγS binding did not differ between any group of ΔFosB84

ON and ∆FosB-OFF mice in any region examined (data not shown). Net CP55,940-stimulated
[35S]GTPγS binding was first compared in vehicle-treated ΔFosB-ON and ∆FosB-OFF mice to
determine whether ∆FosB expression altered cannabinoid-mediated G-protein activity in drugnaïve mice. [35S]GTPγS binding in the amygdala was significantly lower (p < 0.01) in ΔFosBON mice (339 ± 16 nCi/g, when compared to ∆FosB-OFF mice (393 ± 16 nCi/g) (Figure 2.1,
Table 2.1). No differences in CP55,940-stimulated [35S]GTPγS binding were found between
vehicle-treated ∆FosB-ON and ∆FosB-OFF mice in any other region examined. The effect of
repeated THC administration on CP55,940-stimulated [35S]GTPγS binding was then compared
between ∆FosB-ON and ∆FosB-OFF mice. CP55,940-stimulated [35S]GTPγS binding was
significantly lower in repeated THC- compared to vehicle-treated brains from both ∆FosB-OFF
and ΔFosB-ON mice in almost all regions examined (Figure 2.1, Table 2.1). The exception was
the VTA, where there was no significant difference in CP55,940-stimulated [35S]GTPγS binding
between vehicle- and THC-treated ΔFosB-ON mice (118 ± 15 nCi/g for vehicle- versus 82 ± 5
nCi/g for THC-treated), but ∆FosB-OFF mice exhibited a significant reduction in CP55,940stimulated [35S]GTPγS binding after THC treatment (118 ± 14 nCi/g for vehicle versus 76 ± 7
nCi/g for THC-treated, p < 0.05).
CB1R desensitization was then calculated as previously reported (Sim-Selley and Martin,
2002) to compare results between ∆FosB-ON and ∆FosB-OFF mice. Significant differences in
CB1R desensitization between ∆FosB-OFF and ΔFosB-ON mice were found in the substantia
nigra and amygdala. In the substantia nigra, significantly less desensitization was found in
ΔFosB-ON mice (78% ± 4% of ΔFosB-ON vehicle-treated mice) compared to ∆FosB-OFF mice
(56% ± 3% of ∆FosB-OFF vehicle-treated mice) (p < 0.001, Figure 2.5 A). Similarly,
significantly less desensitization was found in the amygdala of ΔFosB-ON mice (45% ± 2% of
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ΔFosB-ON vehicle-treated mice) compared to ∆FosB-OFF mice (35% ± 3% of ΔFosB-OFF
vehicle-treated mice) (p < 0.05, Figure 2.5 A). CB1R desensitization following repeated THC
administration was not significantly different between ΔFosB-ON and ∆FosB-OFF mice in the
prefrontal cortex, nucleus accumbens, caudate-putamen, globus pallidus, hippocampus or
cerebellum.
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Figure 2.1 Net-stimulated [35S]GTPγS binding in brain regions of vehicle- and THC-treated
∆FosB overexpressing (ΔFosB-ON) and control (ΔFosB-OFF) mice expressed as percent of netstimulated binding in control vehicle-treated mice. Vehicle-treated ΔFosB-ON mice exhibited
significantly less net-stimulated [35S]GTPγS binding in the amygdala compared to ΔFosB-OFF
mice (p < 0.01, Bonferroni post-hoc test). Net-stimulated [35S]GTPγS binding was significantly
decreased in all brain regions of ΔFosB-ON and ΔFosB-OFF mice, with the exception of ventral
tegmental area of ΔFosB-ON mice. There were no differences in net-stimulated [35S]GTPγS
binding between ΔFosB-ON and ΔFosB-OFF mice following repeated THC-administration.
Data are normalized to percent vehicle-treated control mice and presented as means ± SEM (n =
8-10 mice per group) * p < 0.05, ** p < 0.01, *** p < 0.001 as compared to vehicle-treated
control. # p < 0.05, ## p < 0.01, ### p < 0.001 as compared to vehicle-treated ΔFosB-ON mice
following two-way ANOVA and Bonferroni post-hoc test.
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TABLE 2.1 Net CP55,940-stimulated [35S]GTPγS binding in brain sections from ΔFosBON and ∆FosB-OFF mice following repeated vehicle or THC treatment.
Net CP55,940-stimulated [35S]GTPγS binding (nCi/g) ± SEM
∆FosB-OFF
Vehicle

∆FosB-OFF
THC

ΔFosB-ON
Vehicle

ΔFosB-ON
THC

446 ± 21

246 ± 15***

456 ± 17

229 ± 11###

403 ± 41

198 ± 37***

443 ± 33

230 ± 27###

CaudatePutamen

205 ± 16

90 ± 13***

225 ± 10

102 ± 16###

Globus Pallidus

613 ± 54

437 ± 53*

649 ± 49

444 ± 48#

Hippocampus

273 ± 17

65 ± 7***

247 ± 17

66 ± 11###

Amygdala

393 ± 16

138 ± 11***

339 ± 12**

153 ± 7 ###

VTA

118 ± 13

76 ± 7*

118 ± 15

82 ± 5

Substantia Nigra

608 ± 48

339 ± 21***

558 ± 40

436 ± 24#

Cerebellum

293 ± 14

150 ± 19***

293 ± 36

143 ± 14###

Brain Region
Prefrontal Cortex
Nucleus
Accumbens

Brain sections were incubated in 0.04 nM [35S]GTPγS, 3 µM CP55,940 and 2 mM GDP and
autoradiograms were analyzed using densitometry. Results are expressed as net CP55,940stimulated [35S]GTPγS binding (nCi/g) ± SEM, one-way ANOVA, Bonferroni post-hoc test. * p
< 0.05, ** p < 0.01, p < 0.001 vs. ∆FosB-OFF vehicle. # p < 0.05, ### p < 0.001 vs. ΔFosB-ON
vehicle. (n = 8-10 per group)
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Figure 2.2 Representative autoradiograms showing CP55,940-stimulated [35S]GTPγS binding in
ΔFosB-OFF and ∆FosB-ON mice following repeated vehicle or THC (10-30-60 mg/kg, b.i.d.,
6.5 days) treatment in regions of the basal ganglia.
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CB1R desensitization is enhanced in the caudate-putamen and reduced in the hippocampus and
ventral midbrain of ΔcJun-ON mice
Studies were conducted to determine whether the expression of ∆cJun, a dominant
negative inhibitor of FosB-mediated transcription, would alter CB1R-mediated G-protein activity
or desensitization. ΔcJun-ON and ∆cJun-OFF mice received the same repeated THC treatment
as the ΔFosB overexpressing mice, and CP55,940-stimulated [35S]GTPγS binding was assessed
in the same regions described above. Basal levels of [35S]GTPγS binding did not differ between
any group of ΔcJun-ON and ∆cJun-OFF mice in any region examined (data not shown).
Analysis of brains from vehicle-treated mice revealed that CP55,940-stimulated [35S]GTPγS
binding in the amygdala was significantly higher in ∆cJun-ON (282 ± 15) compared to ΔcJunOFF (218 ± 16) mice (p < 0.01, Figure 2.3, Table 2.2). No significant differences were found in
CP55,940-stimulated [35S]GTPγS binding between ∆cJun-ON and ∆cJun-OFF mice in any other
region examined. Repeated THC treatment significantly reduced CP55,940-stimulated
[35S]GTPγS binding compared to vehicle-treatment in ∆cJun-ON and ∆cJun-OFF mice in all
regions examined, except for the caudate-putamen in ∆cJun-OFF mice. CP55,940-stimulated
[35S]GTPγS binding did not differ in the caudate-putamen of repeated THC- compared to
vehicle-treated ∆cJun-OFF mice (114 ± 16 nCi/g for vehicle- versus 70 ± 17 nCi/g for THCtreated, Figure 2.3, Table 2.2). In contrast, a significant decrease was found in CP55,940stimulated [35S]GTPγS binding in the caudate-putamen of ΔcJun-ON mice following repeated
THC compared to vehicle treatment (153 ± 16 nCi/g for vehicle- versus 68 ± 16 nCi/g for THCtreated, p < 0.01, Figure 2.3, Table 2.2).
CB1R desensitization was then calculated and compared between ΔcJun-ON and ∆cJunOFF mice. Significantly greater desensitization was found in the caudate-putamen of THC90

treated ΔcJun-ON (39% ± 6% of vehicle-treated ΔcJun-ON mice) compared to ∆cJun-OFF (62%
± 13% of ΔcJun-OFF vehicle-treated mice) mice (Figure 2.5 B). Significantly less CB1R
desensitization was found in the hippocampus of THC-treated ΔcJun-ON compared to ∆cJunOFF mice (37% ± 6% of ΔcJun-ON vehicle-treated mice vs. 18% ± 4% of ΔcJun-OFF vehicletreated mice, p < 0.05, Figure 2.5 B). CB1R desensitization was also less in the VTA of ∆cJunON compared to ∆cJun–OFF mice (36% ± 4% of ΔcJun-ON vehicle-treated mice vs. 24% ± 3%
of ΔcJun-OFF vehicle-treated mice, p < 0.05, Figure 2.5 B). No significant differences in
desensitization between THC-treated ∆cJun-ON and ∆cJun-OFF mice were found in any of the
other regions examined.

91

Figure 2.3 Net-stimulated [35S]GTPγS binding in brain regions of vehicle- and THC-treated
∆cJun overexpressing (ΔcJun-ON) and control (ΔcJun-OFF) mice expressed as percent of netstimulated binding in control vehicle-treated mice. Vehicle-treated ΔcJun-ON mice exhibited
significantly greater net-stimulated [35S]GTPγS binding in the amygdala compared to ΔcJunOFF mice (p < 0.01, Bonferroni post-hoc test). Net-stimulated [35S]GTPγS binding was
significantly decreased in all brain regions of THC- versus vehicle-treated ΔcJun-ON and ΔcJunOFF mice, with the exception of caudate-putamen of ΔcJun-OFF mice. There were no
differences in net-stimulated [35S]GTPγS binding between ΔcJun-ON and ΔcJun-OFF mice
following repeated THC-administration. Data are normalized to percent vehicle-treated control
mice and presented as means ± SEM (n = 8-10 mice per group) ** p < 0.01 and *** p < 0.001 as
compared to vehicle-treated control. ## p < 0.01 and ### p < 0.001 as compared to vehicletreated ΔcJun-ON mice following two-way ANOVA and Bonferroni post-hoc test.
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TABLE 2.2
Net CP55,940-stimulated [35S]GTPγS binding in brain sections from ∆cJun-OFF and
ΔcJun-ON mice following repeated vehicle or THC treatment.
Net CP55,940-stimulated [35S]GTPγS binding (nCi/g) ± SEM
Brain Region

∆cJun-OFF
Vehicle

∆cJun-OFF
THC

ΔcJun-ON
Vehicle

ΔcJun-ON
THC

340 ± 16

185 ± 13***

355 ± 13

193 ± 12###

Nucleus
Accumbens

227 ± 23

99 ± 19**

275 ± 36

155 ± 16##

CaudatePutamen

114 ± 16

70 ± 17

153 ± 16

68 ± 16##

Globus Pallidus

535 ± 30

244 ± 36***

486 ± 44

279 ± 24###

Hippocampus

107 ± 9

19 ± 13***

118 ± 36

44 ± 23###

Amygdala

218 ± 16

62 ± 9***

282 ± 15**

100 ± 15###

VTA

274 ± 17

66 ± 7***

247 ± 18

79 ± 10###

Substantia Nigra

467 ± 29

260 ± 28***

479 ± 29

277 ± 29###

Cerebellum

250 ± 19

128 ± 11***

227 ± 24

126 ± 16###

Prefrontal Cortex

Brain sections were incubated in 0.04 nM [35S]GTPγS, 3 µM CP55,940 and 2 mM GDP and
autoradiograms were analyzed using densitometry. Results are expressed as net CP55,940stimulated [35S]GTPγS binding (nCi/g) ± SEM, one-way ANOVA, Bonferroni post-hoc test. **
p < 0.01, ***p < 0.001 vs. ∆cJun-OFF vehicle. ## p < 0.01, ### p < 0.001 vs. cJun-ON vehicle.
(n = 8-10 per group)
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Figure 2.4 Representative autoradiograms showing CP55,940-stimulated [35S]GTPγS binding in
ΔcJun-OFF and -ON mice following repeated vehicle or THC (10-30-60 mg/kg, b.i.d., 6.5 days)
treatment in regions of the basal ganglia.
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Figure 2.5 Net-stimulated [35S]GTPγS binding in ∆FosB (A) and ∆cJun (B) overexpressing
mice expressed as a percent of net-stimulated [35S]GTPγS binding in the respective vehicletreated mice. As a percentage of their respective vehicles, ΔFosB-ON mice had less
desensitization following repeated THC administration in substantia nigra (**p < 0.001) and
amygdala (*p < 0.05). ΔcJun-ON mice had less desensitization in hippocampus (*p < 0.05) and
ventral tegmental area (*p < 0.05). Data are normalized to values in respective vehicle-treated
mice and represented as mean ± SEM, Student’s t-tests based on planned comparisons by region.
PFC, prefrontal cortex; NAC, nucleus accumbens; CPU, caudate-putamen; GP, globus pallidus;
HIP, hippocampus; AMYG, amygdala; VTA, ventral tegmental area; SN, substantia nigra;
CBLM, cerebellum.
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Tolerance to THC-induced locomotor suppression is enhanced in ΔFosB-ON mice following
repeated THC treatment
THC-mediated in vivo effects were assessed to determine the effect of ∆FosB
overexpression on THC-mediated responses and the development of tolerance after repeated
THC administration. The dose-effect response for THC in ∆FosB-OFF and ΔFosB-ON mice was
first determined for THC-mediated hypothermia, antinociception and catalepsy (data not shown).
Based on these results, mice were tested with 100 mg/kg THC in subsequent studies. Responses
were then compared in repeated vehicle- versus THC-treated mice of each genotype. No
significant differences in baseline measures of body temperature, nociception or locomotor
activity were found between vehicle and THC-treated ∆FosB-ON or ∆FosB-OFF mice (data not
shown). Neither ∆FosB-ON nor ∆FosB-OFF mice exhibited baseline catalepsy. Acute THC
(100 mg/kg) injection produced hypothermia, antinociception and catalepsy in vehicle-treated
∆FosB-ON and ∆FosB-OFF mice, with no significant effect of genotype on THC-mediated
responses. Comparison of THC-mediated hypothermia in repeated vehicle- versus THC-treated
∆FosB-ON and ∆FosB-OFF mice showed a main effect of repeated treatment (F1,28 = 84.01, p <
0.001, Figure 2.6 A ). There was no significant difference in hypothermia between ΔFosB-ON
and ∆FosB-OFF mice that received repeated THC. An effect of repeated THC treatment was also
found for antinociception (F1,28 = 69.66, p < 0.001, Figure 2.1 B), but there were no significant
differences between ∆FosB-OFF and ΔFosB-ON mice that received repeated THC. A main
effect of repeated THC treatment was also found for catalepsy (F1,28 = 94.54, p < 0.001, Figure
2.6 C). Because catalepsy was not produced by100 mg/kg THC for either ∆FosB-OFF or
ΔFosB-ON mice that received repeated THC, a separate group of mice was tested at 200 mg/kg.
At this dose, these mice exhibited catalepsy, but no significant difference was found between
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groups (data not shown). There was a significant main effect of THC treatment for locomotor
activity (F1,27 = 39.00, p < 0.001, Figure 2.6 D). Bonferroni post-hoc test determined that THCtreated ΔFosB-ON mice exhibited significantly less THC-mediated locomotor suppression
compared to vehicle-treated ΔFosB-ON mice (p < 0.001, Figure 2.6 D), whereas THC-mediated
locomotor suppression was similar between vehicle- and THC-treated ∆FosB-OFF mice. A
significant interaction F(1,27 = 9.986, p < 0.01, Figure 2.6 D) was also found and Bonferroni posthoc test determined that ΔFosB-ON mice that received repeated THC administration exhibited
less locomotor suppression compared to ∆FosB-OFF mice that received repeated THC
administration (p < 0.01, Figure 2.6 D). Overall, these results show that THC-treated ∆FosBON and ∆FosB-OFF mice developed tolerance to THC-mediated hypothermia, antinociception
and catalepsy that was similar between genotypes. A genotype-specific difference in the effect
of repeated THC was found for locomotor activity, where tolerance appeared to develop in the
∆FosB-ON, but not ∆FosB-OFF, mice.
Activity data were analyzed to assess thigmotaxis, which is defined as hugging the wall
and can be considered a measure of anxiogenic-like behavior (Simon et al., 1994). There were no
significant differences in baseline measures of thigmotaxis between any groups. ΔFosB-OFF and
ΔFosB-ON mice, with mice spending equal time near the wall and center of the chamber (Figure
2.8 A). Following acute THC administration, there was a significant main effect of genotype
(F1,27 = 11.71, p < 0.05) and an interaction (F1,27 = 11.43, p < 0.05), suggesting differences in the
expression of thigmotaxis between ΔFosB-ON and ΔFosB-OFF mice. Bonferroni post-hoc test
determined that repeated THC-treated ∆FosB-OFF mice exhibited a significant increase in time
spent on the outside zone of the chamber (333% ± 109%, p < 0.05, Figure 2.8 C) compared to
∆FosB-OFF mice that received repeated vehicle (102% ± 33%) and ΔFosB-ON mice that
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received repeated THC (85% ± 23%). These findings suggest that repeated THC administration
can unmask thigmotaxis in mice that receive 100 mg/kg THC.
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Figure 2.6 THC-mediated hypothermia (A), antinociception (B), catalepsy (C) and locomotor
suppression (D) in ΔFosB overexpressing (ΔFosB-ON) and control (ΔFosB-OFF) mice
following repeated vehicle or THC treatment. ΔFosB-ON and ΔFosB-OFF mice treated with
repeated vehicle exhibited THC-mediated hypothermia, antinociception, catalepsy and locomotor
suppression and repeated THC-administration reduced these effects. ΔFosB-ON mice exhibited
significantly less THC-mediated locomotor suppression following repeated THC administration
compared to ΔFosB-OFF mice that received repeated THC administration (p < 0.001 THCtreated ∆FosB-ON vs. THC-treated ΔFosB-OFF mice). Data are presented as mean percent of
respective vehicle ± SEM (n = 8 mice per group). * p < 0.05, *** p < 0.001 as compared to
vehicle-treated control. # p < 0.05 ###, p < 0.001 compared to vehicle-treated ΔFosB-ON mice.
^^, p < 0.01 compared to THC-treated control mice. Two-way ANOVA following Bonferroni
post-hoc test.
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Tolerance to THC-mediated catalepsy is reduced, whereas tolerance to locomotor suppression is
enhanced, in ΔcJun-ON mice following repeated THC administration
∆cJun-ON and ∆cJun-OFF mice were assessed to determine whether blocking ΔFosBmediated transcription would affect THC-mediated in vivo effects or tolerance. No significant
differences were found in baseline measures of body temperature, nociception, or locomotor
activity between any groups (data not shown). Acute THC administration in repeated vehicletreated ΔcJun-OFF and ΔcJun-ON mice, produced hypothermia, antinociception, catalepsy and
locomotor suppression. THC-mediated responses were then compared between THC- and
vehicle-treated mice of each genotype. There was a significant main effect of repeated treatment
on hypothermia (F1, 32 = 80.98, p < 0.001, Figure 2.7 A), but not a significant interaction between
treatment and genotype. Bonferroni post-hoc test determined no significant difference between
ΔcJun-ON and ΔcJun-OFF mice that received either repeated vehicle or THC treatments.
Similarly, there was a significant main effect of repeated treatment for antinociception (F 1, 32 =
84.15, p < 0.001, Figure 2.7 B) in both ΔcJun-ON mice and ΔcJun-OFF mice. Bonferroni posthoc test determined no differences between genotypes for this measure. For catalepsy, there was
a significant main effect of treatment (F1, 30 = 58.66, p < 0.001, Figure 2.7 C), as well as a
significant main effect of genotype (F1, 30 = 6.36, p < 0.05) and an interaction (F1, 30 = 6.36, p <
0.05). Bonferroni post-hoc test determined that ΔcJun-ON mice exhibited significantly more
THC-induced catalepsy compared to ΔcJun-OFF mice (p < 0.001, Figure 2.7 C). Likewise,
there was a significant main effect of treatment for locomotor suppression in ΔcJun-ON and
ΔcJun-OFF mice (F1, 30 = 59.57, p < 0.001, Figure 2.7 D), as well as a significant main effect of
genotype (F1, 30 = 6.36, p < 0.05) and an interaction (F1, 30 = 6.36, p < 0.05). Bonferroni post-hoc
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test determined that ΔcJun-ON mice that received repeated THC administration exhibited less
locomotor suppression compared to control mice that received repeated THC administration (p <
0.01, Figure 2.7 D). These results indicate that less tolerance to THC-mediated catalepsy and
more tolerance to THC-mediated locomotor suppression developed in ∆cJun-OFF compared to
∆cJun-ON mice, whereas tolerance to hypothermia and antinociception did not differ between
genotypes. Thigmotaxis was also measured in ΔcJun-ON and ∆cJun-OFF mice. There was no
significant difference in baseline or THC-induced thigmotaxis between ΔcJun-OFF and ΔcJunON mice following either repeated vehicle or THC administration, (Figure 2.8 B and D).
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Figure 2.7

THC-mediated hypothermia (A), antinociception (B), catalepsy (C) and locomotor

suppression (D) in ΔcJun overexpressing (ΔcJun-ON) and control (ΔcJun-OFF) mice following
repeated vehicle or THC treatment. ΔcJun-OFF and ΔcJun-ON mice treated with repeated
vehicle exhibited THC-mediated hypothermia, antinociception, catalepsy and locomotor
suppression and repeated THC-administration reduced these effects. ΔcJun-ON mice that
received repeated THC administration exhibited significantly less catalepsy compared to control
mice (p < 0.001). ΔcJun-ON mice that received repeated THC administration also exhibited
signficantly less locomotor suppression compared to control mice (p < 0.01). Data are presented
as percent of respective vehicle with mean ± SEM (n = 8-10 mice per group). * p < 0.05, *** p <
0.001 as compared to vehicle-treated control. # p < 0.05 ###, p < 0.001 compared to vehicletreated ΔcJun-ON. ^^^, p < 0.001 compared to THC-treated control mice. Two-way ANOVA
following Bonferroni post-hoc test.
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Figure 2.8 Baseline thigmotaxis in (A) ΔFosB-OFF and ΔFosB-ON mice and (B) ΔcJun-OFF
and ΔcJun-ON mice. Baseline thigmotaxis did not differ for either ΔFosB-ON/OFF or ΔcJunON/OFF mice following either repeated vehicle or THC. (C) ΔFosB-OFF mice that received
repeated THC administration exhibited significantly greater THC-mediated thigmotaxis
compared to both control mice that received repeated vehicle (p < 0.05) and ΔFosB-ON mice
that received repeated THC (p < 0.05). (D) THC-mediated thigmotaxis was similar in ΔcJunON/OFF mice that received either repeated vehicle or THC. Data are presented as percent of
time spent in the outside zone/time spent in the inside zone x 100 ± SEM (n = 8-10 mice per
group). * p < 0.05 compared to vehicle-treated control mice and ^ p < 0.05 compared to THCtreated control mice following two-way ANOVA following Bonferroni post-hoc test.
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2.4 Discussion
The present study was conducted to determine whether expression of ∆FosB regulates
CB1R-mediated G-protein signaling after acute or repeated activation by cannabinoids. Regional
analyses in brains from vehicle-treated mice showed that overexpression of ∆FosB attenuated
CP55,940-stimulated [35S]GTPγS binding in the amygdala, whereas functional inactivation of
∆FosB by expression of ∆cJun enhanced cannabinoid-stimulated activity. Expression of ∆FosB
also attenuated CB1R desensitization in the amygdala, further supporting a role for this
transcription factor in CB1R signaling in the amygdala. ∆FosB expression did not affect CB1Rmediated G-protein activity in the striatum of vehicle-treated mice, consistent with our previous
findings (Sim-Selley et al., 2011) and suggesting that the effect of ∆FosB on CB1R signaling is
region-dependent. We proposed that ∆FosB might inhibit CB1R desensitization following
repeated THC treatment based in part on the finding that THC-induced CB1R desensitization and
∆FosB induction exhibited an inverse regional relationship (Chapter 1). Overexpression of
∆FosB in D1R-positive MSNs attenuated CB1R desensitization in the substantia nigra and VTA,
targets of MSNs of the direct striatal pathway. Expression of ∆cJun in D1R and D2R positive
MSNs enhanced CB1R desensitization in the caudate-putamen and enhanced tolerance to THCmediated locomotor suppression. However, ∆cJun expression also reduced tolerance to THCmediated catalepsy and ∆FosB expression enhanced tolerance to locomotor suppression. Despite
these unexpected results, the effects of ∆FosB and ∆cJun expression on CB1R desensitization in
striatal circuits and of ∆cJun on tolerance to locomotor suppression support our hypothesis that
∆FosB can inhibit CB1R desensitization.
Bitransgenic mice overexpress ΔFosB or ΔcJun in the caudate-putamen, nucleus
accumbens, cerebral cortex and hippocampus (Chen et al., 1998; Peakman et al., 2003).
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Tolerance to THC-mediated hypothermia and antinociception did not differ between mice
overexpressing ΔFosB or ∆cJun and their controls, which agree with the restricted anatomical
overexpression of ∆FosB/∆cJun in these mice. Cannabinoid-induced hypothermia is associated
with CB1R activity in the preoptic area (Rawls et al., 2002) and antinociception involves CB1Rs
in the PAG and spinal cord (Lichtman and Martin, 1991). Both mouse lines overexpress the
appropriate transcription factor in D1R/dynorphin MSNs of the caudate-putamen and nucleus
accumbens, whereas ΔcJun is also overexpressed in D2R/enkephalin MSNs. Overexpression of
∆FosB or ∆cJun did not affect CB1R signaling the caudate-putamen or nucleus accumbens of
drug naïve mice, as we previously reported in homogenates prepared from the nucleus
accumbens (Sim-Selley et al., 2011). Mice overexpressing ΔFosB that were treated with
repeated THC did not exhibit differences in CB1R desensitization in the caudate-putamen or
nucleus accumbens when compared to control mice. Mice overexpressing ΔcJun showed
enhanced CB1R desensitization in the caudate-putamen, but no difference in the nucleus
accumbens. The finding that functional inhibition of ΔFosB by ∆cJun expression enhanced
CB1R desensitization supports our hypothesis, but ΔFosB overexpression did not enhance
desensitization as we would predict. It is possible that the result in the ΔFosB overexpressing
mice is due to the restricted overexpression to only D1R-positive MSNs. CB1Rs in the caudateputamen and nucleus accumbens are expressed by both D1R and D2R MSN populations, as well
as on glutamatergic, but not dopaminergic, afferent projections (Hohmann and Herkenham,
2000; Pickel et al., 2004). It is also possible that the dose of THC administered in this study was
sufficient to overcome the effects of ΔFosB in reducing CB1R desensitization.
CB1R desensitization was measured in the substantia nigra and VTA, the projection
regions of the caudate-putamen and nucleus accumbens, respectively. D1R/dynorphin MSNs
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comprise the direct pathway that projects from the striatum to the substantia nigra, which has a
very high density of CB1Rs, and VTA (Fitzgerald et al., 2012). Mice overexpressing ΔFosB in
D1R-positive MSNs exhibited less CB1R desensitization in both the substantia nigra and VTA,
suggesting that ΔFosB inhibited CB1R desensitization in these terminal field regions. The direct
pathway is associated with activation of locomotor activity (Kravitz et al., 2010), but it is not
clear if the locomotor suppressing effect of THC is mediated through activation of CB1Rs in this
pathway (Monory et al., 2007). THC-treated ∆cJun mice showed enhanced tolerance to THCmediated locomotor inhibition, which corresponds to the enhanced CB1R desensitization
measured in the caudate-putamen. Surprisingly, THC-treated mice that overexpressed ΔFosB
exhibited greater tolerance to locomotor suppression. However, studies have reported that
unilateral intra-nigral injections of THC alone (Sanudo-Pena et al., 1996) or in combination with
muscimol (Wickens and Pertwee, 1995) produced contralateral circling, an indicator of
hyperactivity (Amalric and Koob, 1989). Furthermore, systemic THC administration in mice
that have a unilateral lesion of the substantia nigra produced ipsilateral circling, similar to
amphetamine (Sakurai et al., 1985). Therefore, it is possible that mice overexpressing ΔFosB
exhibited less desensitization in the substantia nigra, but similar desensitization occurred in other
basal ganglia regions, therefore they exhibited greater locomotor activity. This would agree with
studies indicating that inhibition of glutamatergic neurotransmission contributes to cannabinoidmediated locomotor suppression (Monory et al., 2007).
The finding that control mice exhibited significantly more thigmotaxis when compared to
mice overexpressing ΔFosB might also be relevant to the interpretation of these data.
Thigmotaxis is considered an anxiogenic-like phenotype (Simon et al., 1994) and mice
exhibiting this behavior also tend to exhibit locomotor suppression (Hoy et al., 1999). It is
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possible that ΔFosB overexpressing mice displayed more exploratory behavior because they did
not exhibit an anxiogenic-like phenotype.
Mice overexpressing ΔcJun exhibited significantly more catalepsy following repeated
THC administration compared to controls, suggesting that less tolerance developed. Early
research suggested that the globus pallidus was involved in modulating cannabinoid-mediated
catalepsy (Wickens and Pertwee, 1993); however more recent research has also implicated the
nucleus accumbens (Sano et al., 2008). Our finding that mice overexpressing ΔcJun exhibited
less desensitization in the VTA would support this more recent finding because D1R/dynorphin
MSNs in the nucleus accumbens project to the VTA. One caveat is that there was also less
desensitization in the VTA of mice overexpressing ΔFosB, but no difference in catalepsy was
found between ∆FosB-ON and ∆FosB-OFF mice. ΔFosB bitransgenic mice are a cross between
FVB and C57BL/6J mouse strains (Chen et al., 1998), whereas ΔcJun mice are on a pure FVB
background (Peakman et al., 2003). There are ~49% more dopaminergic neurons in the VTA of
FVB mice compared to C57BL/6J mice (Nelson et al., 1996), suggesting a possible straindependent difference that could affect the results.
Overexpression of ΔcJun in both the D1R/dynorphin and D2R/enkephalin MSN
populations did not enhance desensitization in either the substantia nigra or globus pallidus, but
did reduce desensitization in the VTA. This finding suggests that dominant negative inhibition
of ΔFosB can also reduce CB1R desensitization; however, ΔcJun also inhibits the transcriptional
regulation of other Fos family members (Peakman et al., 2003), making it difficult to determine
if this effect is due to inhibition of ΔFosB alone. Moreover, this same effect was found in the
hippocampus of ΔcJun overexpressing mice, a region in which ΔFosB is not induced by repeated
THC administration (Chapter 1). This finding in the hippocampus is the first to demonstrate a
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possible mechanism through which CB1R desensitization could be inhibited in this region. It is
not clear which Fos family member(s) might be involved, but c-Fos and FosB are likely
candidates because they are also induced by THC administration in both nucleus accumbens and
hippocampus (Marie-Claire et al., 2003; Porcella et al., 1998; Rubino et al., 2006). ΔFosB is
known to regulate c-Fos induction (Renthal et al., 2008) so it is possible that overexpression of
both ΔFosB and ΔcJun could inhibit c-Fos transcription and reduce CB1R desensitization.
Overexpression of ΔFosB or ΔcJun produced opposing effects on CB1R G-protein
signaling in the amygdala of drug-naive mice. Basal levels of ∆FosB are normally low in the
amygdala, but administration of drugs of abuse, including opioids, cocaine, ethanol and THC,
induce ∆FosB expression (Perrotti et al., 2008). This suggests that CB1R signaling in the
amygdala could be altered after use of these drugs. Systemic administration of cannabinoids
typically produces a biphasic effect in anxiety-like behaviors, where lower doses produce
anxiolytic-like effects and higher doses produce anxiogenic-like effects (Viveros et al., 2005),
and these anxiogenic effects are mediated by the basolateral amygdala (Rubino et al., 2008). It
is important to note that Rubino et al. 2008 found that these anxiogenic effects were evident at
lower doses of THC (1 µg/microinjection) but not at higher doses. The amygdala is also
involved in drug reinstatement as research suggests its involvement in consolidation of drugpaired cues (Luo et al., 2013). Specifically, excitotoxic lesion of the basolateral amygdala
abolishes cocaine conditioned place preference (Fuchs et al., 2002) and heroin-induced
reinstatement (Fuchs and See, 2002).
Following repeated THC administration, there was a significant difference between
ΔFosB-ON and ΔFosB-OFF mice for both CB1R-desensitization in amygdala and THCmediated thigmotaxis. Mice overexpressing ΔFosB had significantly less CB1R desensitization
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in the amygdala and also exhibited a similar amount of thigmotaxis as mice that received
repeated vehicle. It appears that significant desensitization in amygdala can unmask an
anxiogenic-like phenotype in mice given 100mg/kg THC. The differences in CB1R G-protein
signaling in the amygdala are surprising because neither ΔFosB nor ΔcJun overexpression is
found in the amygdala of these transgenic mice (Chen et al., 1998; Peakman et al., 2003), which
suggests that these effects result from afferent projections to amygdala from another brain
region. Immunohistochemical and electron microscopic data suggest that CB1Rs are found
primarily on cholecystokinin (CCK)-positive GABAergic interneurons and on symmetrical
(glutamatergic) synapses in the amygdala (Katona et al., 2001; Marsicano and Lutz, 1999; Tsou
et al., 1998).
Overexpression of either ΔFosB or ΔcJun reduced CB1R desensitization in a brain
region-dependent manner. These results suggest that transcriptional regulation of CB1Rs by Fos
family members regulates desensitization in different brain regions. Inhibition of ERK
phosphorylation modulated CB1R desensitization in the caudate-putamen and cerebellum, but
not in the prefrontal cortex and hippocampus (Rubino et al., 2005). However, it is not known
whether ΔFosB or ΔcJun modulates ERK activity. Another possible mechanism could be the
repression of c-Fos expression by ΔFosB (Renthal et al., 2008). THC-mediated c-Fos induction
is attenuated following repeated THC administration in the striatum (Miyamoto et al., 1997) and
prefrontal cortex (Rubino et al., 2004). Therefore, inhibition of c-Fos by either ΔFosB or ΔcJun
could explain reduced CB1R desensitization in some regions.
Overall, these studies suggest a role for the Fos family of transcription factors in
modulating CB1R desensitization; specifically, ΔFosB can reduce desensitization and dominant
negative inhibition of ΔFosB can enhance CB1R desensitization in certain forebrain regions.
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Results in mice with overexpression of ΔcJun also suggest a possible role for Fos family
members in reducing CB1R desensitization, especially in hippocampus. This result may provide
a mechanism through which the memory impairing effects of THC could be mitigated.
Reductions in CB1R desensitization led to reductions in the development of tolerance to certain
cannabinoid-mediate behaviors, whereas enhanced CB1R desensitization led to enhanced
tolerance. These findings further support the hypothesis that CB1R desensitization contributes to
the development of tolerance to cannabinoid-mediated effects and provide new insights into the
role transcription factors play in mediating both desensitization and tolerance.
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Chapter 3: Role of dopamine type 1 receptors and DARPP-32 in THC-mediated induction
of ΔFosB in forebrain regions
3.1 Introduction
Cannabinoids including THC, the primary psychoactive constituent of marijuana,
produce rewarding and motor effects by activating CB1Rs in the mesolimbic and nigrostriatal
systems (Haring et al., 2011; Shi et al., 2005; Steiner et al., 1999; Tanda and Goldberg, 2003).
Anatomical and functional studies have shown that cannabinoid-mediated reward and motor
effects are produced by interactions of CB1Rs with dopamine systems in these circuits
(Fitzgerald et al., 2012; Glass and Felder, 1997; Julian et al., 2003; Seif et al., 2011). For
example, CB1Rs enhance dopamine release in the striatum directly and by regulating the activity
of midbrain dopaminergic neurons (Cheer et al., 2003; Gardner, 2005a; Wu and French, 2000).
CB1Rs in the caudate-putamen and nucleus accumbens are located on both axonal projections
from other regions, including glutamatergic projections from the cortex, and expressed by
GABAergic MSNs of the direct and indirect pathways, which predominantly express D1Rs and
dynorphin or D2Rs and enkephalin, respectively (Hohmann and Herkenham, 2000; Pickel et al.,
2004). THC produces some of the same cellular effects as other drugs of abuse, including an
increase in phosphorylation of the dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa
(DARPP-32) at threonine 34 (Bateup et al., 2008; Borgkvist et al., 2008) and induction of ∆FosB
in the striatum (McClung et al., 2004; Perrotti et al., 2008)(Chapter 1). Dopamine D1Rs and
DARPP-32 increase neuronal activity in D1R/dynorphin MSNs, and this activity is thought to
contribute to the rewarding effects of drugs of abuse (Le Foll et al., 2009). Currently, the role of
the D1R system in THC-mediated ∆FosB induction in the striatum is not clearly defined.
∆FosB, a stable transcription factor, accumulates in striatal neurons during repeated
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treatment with drugs of abuse (Perrotti et al., 2008). Transgenic overexpression of ΔFosB
enhanced the rewarding effects of cocaine (Colby et al., 2003) and morphine (Zachariou et al.,
2006a), whereas expression of a dominant negative form of its binding partner, ∆cJun, reduced
conditioned place preference at lower doses of cocaine and at higher doses of morphine
(Peakman et al., 2003; Zachariou et al., 2006a). We reported that repeated THC-mediated ∆FosB
induction in the striatum was abolished in mice lacking CB1Rs (Chapter 1). Anatomical studies
showed that CB1Rs were both co-localized with ∆FosB in striatal neurons and also expressed in
puncta surrounding FosB/ΔFosB positive neurons (Chapter 1). The latter observation suggests
that THC might trans-synaptically induce ∆FosB in striatal neurons. CB1Rs enhance dopamine
release in the striatum (Oleson and Cheer, 2012), which would activate D1Rs and provides a
potential trans-synaptic mechanism for ∆FosB induction. Consistent with this hypothesis,
ΔFosB expression is primarily restricted to the D1R/dynorphin containing MSNs in the striatum
following repeated cocaine administration (Moratalla et al., 1996; Nye et al., 1995). Moreover,
previous studies showed that the D1R antagonist, SCH23390, blocked induction of ΔFosB by
cocaine (Nye et al., 1995) and morphine (Muller and Unterwald, 2005). Thus, by analogy with
other abused drugs, THC might also induce ∆FosB via D1R activation.
The role of D1Rs in the central nervous system has been demonstrated for several drugs
of abuse, but the signaling pathways that mediate these effects are under investigation. D1R
agonists and psychomotorstimulants increase phosphorylation of DARPP-32 at threonine 34 in
D1R/dynorphin MSNs (Bateup et al., 2008). When DARPP-32 is phosphorylated at this site, it
becomes an inhibitor of protein phosphatase-1, which results in the enhancement in the
phosphorylation of substrates downstream of protein kinase A (PKA) (Desdouits et al., 1995;
Hemmings et al., 1984a; Kwon et al., 1997). ΔFosB induced by repeated cocaine administration
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was attenuated in mice with genetic deletion of DARPP-32 or mutation of the threonine 34 site
to prevent protein kinase A (PKA)-mediated phosphorylation (Hiroi et al., 1999; Zachariou et al.,
2006b). The CB1R agonist CP55,940 increased phosphorylation of DARPP-32 at threonine 34
in the striatum, which was blocked by adenosine 2A (A2A) or D2R antagonists and in mice with
genetic deletion of these receptors (Andersson et al., 2005). Administration of THC also
increased phosphorylation of DARPP-32 at threonine 34 in the striatum, and this effect was
blocked by antagonism of A2A or D1 receptors (Borgkvist et al., 2008). DARPP-32 also
contributes to cannabinoid-mediated in vivo effects. Genetic deletion of DARPP-32 or mutation
of the PKA site at threonine 34 reduced CP55,940-induced catalepsy (Andersson et al., 2005).
Phosphorylation of DARPP-32 at threonine 34 is known to increase PKA activity (Blank et al.,
1997), which could also interfere with the development of tolerance to this cannabinoidmediated effect because inhibition of PKA has been shown to reduce tolerance to the locomotor
suppressing effects of THC (Bass et al., 2004).
While it is clear that D1Rs can modulate the induction of ∆FosB produced by
psychomotorstimulants and opioids, the role of D1 Rs in THC-mediated ∆FosB induction is not
known. The current study was conducted to determine whether THC-mediated induction of
ΔFosB is D1R-dependent and whether THC-induced ∆FosB is localized to D1R-positive MSNs
of the caudate-putamen and nucleus accumbens. The role of DARPP-32 in THC-mediated
∆FosB induction was also investigated because this protein is downstream of dopamine receptors
and also modulates ΔFosB induction. The contribution of dopamine-mediated signaling to THCmediated in vivo responses was determined by testing naïve and THC-treated DARPP-32
knockout mice. Results showed that D1Rs and DARPP-32-mediated signaling are involved in
THC-mediated ΔFosB induction and that genetic deletion of DARPP-32 enhances both acute
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THC-mediated locomotor suppression and tolerance to this response.

3.2 Materials and Methods
Materials
Sources of THC and antibodies are provided in Chapter 1. Goat anti-preprodynorphin
antibody was purchased from Millipore (Billerica, MA). (R)-(+)-7-Chloro-8-hydroxy-3-methyl1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) and (6aS-trans)-11Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol
hydrobromide (SCH39166) were purchased from Tocris Bioscience (Minneapolis, MN). Refer
to Chapter 1 for secondary antibodies and mounting media. All other reagent grade chemicals
were obtained from Sigma Chemical Co. or Fisher Scientific.
Subjects and Drug treatments
Male ICR mice (n=8 per group) (Harlan Laboratories, Indianapolis, IN) weighing 25-30
grams were used to assess the effect of D1R antagonists on THC-mediated ∆FosB induction. All
mice were housed four to six per cage and maintained on a 12-hr light/dark cycle in a
temperature controlled environment (20-22°C) with food and water available ad libitum. THC
was dissolved in a 1:1:18 solution of ethanol, emulphor and saline (vehicle). SCH23390 and
SCH39166 were dissolved in saline. SCH23390 is a high affinity D1R antagonist with agonist
properties at 5HT1/2c receptors and SCH39166 is a high affinity D1R antagonist with lower
affinity for D2R, 5-HT and A2A receptors. Mice were pretreated with an intraperitoneal (i.p.)
injection of either saline or 1 mg/kg SCH23390 or SCH39166 and 30 minutes later were injected
subcutaneously (s.c.) with either THC (ramping doses of 10-20-30 mg/kg increased every 2
days) or vehicle at 08:00 and 16:00 h for 6 days. On day 7, mice received morning injections
114

only, and 24 hours later mice were sacrificed by decapitation and brains were extracted. A
separate group of male ICR mice (n = 4) was treated with THC or vehicle using the same
treatment protocol for co-localization studies.
DARPP-32 knockout mice on a C57BL/6J background and littermate controls (Hiroi et
al., 1999)(n = 8 per group) were used to determine the role of DARPP-32 in THC-mediated
∆FosB induction and THC-mediated in vivo effects. Mice were treated using a protocol that we
have shown produces ΔFosB induction in C57BL/6J mice (Chapter 1). Mice were injected (s.c.)
with 10 mg/kg THC or vehicle at 08:00 and 16:00 h for 13 days. On day 14, mice received only
a single injection (08:00), and 24 hours later mice were assessed for THC-induced
antinociception, hypothermia, catalepsy and locomotor suppression. 24 hours after in vivo
assessment, mice were sacrificed by decapitation and brains were extracted. All experiments
were performed with the approval of the Institutional Animal Care and Use Committee at
Virginia Commonwealth University in accordance with the National Institutes of Health guide
for the care and use of Laboratory animals 7th edition.
Brain Dissections
Brain regions were dissected as described in Chapter 1. For these experiments, the
amygdala dissection included the central nucleus and basolateral and basomedial nuclei.
Immunoblot
Immunoblots were conducted as detailed in the Methods section of Chapter 1.
Immunohistochemistry
Preprodynorphin was used as a marker for D1R/dynorphin MSNs to determine the
localization of ΔFosB/FosB following repeated THC administration in this MSN population.
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Refer to Chapter 1 for incubation and washing methods. Slides were incubated overnight at 4°C
in PBS containing 2.5% normal donkey serum and antibodies against preprodynorphin (1:500;
guinea-pig) and FosB/ΔFosB (1:500; sc-48/rabbit). Refer to Chapter 1 for capturing methods.
Images were taken at 40 X magnification and the number of cells that were positive for DAPI
was counted.

Then, the numbers of cells that contained FosB/ΔFosB-ir + dynorphin-ir or

FosB/ΔFosB-ir alone were counted. ~40-50 cells per image for 4 separate animals per treatment
group were counted and averaged together.
Assessment of in vivo responses
The measures of nociception, body temperature, spontaneous activity and catalepsy were
done as described in Chapter 2. Baseline measures were assessed for all behaviors, and then
separate groups of mice were injected (i.p.) with 70 mg THC or vehicle. Locomotor suppression
was determined 20 minutes after THC injection and measures for catalepsy, antinociception and
hypothermia were assessed 30, 60, 120 and 180 minutes after injection, based on the published
time course for these cannabinoid-mediated affects (Andersson et al., 2005; Wiebelhaus et al.,
2012). Hyperreflexia was also assessed (Dewey 1986; Patel 2001) and defined as “popcorning”
or an exaggerated movement due to auditory or tactile cues.
Statistical Analysis
For all experiments, data were analyzed with Prism® version X (GraphPad Software, San
Diego, CA). For comparisons of ΔFosB expression in D1R antagonist studies, one-way
ANOVAs were performed with Bonferroni post-hoc test. For co-localization studies, the number
of cells containing either FosB/ΔFosB-ir + dynorphin-ir or FosB/ΔFosB-ir alone was normalized
to the total number of DAPI-containing cells. One-way ANOVA and Bonferroni post-hoc test
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were used to determine significance. For comparison of ΔFosB expression in DARPP-32
knockout mice, a two-way ANOVA was used with Bonferroni post-hoc test. For comparisons in
the development of tolerance to hypothermia and antinociception, a repeated measures ANOVA
was used with Bonferroni post-hoc test. For comparisons of catalepsy and locomotor activity, a
two-way ANOVA was used with Bonferroni post-hoc test. For hyperreflexia, a z-test was used
with a Bonferroni adjustment. Data are represented as % of appropriate controls ± SEM, % MPE
((test latency - baseline) /(total length of test)] X 100) ± SEM. Significance was determined with
p < 0.05.
3.3 Results
SCH23390 blocks THC-mediated induction of ΔFosB
Mice received the D1R antagonist SCH23390 or saline prior to administration of THC or
vehicle during the 6.5 days of treatment, and ΔFosB expression was measured 24 hours after the
last injection. Data were first assessed to determine whether pretreatment with SCH23390
altered ∆FosB expression in vehicle-treated mice. ∆FosB-ir was significantly increased by 55%
± 15% in the nucleus accumbens of SCH23390/vehicle compared to saline/vehicle treated mice
(p < 0.05). Treatment with SCH23390/THC increased ∆FosB expression by 77% ± 21 %
compared to saline/vehicle control mice (p < 0.01) (Figure 3.2 C), but there was no significant
difference in ∆FosB-ir between SCH23390/vehicle and SCH23390/THC-treated groups. There
were no significant differences between mice pretreated with saline or SCH23390 in the other
regions examined (Figure 3.2). Because SCH23390 administration induced ∆FosB-ir in the
nucleus accumbens, subsequent data are presented as the percent of ∆FosB-ir in the respective
vehicle controls. The effect of THC on ∆FosB expression was determined by comparing saline
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pretreated THC- and vehicle-treated mice. Repeated THC administration significantly increased
ΔFosB expression compared to saline/vehicle control in the prefrontal cortex by 80% ± 12%
(F3,28, p <0.05; Figure 3.1 A), in caudate-putamen by 64% ± 17% (F3,28, p <0.01; Figure 3.1 B),
in nucleus accumbens by 49% ± 9% (F3,28, p <0.05; Figure 3.1 C) and in amygdala by 64% ±
24% (F3,28, p < 0.05, Figure 3.1 D). Pretreatment with SCH23390 blocked THC-mediated ΔFosB
induction in all four regions examined, and the levels of ∆FosB-ir did not significantly differ
between SCH23390/vehicle and SCH23390/THC-treated mice in any region. These data
indicate that D1Rs are necessary for THC-mediated induction of ∆FosB in these forebrain
regions.
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Figure 3.1 Pretreatment with the D1R antagonist SCH23390 blocked THC-mediated ΔFosB
induction in the prefrontal cortex, caudate-putamen, nucleus accumbens and amygdala following
repeated THC administration. Graphs show ΔFosB-ir expressed as % respective saline/vehicle
and SCH23390/vehicle controls ± SEM in A) prefrontal cortex, B) caudate-putamen, C) nucleus
accumbens and D) amygdala. Repeated THC administration alone significantly increased
ΔFosB induction in the prefrontal cortex, caudate-putamen, nucleus accumbens and amygdala,
which was blocked by pretreatment with SCH23390. One-way ANOVAs were performed to
determine significance with Bonferroni post-hoc test * p < 0.05 compared to saline/vehicle
treated mice. SV = saline/vehicle, ST = saline/THC, DV = SCH23390/vehicle, DT =
SCH23390/THC
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Figure 3.2 Repeated administration of SCH23390/vehicle significantly increased ΔFosB in the
nucleus accumbens. Graphs representing ΔFosB-ir expressed as % saline/vehicle mice ± SEM in
A) prefrontal cortex, B) caudate-putamen, C) nucleus accumbens and D) amygdala with
representative immunoblots. In the nucleus accumbens, repeated SCH23390 treatment in
combination with vehicle or THC treatment significantly increased ΔFosB expression compared
to saline/vehicle controls by 55% ± 15% (p < 0.05) and 77% ± 21% (p < 0.01), respectively.
One-way ANOVAs were performed to determine significance with Bonferroni post-hoc test * p
< 0.05 and ** p < 0.01 compared to saline/vehicle controls. SV = saline/vehicle, ST =
saline/THC, DV = SCH23390/vehicle, DT = SCH23390/THC
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SCH39166 blocks THC-mediated induction of ΔFosB
SCH23390 administration increased ∆FosB-ir in the nucleus accumbens and can act as an
agonist at 5HT1 and 5HT2c receptors. Therefore mice were pretreated with another D1R
antagonist, SCH39166, to confirm the results obtained using SCH23390. ∆FosB-ir was first
assessed in vehicle-treated mice to determine whether SCH39166 treatment affected ∆FosB
expression. No significant differences were found in ∆FosB-ir between SCH39166/vehicle and
saline/vehicle treated mice in any region examined (Figure 3.4). The effect of THC treatment on
∆FosB-ir was then determined by comparing results in brains from saline-pretreated vehicle- and
THC-treated mice. Saline/THC treatment significantly increased ΔFosB expression compared to
saline/vehicle control in the prefrontal cortex, by 93% ± 30% (F3,28, p < 0.05; Figure 3.3 A), in
caudate-putamen by 73% ± 18% (F3,28, p < 0.001; Figure 3.3 B), in nucleus accumbens 58% ±
16% (F3,28, p < 0.001; Figure 3.3 C) and in amygdala by 61% ± 11% (F3,28, p < 0.01; Figure 3.3
D). In the nucleus accumbens, treatment with SCH39166 and THC also significantly increased
ΔFosB expression compared to the saline/vehicle treatment group 38% ± 4% (F3,28, p < 0.05;
Figure 3.4 C). SCH39166 pretreatment blocked THC-induced ΔFosB expression in all brain
regions examined, because ∆FosB-ir did not significantly differ between brains from
SCH39166/THC and SCH39166/vehicle-treated mice. These results further support the
hypothesis that D1Rs are necessary for THC-mediated induction of ∆FosB in the forebrain.
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Figure 3.3 Pretreatment with the D1R antagonist SCH39166 blocked ΔFosB induction in the
prefrontal cortex, caudate-putamen, nucleus accumbens and amygdala when administered during
repeated THC treatment. Graphs show ΔFosB-ir expressed as % respective saline/vehicle or
SCH39166/vehicle mice ± SEM in A) prefrontal cortex, B) caudate-putamen, C) nucleus
accumbens and D) amygdala. Repeated THC administration alone significantly increased
ΔFosB-ir in the prefrontal cortex, caudate-putamen, nucleus accumbens and amygdala, which
was blocked by pretreatment with SCH39166. One-way ANOVAs were performed to determine
significance with Bonferroni post-hoc test * p < 0.05, ** p < 0.01, ***p < 0.001 compared to
saline/vehicle mice. SV = saline/vehicle, ST = saline/THC, DV = SCH39166/vehicle, DT =
SCH39166/THC
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Figure 3.4 The combination of the D1R antagonist SCH39166 and THC significantly increased
ΔFosB expression in nucleus accumbens compared to saline/vehicle control mice. Graphs
representing ΔFosB-ir expressed as % saline/vehicle mice ± SEM in A) prefrontal cortex, B)
nucleus accumbens, C) caudate-putamen and D) amygdala with representative immunoblots. In
nucleus accumbens, repeated SCH39166 treatment in combination with THC significantly
increased ΔFosB expression above saline/vehicle control mice 38% ± 5% (p < 0.05). Data
represented as % saline/vehicle control ± SEM. One-way ANOVAs were performed to
determine significance with Bonferroni post-hoc test * p < 0.05 compared to saline/vehicle
controls. SV = saline/vehicle, ST = saline/THC, DV = SCH23390/vehicle, DT =
SCH23390/THC
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FosB/ΔFosB positive nuclei co-localize with dynorphin-ir in striatal cells
Results showing that D1R antagonists block THC-mediated ∆FosB induction suggest that
THC induces ∆FosB in D1R positive MSNs. However, anatomical data to support this
conclusion are lacking. Therefore, dual immunohistochemistry was performed using antibodies
that recognize FosB/ΔFosB and preprodynorphin, which is co-localized with D1Rs in MSNs of
the direct pathway. Dynorphin was visualized in green and FosB/∆FosB-ir was visualized in red
(Figure 3.5 and 3.6). DAPI (blue) was used to identify cell nuclei. Dynorphin diffusely stained
both the dorsal and ventral striatum and appeared to be localized in striatal cells. This was
confirmed by DAPI staining, which identified cell nuclei of dynorphin-ir cells. FosB/ΔFosB-ir
appeared to be localized in cell nuclei, which was confirmed by DAPI staining (Figure 3.5 A and
E and Figure 3.6 A and E). FosB/ΔFosB-ir positive cells were seen in brains from vehicle-treated
mice in both the caudate-putamen (Figure 3.5 B) and nucleus accumbens (Figure 3.6 B). Cell
counting showed that approximately half of DAPI-positive cells contained both FosB/ΔFosB-ir
and dynorphin-ir in both the caudate-putamen (49% ± 3%, Figure 3.5 D and I) and nucleus
accumbens (47% ± 2%, Figure 3.6 D and I). The number of dual FosB/ΔFosB-ir and dynorphinir cells was significantly greater than the number of cells that only expressed FosB/ΔFosB-ir
(26% ± 2% in caudate-putamen and 31% ± 2% in nucleus accumbens (p < 0.001). Following
repeated THC administration, the percent of DAPI positive cells that contained both
FosB/ΔFosB-ir and dynorphin-ir did not differ from vehicle-treated mice (55% ± 2% and 52% ±
1%, caudate-putamen (Figure 3.5 G and I) and nucleus accumbens (Figure 3.6 G and I),
respectively). The number of cells positive for FosB/ΔFosB-ir and dynorphin-ir cells was
significantly greater than the number of FosB/ΔFosB-ir cells (26% ± 2% in caudate-putamen and
25% ± 4% in nucleus accumbens (p < 0.001)). In both regions, ~75%-85% of DAPI-positive
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cells co-localized with FosB/ΔFosB-ir, which would suggest that FosB/ΔFosB-ir is
predominantly expressed in MSNs, which represent ~95% of neurons of striatum.
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Figure 3.5 Representative images (40X) showing FosB/∆FosB-ir (red), Dynorphin (green) and
DAPI (blue) in the caudate-putamen of mice that received repeated vehicle (top row) or THC
(bottom row) treatment. In both vehicle (B) and THC (F) treated mice, FosB/ΔFosB-ir was
localized to the nucleus, which was visualized with DAPI (A and E), while dynorphin-ir (C,
vehicle; G, THC) was localized to the cell body. (D and H) The majority of FosB/ΔFosB-ir cells
were also positive for dynorphin-ir in both vehicle- and THC-treated mice (I). The number of
cells positive for either FosB/ΔFosB-ir and dynorphin-ir (white bar) or FosB/ΔFosB-ir (black
bar) cells as a percentage of DAPI-positive cells, were compared and results determined that a
significantly higher percentage of cells contained both FosB/ΔFosB-ir and dynorphin-ir in both
vehicle- and THC-treated mice (p < 0.001). One-way ANOVAs were performed with
Bonferroni post-hoc test. *** p < 0.001 compared to FosB/ΔFosB-ir alone in vehicle-treated.
### p < 0.001 compared to FosB/ΔFosB-ir alone in THC-treated.
126

Figure 3.6 Representative images (40X) showing FosB/∆FosB-ir (red), Dynorphin (green) and
DAPI (blue) in the nucleus accumbens of mice that received repeated vehicle (top row) or THC
(bottom row) treatment. In both vehicle (B) and THC (F) treated mice, FosB/ΔFosB-ir was
localized to the nucleus, which was visualized with DAPI (A and E), while dynorphin-ir (C,
vehicle; G, THC) was localized to the cell body. (D and H) The majority of cells positive for
FosB/ΔFosB-ir were also positive for dynorphin-ir in both vehicle- and THC-treated mice (I).
The number of cells positive for either FosB/ΔFosB-ir and dynorphin-ir (white bar) or
FosB/ΔFosB-ir (black bar) cells as a percentage of DAPI-positive cells, were compared and
results determined that a significantly higher percentage of cells contained both FosB/ΔFosB-ir
and dynorphin-ir in both vehicle- and THC-treated mice (p < 0.001). One-way ANOVAs were
performed with Bonferroni post-hoc test. *** p < 0.001 compared to FosB/ΔFosB-ir alone in
vehicle-treated. ### p < 0.001 compared to FosB/ΔFosB-ir alone in THC-treated.
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Acute, but not repeated, THC-mediated FosB induction is abolished in DARPP-32 knockout mice
DARPP-32 knockout and littermate wild-type mice were treated for 13.5 days with THC
or vehicle and then assessed for in vivo measures by administering a single injection of THC (70
mg/kg) or vehicle. Therefore, mice of each genotype were treated as follows: repeated vehicle +
acute vehicle (VEH-VEH group), repeated vehicle + acute THC (VEH-THC) and repeated THC
+ acute THC (70 mg/kg) (THC-THC). Mice were first tested in the in vivo measures, and then
brains from the six groups (VEH-VEH, VEH-THC, THC-THC for DARPP-32 knockout and
wild-type mice) were collected to measure ∆FosB-ir. In the caudate-putamen, A 3 X 2- way
ANOVA (treatment X genotype) determined a significant main effect of both treatment (F 2, 36 =
68.58 p < 0.0001) and an interaction (F 2,36 = 12.40, p < 0.001) (Figure 3.7 A). ΔFosB expression
did not significantly differ between VEH-VEH-treated wild type and DARPP-32 knockout mice
in the caudate-putamen. An acute injection of THC in repeated vehicle-treated mice (VEHTHC) significantly increased ΔFosB expression in wild type mice (32% ± 4%, p < 0.001, relative
to VEH-VEH wild type mice, Figure 3.7 A), but not in DARPP-32 knockout mice (4% ± 5%,
relative to VEH-VEH wild type mice, Figure 3.7 A). Acute THC-induced ΔFosB-ir in wild type
mice also significantly differed from ∆FosB-ir in DARPP-32 knockout mice (p < 0.001, Figure
3.7 A). Following repeated THC administration, ΔFosB expression was significantly increased
in both wild type (50% ± 5%, p < 0.001, relative to VEH-VEH wild type mice) and DARPP-32
knockout (60% ± 6%, p < 0.001, relative to VEH-VEH wild type mice) mice. The level of
∆FosB-ir in DARPP-32 knockout mice was also significantly different from DARPP-32
knockout mice that had received only vehicle (VEH-VEH) (p < 0.001, Figure 3.7 A). ΔFosB
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expression did not significantly differ between wild type and DARPP-32 knockout mice that
received repeated THC treatment (THC-THC).
In the nucleus accumbens, a 3 X 2- way ANOVA (treatment X genotype) determined a
significant main effect of both treatment (F 2, 36 = 13.71 p < 0.0001) and genotype (F 1,36 = 12.04,
p < 0.05) (Figure 3.7 B). ΔFosB expression did not significantly differ between wild type and
DARPP-32 knockout mice that received only vehicle (VEH-VEH). There was a significant
difference in ∆FosB-ir between vehicle-treated wild type and DARPP-32 knockout mice that
received an acute injection of THC (VEH-THC) (26 % ± 10% versus -15% ± 11%, p < 0.05,
relative to VEH-VEH wild type mice, Figure 3.7 B). There was a significant increase in ΔFosB
expression following repeated THC administration in wild type (34% ± 7%, p < 0.05, Figure 3.7
B), but not DARPP-32 knockout (16% ± 16%, Figure 3.7 B) mice compared to wild type
vehicle-treated mice. ΔFosB expression was not significantly different between wild type and
DARPP-32 knockout mice that received repeated THC treatment (THC-THC). These results
show that deletion of DARPP-32 blocked ∆FosB induction produced by an acute injection of
THC, but does not inhibit ∆FosB induction after repeated THC treatment in the caudateputamen. A similar pattern was found in the nucleus accumbens; however induction of ∆FosB by
repeated THC was not significant in this region.
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Figure 3.7 Genetic deletion of DARPP-32 attenuated induction of ΔFosB following a single
injection of THC in the caudate-putamen and nucleus accumbens and attenuated induction of
ΔFosB following repeated THC administration in nucleus accumbens. Graphs show ΔFosB-ir
expressed as % VEH-VEH wild type mice ± SEM in A) nucleus accumbens and B) caudateputamen. 3 X 2-way ANOVA was performed with Bonferroni post-hoc test, * p < 0.05 and ***
p < 0.001 compared to VEH-VEH wild type control. ^ p < 0.05 and ^^^ p < 0.001 compared to
VEH-THC wild type.

### p < 0.001 compared to VEH-VEH knockout.
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DARPP-32 knockout mice exhibit enhanced THC-mediated locomotor suppression and greater
tolerance to this effect and exhibit less THC-mediated hyperreflexia following repeated THC
administration
DARPP-32 knockout mice and wild type littermate controls that received repeated THC
or vehicle were assessed for THC-mediated locomotor suppression, hypothermia,
antinociception, catalepsy and hyperreflexia. A separate group of mice that received repeated
vehicle were challenged with vehicle to verify that there was no effect of multiple assessments
on these measures (data not shown). , Acute THC administration produced significantly greater
locomotor suppression in vehicle-treated DARPP-32 knockout mice as compared to wild-type
mice (206 ± 13 vs. 258 ± 10 seconds immobile, wild type and DARPP-32 knockout mice,
respectively, p < 0.05) (Figure 3.8 A). There was no significant difference in THC-mediated
locomotor suppression between vehicle and THC-treated wild type mice (Figure 3.8 A).
However, significantly less THC-mediated locomotor suppression was found in DARPP-32
knockout mice compared to their respective vehicle-treated control (258 ± 10 vs. 135 ± 21
seconds immobile, vehicle and THC treated, respectively, p < 0.001, Figure 3.8 A), indicating
that tolerance had developed to this effect. DARPP-32 knockout mice also exhibited
significantly less locomotor suppression than wild-type mice following repeated THC
administration (187 ± 15 vs. 135 ± 21 seconds immobile, wild type and DARPP-32 knockout
mice respectively, p < 0.05, Figure 3.8 A).
For the measure of catalepsy, comparisons were made at the 180 minute time point
because mice also exhibited hyperreflexia at earlier time points (Figure 3.8 E). There was no
significant difference between vehicle-treated wild type and DARPP-32 knockout mice because
both genotypes remained immobile on the bar for a similar period of time after THC
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administration (54 ± 2 versus 49 ± 4 seconds immobile, wild type and DARPP-32 knockout mice
respectively, Figure 3.8 B). Following repeated THC administration, there was also no
significant difference between wild type or DARPP-32 knockout mice (49 ± 3 versus 41 ± 4,
seconds immobile, wild type and DARPP-32 knockout respectively, Figure 3.8 B). Time spent
immobile on the bar did not differ between repeated vehicle-or THC-treated mice for either
genotype, suggesting that tolerance did not develop for this measure. Interestingly, there was a
significant difference in the percentage of mice that exhibited hyperreflexia. A significantly
higher percentage of THC-treated wild type mice exhibited hyperreflexia compared to either
vehicle-treated wild type mice or repeated THC-treated DARPP-32 knockout mice (Figure 3.8
E). At 30 minutes, 87.5% of wild type mice that received repeated THC administration exhibited
hyperreflexia, whereas 25% of either THC-treated DARPP-32 knockout mice or vehicle-treated
wild type mice exhibited hyperreflexia. The percentage of repeated THC-treated wild type mice
that exhibited hyperreflexia was also greater at the 60 minute time point compared to wild type
mice that received repeated vehicle and greater at the 60 and 120 minute time points compared to
DARPP-32 knockout mice that received repeated THC (Figure 3.8 E).
Both vehicle-treated wild type and DARPP-32 knockout mice exhibited antinociception
following acute THC administration and the time-course of the effect was similar between
genotypes (Figure 3.8 C). Antinociception, measured as % MPE, was significantly decreased at
all time points in THC- compared to vehicle-treated wild type and DARPP-32 knockout mice
(Figure 3.8 C). Antinociception was not significantly different between repeated THC-treated
wild type and DARPP-32 knockout mice over the time period examined (Figure 3.8 C). Vehicletreated wild type and knockout mice both exhibited hypothermia following acute THC
administration (Figure 3.8 D). Vehicle-treated wild type and DARPP-32 knockout mice had
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similar body temperatures at 30 minutes (32.8°C ± 0.5°C versus 32.7°C ± 0.6°C, wild type and
DARPP-32 knockout mice, respectively) and temperature remained stable for the remaining 120
minutes, suggesting a similar time course for hypothermia between genotypes. Body temperature
was significantly higher in THC-treated mice compared to the respective vehicle-treated mice of
each genotype (Figure 3.8 D). Body temperature did not significantly differ between repeated
THC treated wild type and DARPP-32 knockout mice 30 minutes after THC administration
(37.1°C ± 0.2°C vs. 32.0°C ± 0.3°C, wild type and DARPP-32 knockout, respectively) and
values remained stable for both wild type and DARPP-32 knockout mice throughout testing
(Figure 3.8 D).
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Figure 3.8 DARPP-32 knockout mice exhibited greater acute THC-mediated locomotor
suppression and tolerance to THC-mediated locomotor suppression following repeated THC
administration. Graphs show differences between wild type and DARPP-32 knockout mice
following repeated THC administration for A) locomotor suppression, B) catalepsy, C)
antinociception, D) hypothermia and E) hyperreflexia. For locomotor suppression data are
presented as time immobile and catalepsy as time immobile on a bar in seconds ± SEM.
Antinociception is presented as % MPE ((test latency - baseline)/(total length of test)] X 100) ±
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SEM. Hypothermia presented as difference from baseline ± SEM. Hyperreflexia is represented
as percent mice exhibiting hyperreflexia. For antinociception and hypothermia repeated
measures ANOVA were performed with Bonferroni post-hoc test *** p < 0.001 compared to
repeated vehicle treated wild type mice and ^^^ p < 0.001 compared to repeated vehicle treated
DARPP-32 knockout mice. For locomotor suppression and catalepsy, two-way ANOVA was
performed with Bonferroni post-hoc test * p < 0.05 compared to repeated vehicle treated wild
type mice, ^^^ p < 0.001 compared to repeated THC-treated DARPP-32 knockout mice and # p
< 0.05 compared to repeated THC-treated wild type mice. For hyperreflexia, z-tests with
Bonferroni correction were performed, * p < 0.05 compared to repeated vehicle-treated wild type
mice and # p < 0.05 compared to repeated THC-treated DARPP-32 knockout mice.
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3.4 Discussion
The present study was conducted to investigate the role of D1Rs and DARPP-32 in THCmediated induction of ∆FosB and to determine the role of DARPP-32 in THC-mediated motor
responses in drug naïve and THC-treated mice. A pharmacological approach was used by
administering D1R-selective antagonists, SCH23390 or SCH39166, prior to treatment with THC
during the 6.5 days of treatment, and then measuring ∆FosB induction. Administration of either
SCH23390 or SCH39166 blocked THC-mediated induction of ∆FosB in the prefrontal cortex,
striatum, and amygdala, indicating that D1Rs are required for THC-mediated effects on
transcription via ∆FosB in these regions. Neuroanatomical studies revealed that a majority of
FosB/∆FosB positive cells in the striatum were also dynorphin positive, suggesting that ∆FosB-ir
is increased mainly in D1R-containing MSNs of the direct pathway. Studies in DARPP-32
knockout mice showed that deletion of DARPP-32 attenuated the effect of acute, but not
repeated, THC on ∆FosB induction. Moreover, deletion of DARPP-32 enhanced both acute
THC-mediated locomotor suppression and tolerance to this effect. Overall, these results support
a role for D1R-mediated signaling in the effects of acute and repeated THC administration.
We previously reported that THC-mediated ΔFosB induction in the caudate-putamen and
nucleus accumbens was abolished in CB1R knockout mice, demonstrating that THC induces
∆FosB in a CB1R-dependent manner (Chapter 1). Neuroanatomical studies in which striatal
sections were dual stained for CB1Rs and ∆FosB showed that CB1R-ir puncta surrounded
ΔFosB-ir cells and also that CB1R-ir and FosB/ΔFosB-ir were co-localized in some cells
(Chapter 1). These findings suggested that activation of CB1Rs by THC might increase ΔFosB
expression both directly and via trans-synaptic events. Cannabinoids acting at CB1Rs increase
the activity of dopaminergic neurons in the substantia nigra and ventral tegmental area, leading
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to increased dopamine release in the caudate-putamen and nucleus accumbens (Cheer et al.,
2003; Riegel and Lupica, 2004; Wu and French, 2000). Cannabinoids can also directly modulate
dopamine release at nerve terminals within the striatum (Cheer et al., 2004). Therefore, it is
likely that THC-mediated dopamine release activates D1Rs in the striatum. The results of the
current study showed that THC-mediated ΔFosB induction in the striatum, as well as in the
prefrontal cortex and amygdala, required D1R activation. This finding extends our previous
study by showing that D1R antagonists also blocked ΔFosB induction in the prefrontal cortex and
amygdala, which has not been shown for other drugs of abuse. Morphine-mediated induction of
ΔFosB was found to be D1R-independent in frontal cortex (Muller and Unterwald, 2005),
supporting the idea that D1Rs are involved in ∆FosB induction in non-striatal regions.
Cannabinoids enhance dopamine release in the prefrontal cortex and amygdala (Polissidis et al.,
2010; Polissidis et al., 2013), suggesting that CB1R-mediated dopamine release could be a
common mechanism of D1R-mediated induction of ΔFosB in all of these forebrain regions.
CB1Rs are located on both D1R/dynorphin and D2R/enkephalin MSN populations in the
striatum (Hohmann and Herkenham, 2000), but pharmacological results indicate that THC
induced ΔFosB primarily in D1R/dynorphin MSNs in both the caudate-putamen and nucleus
accumbens. This finding agrees with previous findings that acute THC-mediated increases in
Fos-immunoreactive cells in the striatum were attenuated by administration of D1R, but not D2R,
antagonist (Miyamoto et al., 1996). Overexpression of ΔFosB in D1R-positive MSNs increases
the rewarding properties of other drugs of abuse, including cocaine (Kelz et al., 1999)
(Muschamp et al., 2012), morphine (Zachariou et al., 2006a) and naturally rewarding behaviors
(Pitchers et al., 2010; Werme et al., 2002). These findings would suggest that THC-mediated
motivated behaviors might also be enhanced following ∆FosB induction. THC-mediated reward
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is difficult to determine in preclinical models in rodents, but has been shown in squirrel monkeys
(Justinova et al., 2003; Tanda et al., 2000). THC-mediated ∆FosB induction might also enhance
the effects of other psychoactive drugs. For example, nicotine self-administration (Panlilio et al.,
2013) and cocaine-induced locomotor activity (Dow-Edwards and Izenwasser, 2012) were
enhanced in mice that were previously exposed to THC. The current data would suggest that
THC-mediated ΔFosB induction in D1R/dynorphin MSNs is a possible mechanism underlying
these observations. However, pre-exposure to THC does not increase the likelihood of selfadministration of heroin (Solinas et al., 2004) or cocaine (Panlilio et al., 2007), so it is not clear
whether the rewarding effects of all drugs of abuse are enhanced after pre-exposure to THC.
Previous studies have shown that administration of D1R antagonists or genetic deletion of
D1Rs attenuated the induction of ∆FosB and other Fos family members produced by morphine or
cocaine (Muller and Unterwald, 2005; Nye et al., 1995; Zhang et al., 2002). Moreover,
psychomotorstimulants like cocaine and methylphenidate also induced ∆FosB in D1R-positive
striatal neurons (Hostetler and Bales, 2012; Kim et al., 2009; Nye et al., 1995). The present
findings with THC support a role for D1R-mediated ∆FosB induction with drugs that cause
dopamine release within striatum. Previous studies in which SCH23390 was administered did
not report a significant increase in ΔFosB induction with SCH23390 alone (Muller and
Unterwald, 2005; Nye et al., 1995; Pitchers et al., 2010). This might be due to methodological
differences because we pretreated twice daily, every day, whereas other studies used once-daily
or intermittent drug administration. It is also possible that non-D1R activity of SCH23390
induced ∆FosB because this effect was seen only in the nucleus accumbens and was not seen
after treatment with SCH39166. SCH23390 is also a high affinity agonist for 5HT1c (Taylor et
al., 1991) and 5HT2c (Millan et al., 2001) receptors. For example, SCH23390 blocked the
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sensitization effects of 3,4-methylenedioxymethamphetamine (MDMA) via agonist activity at
5HT2c receptors and not via D1R antagonist properties (Ramos et al., 2005). 5HT2c receptors are
located on dopaminergic neurons of the ventral tegmental area that project to the nucleus
accumbens (Bubar et al., 2011). SCH39166 is a more selective D1R antagonist and has much
lower affinity for D2R and 5HT receptors (Alburges et al., 1992; Duffy et al., 2000; Tice et al.,
1994; Wamsley et al., 1991). This might explain why SCH39166 did not significantly increase
ΔFosB in the nucleus accumbens like SCH23390. The finding that SCH39166 in combination
with THC increased ΔFosB expression above levels in control mice suggests that other receptors
could be involved in the THC-mediated induction of ΔFosB in this region. A study that
investigated THC-mediated ERK phosphorylation showed that antagonism of D2Rs and NMDA
receptors reduce ERK phosphorylation after acute THC administration, but to a lesser degree
than D1R antagonism (Valjent et al., 2001). Our data show that antagonism of D1Rs blocked
THC-mediated ∆FosB induction, but also suggest that activation of 5HT 1/2c receptors might
cause induction of ΔFosB in the nucleus accumbens.
Antagonist studies showed that D1R activation was necessary for THC-mediated
induction of ΔFosB, but the signaling pathway(s) that mediate this effect has not been identified.
D1R-mediated activation of PKA leads to phosphorylation of DARPP-32 on threonine 34, which
allows DARPP-32 to inhibit protein phosphatase-1 (Desdouits et al., 1995; Hemmings et al.,
1984a; Kwon et al., 1997), thereby enhances the effects of PKA. Genetic deletion of DARPP32 or point mutation of DARPP-32 at the threonine 34 site attenuates cocaine-mediated
induction of ΔFosB in the nucleus accumbens but not caudate-putamen (Hiroi et al., 1999;
Zachariou et al., 2006b). Results showed that deletion of DARPP-32 abolished acute THCmediated ΔFosB induction in both the caudate-putamen and nucleus accumbens. ΔFosB is not
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significantly induced following acute administration of morphine or psychostimulants (Grueter et
al., 2013), but the effect of THC might be due to the large dose of THC administered (70 mg/kg)
and/or the long duration of action of THC (Ashton, 2001; Whitlow et al., 2002). This difference
in the pharmacokinetic properties of THC could have produced long-lasting activation of CB1Rs
and perpetuated increased expression of ΔFosB because brains were collected 24 hours after
injection. Recent studies have suggested that ΔFosB might affect locomotor activity and rewardrelated behaviors through changes in AMPA and NMDA receptors at earlier time points than
previously hypothesized (Grueter et al., 2013). Following repeated THC administration, wild
type mice exhibited significant ΔFosB induction in nucleus accumbens, whereas this effect was
abolished in DARPP-32 knockout mice. In contrast, THC-mediated ΔFosB induction was
similar in the caudate-putamen of wild type and DARPP-32 knockout mice. These results agree
with previous results showing that repeated cocaine administration in DARPP-32 knockout mice
significantly increased ΔFosB expression in the caudate-putamen, but not nucleus accumbens
(Hiroi et al., 1999). The finding that DARPP-32 primarily modulates acute THC- but not
repeated THC-, mediated induction of ΔFosB suggests the possibility that epigenetic changes at
the FosB promoter might make DARPP-32 unnecessary for further ΔFosB induction. In fact,
enhanced cocaine-mediated induction of ΔFosB in cocaine-experienced animals did not depend
on changes in upstream signaling factors, like ERK, which are also known to mediate ΔFosB
induction (Damez-Werno et al., 2012). DARPP-32 was shown to be necessary for acute THCmediated ERK phosphorylation in the nucleus accumbens shell (Valjent et al., 2005). ERK
phosphorylation might mediate acute ΔFosB induction, but this pathway might not be necessary
for ΔFosB induction after repeated THC administration. Mice with genetic deletion of RasGRF1, which have reduced ERK phosphorylation following D1R activation, also exhibit
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reductions in FosB/ΔFosB immunopositive cells following repeated cocaine administration in
the striatum (Fasano et al., 2009). However, ERK phosphorylation was not completely blocked
in Ras-GRF1 knockout mice, providing further evidence that ERK might not be necessary for
ΔFosB induction following repeated drug administration.
We have previously shown an inverse correlation between ΔFosB induction and CB1R
desensitization (Chapter 1) and others have demonstrated that inhibition of PKA reduced
tolerance to THC-mediated in vivo effects (Bass et al., 2004). Therefore, studies were performed
in DARPP-32 knockout mice to determine the role that this protein might play in the
development of tolerance to THC-mediated responses. Previous studies determined that mice
with a mutation of DARPP-32 at the threonine 34 site that prevented its conversion to a PP1
inhibitor exhibited attenuated catalepsy following acute treatment with the cannabinoid agonist,
CP55,940 (Andersson et al., 2005). Our results did not find a similar attenuation of cannabinoidmediated catalepsy with THC. Methodological differences, as well as differences in the
cannabinoid agonist administered might explain these conflicting results. The previous study
used the high efficacy partial agonist CP55,940 and tested catalepsy using a tilted grid, whereas
we used the partial agonist, THC, and the bar test to measure catalepsy. Additionally, the
previous study used mice with a mutation at the threonine 34 site of DARPP-32, whereas mice in
the current study had genetic deletion of DARPP-32. Mice also exhibited hyperreflexia until the
third hour time point. At this time point, the previous study also found no difference in
catalepsy. The previous authors did not report hyperreflexia, even though this response has
previously been reported after CP55,940 treatment (Patel and Hillard, 2001). Following acute
THC administration, DARPP-32 knockout mice did exhibit greater locomotor suppression.
Furthermore, following repeated THC administration, DARPP-32 knockout mice developed
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tolerance to the locomotor suppressing effects of THC whereas wild type mice did not. The lack
of tolerance to the locomotor suppressing effects of THC in wild type mice was probably due to
the low dose of THC administered in this study because we previously reported that mice treated
with this paradigm did not exhibit desensitization in striatal regions (Chapter 1) and a one week
treatment with this paradigm did not produce tolerance to this effect (McKinney et al., 2008).
There were no differences in the development of tolerance to THC-mediated hypothermia or
antinociception, which agrees with the expression profile of DARPP-32 because it is expressed
mainly in the striatum and not in the hypothalamus or midbrain (Perez and Lewis, 1992). There
was, however, a difference in the percent of mice that exhibited hyperreflexia. Vehicle-treated
wild type and DARPP-32 knockout mice and THC-treated DARPP-32 knockout mice exhibited
similar percentages of hyperreflexia, whereas the percentage of wild type mice that exhibited
hyperreflexia following repeated THC administration was significantly higher. This is an
interesting finding because hyperreflexia has been associated with activation of CB1Rs in the
cerebellum and dopamine agonists do not attenuate this effect (Patel and Hillard, 2001). The
cerebellum does not contain dopaminergic projections, but DARPP-32 has been detected in this
region (Schalling et al., 1990). Future studies are necessary to determine the role that DARPP32 may play in mediating this effect and whether it is cerebellar-mediated.
These studies demonstrate a neurochemical commonality between THC and other drugs
of abuse, such as cocaine and morphine, where ΔFosB induction is blocked by antagonism of
D1Rs and ΔFosB induction is primarily restricted to the D1R/dynorphin MSNs of striatum. This
similarity in the action of these drugs of abuse suggests that future therapeutic targets targeting
these systems could be effective in treating polydrug use. We also found that antagonism of
D1Rs blocks THC-mediated induction of ΔFosB in the prefrontal cortex, where changes in this
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region are thought to contribute to the loss of control of drug intake in addicts (Goldstein and
Volkow, 2011), and the amygdala, which is proposed to mediate drug reinstatement (Stamatakis
et al., 2013). In the striatum, DARPP-32 appeared to mediate acute induction of ΔFosB by THC
while it has a diminished role in mediating ΔFosB induction following repeated THC
administration. This suggests that different mechanisms are responsible for the acute induction
of ΔFosB compared to induction of ΔFosB following repeated THC administration in striatum.
DARPP-32 also plays a role in reducing tolerance to THC-mediated locomotor suppression, a
behavior that is known to be resistant to tolerance in humans (D'Souza et al., 2008), suggesting
that this protein could be targeted to enhance tolerance to this side-effect.
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Chapter 4: Brain region-dependent differences in ΔFosB signaling following THCchallenge in THC-experienced versus drug naïve mice
4.1 Introduction
Long-term drug use produces physiological changes that are not present upon initial drug
use. Some of these changes are due to the induction of transcription factors that can control
multiple genes (Lazenka et al., 2013), thus altering signaling. One transcription factor thought to
mediate these physiological changes is ΔFosB, a stable splice variant of FosB that is typically
induced after repeated drug administration. Recent studies have determined that repeated
administration of THC, the main psychoactive constituent of marijuana, induces ΔFosB in the
prefrontal cortex, caudate-putamen, nucleus accumbens, amygdala and cerebellum (Perrotti et
al., 2008) (Chapter 1). ΔFosB has been implicated in mediating the rewarding effects of drugs of
abuse through transcriptional regulation of specific target genes (McClung and Nestler, 2003;
Perrotti et al., 2008).
Since ΔFosB has a long half-life in neurons and is stable for weeks (Ulery-Reynolds et
al., 2009; Ulery et al., 2006), it is proposed that it can mediate the long-term changes associated
with drugs of abuse (Nestler et al., 2001). Studies in mice that received repeated cocaine
administration or had genetic overexpression of ΔFosB have found that ΔFosB regulates the
expression of several target genes including cyclin dependent kinase 5 (CDK5), the neuronalspecific activator of CDK5 (p35) and calmodulin-dependent protein kinase II (CAMKII) (Bibb et
al., 2001a; McClung and Nestler, 2003). The expression of some of these proteins has been
examined in humans, where post-mortem studies found that both ΔFosB and CAMKII were
increased in the nucleus accumbens of cocaine users (Robison et al., 2013).
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The long-term changes that occur following prolonged drug include increased dendritic
spine formation and other cytoskeletal-dependent changes that are mediated by CDK5 (Dhavan
and Tsai, 2001; Norrholm et al., 2003), and regulation by CDK5 is dependent on its coactivators:
p35 and p39 (Ko et al., 2001). CDK5 produces cytoskeletal changes partly through direct
phosphorylation of the microtubule associated protein, tau (Baumann et al., 1993), but also
indirectly through phosphorylation of glycogen synthase kinase-3β (GSK3β) (Morfini et al.,
2004), which also phosphorylates tau. CDK5 can also alter the function of the dopamine- and
cAMP-regulated neuronal phosphoprotein of 32 kDA (DARPP-32) in striatal neurons by
phosphorylating DARPP-32 at threonine 75 (Bibb et al., 1999). Phosphorylation at this site
attenuates PKA activity and reduces dopamine type 1 receptor (D1R) signaling (Bibb et al.,
2001b). In contrast to repeated cocaine administration, acute cocaine increases phosphorylation
of DARPP-32 at threonine 34 (Zachariou et al., 2006b), which enhances PKA activity. Acute
administration of THC also increases phosphorylation of DARPP-32 at threonine 34 (Borgkvist
et al., 2008), although levels return to baseline within one hour.
Finally, epigenetic changes play a role in long-term adaptation to prolonged drug
exposure, through either enhancement of repression of gene promoters. Epigenetic changes that
occur with repeated cocaine administration include changes at the DNA level through either
methylation/demethylation of the C5 position of cytosines located in CpG islands or
acetylation/deacetylation and methylation at histones at the promoters of genes (Anier et al.,
2010; Nestler, 2013; Robison and Nestler, 2011). The following studies investigated whether
there are brain region-dependent differences in the regulation of these signaling proteins
following either acute or repeated THC administration. Further, it was determined whether THC
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administration in mice with prior THC experience regulates these proteins differently than THC
in drug naïve mice.
4.2 Materials and Methods
Materials
THC was received from the same source as in Chapter 1. The antibodies used are listed
in Table 4.1. The same secondary antibodies were used as reported in Chapter 1. For RT-qPCR
studies, the High Capacity cDNA Reverse Transcription Kit was purchased from Applied
Biosystems Inc. (Foster City, CA) and the 2x QuantiFast ® SYBR® Green PCR kit was purchased
from Qiagen (Valencia, CA).

All other reagent grade chemicals were obtained from Sigma

Chemical Co. or Fisher Scientific.

TABLE 4.1
List of antibodies used for immunoblot studies
Antibody (animal)
α-tubulin (mouse, ab7291)
FosB (rabbit, sc-7203)
CDK5 (rabbit, sc-173)
p35/p25 (rabbit)
Total ERK1 (rabbit)
pERK1 (mouse)
DARPP-32 (mouse)
pT34DARPP-32 (rabbit)
pT75DARPP-32 (rabbit)
pGSK3β(mouse)
pTau (AT8, mouse)

Company
Abcam
Santa Cruz Biotechnology
Santa Cruz Biotechnology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Santa Cruz Biotechnology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Pierce Scientific

Dilution
1:20000
1:500
1:2000
1:1000
1:2000
1:2000
1:2000
1:1000
1:1000
1:1000
1:500

Drug Treatments
Male C57Bl/6J mice (Jackson Laboratories, Indianapolis, IN) 8 weeks old were used for
all treatments. Mice were housed four to six per cage and maintained on a 12-hr light/dark cycle
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in a temperature controlled environment (20-22°C) with food and water available ad libitum.
THC (10 mg/kg) was dissolved in a 1:1:18 solution of ethanol, emulphor and saline (vehicle).
Mice were injected subcutaneously with either vehicle (VEH) or THC at 07:00 and 16:00 h for
13 days. On the morning of day 14, both vehicle- and THC-treated groups of mice were divided
in half and received either vehicle or 10 mg/kg THC injection to produce 4 groups: VEH-VEH,
VEH-THC, THC-VEH and THC-THC. Brains were extracted 45 minutes after the final
injection and dissected into appropriate regions for immunoblots (n = 8 mice per group) or RTqPCR (n= 5-6 mice per group). The 45 minute time point was chosen because DARPP-32
phosphorylation at threonine 34 returns to baseline within one hour (Borgkvist et al., 2008) and
FosB/ΔFosB mRNA is maximally induced by this time point (Damez-Werno et al., 2012). All
experiments were performed with the approval of the Institutional Animal Care and Use
Committee at Virginia Commonwealth University in accordance with the National Institutes of
Health guide for the care and use of Laboratory animals 7 th edition.
Dissections
Regions of interest were dissected from fresh whole brains as described in Chapter 1 for
immunoblots. For the globus pallidus, a cut was made directly anterior to the optic chiasm and
directly posterior to the optic chiasm. The globus pallidus was isolated by removing the tissue
bordered laterally by the caudate-putamen and internal capsule and dorsally by the ventral
pallidum. The substantia nigra was dissected by making a first cut rostral to the mammillary
bodies and a second cut rostral to the cerebellar peduncles, and then collecting tissue from the
ventral aspect of the section located lateral to the mammillary bodies and ventral tegmental area
and parabrachial pigmented nucleus. For RT-qPCR, regions of interest were dissected as
described in Chapter 1.
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Immunoblots
Immunoblots were performed as described in Chapter 1.
Real time quantitative polymerase chain reaction (RT-qPCR)
RNA was extracted from brain tissue immersed in Trizol® and were homogenized using a
Powergen 125 homogenizer (Fischer Scientific). RNA (5 µg) was then converted into cDNA
using a High Capacity cDNA Reverse Transcription Kit. cDNA (10 ng) was then added to 0.2
ml wells containing a master mix from the 2x QuantiFast ® SYBR® Green PCR kit and specific
primers at a final concentration of 0.4 µM and water was added to a final volume of 25
µl. Additional wells with no cDNA added served as no template controls (NTC) for each primer
set. Samples were placed in a BioRad real-time thermocycler programed to a 2-step cycling
protocol, followed by a melt curve step at the end of the reaction. Cycle threshold (Ct) values
were initially normalized to ΔCt values by subtracting sample Ct values from β-actin Ct
values. Data were further converted to ΔΔCt values and final mRNA quantification was
calculated using the following equation: 2^(- ΔΔCt) x 100 = % mRNA expression. Primers
described previously (Alibhai et al., 2007) for FosB and ΔFosB were used: FosB: Forward 5’GTGAGAGATTTGCCAGGGTC-3’ and Reverse 5’-AGAGAGAAGCCGTCAGGTTG-3’, and
ΔFosB: Forward 5’-AGGCAGAGCTGGAGTCGGAGAT-3’ and Reverse 5’
GCCCGAGGACTTGAACTTCACTCG-3’. Primers described previously for CDK5 (Hawasli
et al., 2007) were used: Forward 5'-GGCTAAAAACCGGGAAACTC-3' and Reverse 5'CCATTGCAGCTGTCGAAATA-3’ A previously described β-actin primer (Grimaldi and
Capasso, 2012) was also used: Forward 5’-TGTTACCAACTGGGACGA-3’ and Reverse
5’GTCTCAAACATGATCTGGGTC-3’.
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Data Analysis
For all experiments, data were analyzed with Prism® version X (GraphPad Software, San
Diego, CA). For immunoblots and RT-qPCR, one-way ANOVAs were performed with
Bonferroni post-hoc test. Significance was determined with p < 0.05. All one-way ANOVA data
are normalized to the VEH-VEH group and presented as % VEH controls ± SEM. For
comparisons of net differences from repeated treatment, data were first normalized to the VEHVEH group and values calculated as: VEH-THC – VEH-VEH and THC-THC – THC-VEH.
Significance for these data was determined with Student’s t-tests with p < 0.05 as significance.

4.3 Results
THC administration increases ΔFosB expression in the prefrontal cortex, nucleus accumbens and
caudate-putamen.
We have previously shown that repeated THC treatment induced ∆FosB when measured
24 hours after the last drug injection (Chapter 1). However, the effect of previous treatment with
THC on acute THC-mediated ∆FosB induction has not been determined. Therefore, studies were
conducted to determine whether ∆FosB is induced by a single injection of THC and whether
previous repeated THC treatment alters that response. Repeated vehicle- (drug naïve) or THC(THC-experienced) treated mice received a final injection of either vehicle or THC and brains
were collected 45 minutes after injection to measure ∆FosB. No significant differences were
found in the nucleus accumbens using one-way ANOVA, but post-hoc test determined that
ΔFosB-ir was significantly different in THC-THC compared to VEH-VEH (increased by 36% ±
13% compared to VEH-VEH; p < 0.05, Figure 4.1 B) treated mice. One-way ANOVA in the
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caudate-putamen showed a significant effect of treatment (F3, 28 = 5.548 p < 0.01). ΔFosB-ir was
significantly increased by 46% ± 12% (p < 0.01, Figure 4.1 C) in THC-VEH compared to VEHVEH-treated mice. ∆FosB-ir in VEH-THC-treated mice was also significantly different from
values in VEH-THC-treated mice (p < 0.05, Figure 4.1 C). One-way ANOVA determined a
significant difference in ∆FosB-ir between groups in the prefrontal cortex (F3,28 = 8.116, p <
0.001). ΔFosB-ir was significantly increased by 66% ± 6% in THC-THC-compared to VEHVEH-treated mice (p < 0.001, Figure 4.1 A). ∆FosB-ir in THC-THC treated mice was also
significantly different from levels in mice that received VEH-THC (p < 0.01, Figure 4.1 A) or
THC-VEH (p < 0.05, Figure 4.1 A) treatment. There was no significant change in ΔFosB-ir
following acute or repeated THC administration in the hippocampus, consistent with our
previous studies (Figure 4.1 D). These results suggest that while ∆FosB is not induced by acute
THC administration, ΔFosB-ir is increased following repeated THC administration. Further,
ΔFosB induction following THC-challenge in THC-experienced animals is enhanced compared
to a single administration of THC in naïve animals in the nucleus accumbens and prefrontal
cortex.
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Figure 4.1 ΔFosB expression is increased following repeated THC administration in the
prefrontal cortex, nucleus accumbens, caudate-putamen but CDK5 expression is only increased
in the prefrontal cortex. Graphs representing ΔFosB-ir and CDK5-ir expressed as percent
expression in VEH-VEH-treated control mice for (A) prefrontal cortex (B) nucleus accumbens
(C) caudate-putamen and (D) hippocampus. Values are represented as % VEH-VEH controls ±
SEM. Significance was determined with one-way ANOVA and Bonferroni post-hoc test * p<
0.05, ** p < 0.01 and ***p < 0.001 compared to VEH-VEH controls. # p < 0.05 and ## p < 0.01
compared to VEH-THC treated mice. ^ p < 0.05 compared to THC-VEH treated mice. N = 8 per
group
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THC administration enhances CDK5 expression in the prefrontal cortex
CDK5 has been identified as a downstream target of ∆FosB following induction by
cocaine treatment, but the effect of THC treatment on CDK5 is not known. Therefore, CDK5
was measured by immunoblot in the same brain regions of the four treatment groups.
In contrast to the results with ∆FosB, there were no significant differences in CDK5-ir between
any treatment groups in the nucleus accumbens (Figure 4.1 B) or caudate-putamen (Figure 4.1
C). There were also no significant differences in the expression of CDK5-ir between treatment
groups in the hippocampus (Figure 4.1 D). Results in the prefrontal cortex showed a significant
effect of treatment on CDK5-ir between treatment groups (F3,28 = 11.59, p < 0.001). CDK5-ir
was significantly increased by 43% ± 3% in THC-THC-treated mice compared to VEH-VEH- (p
< 0.001, Figure 4.1 A), VEH-THC- (p < 0.001) and THC-VEH-treated (p < 0.05) mice. CDK5ir was also significantly increased by 22% ± 4% in THC-VEH compared to VEH-VEH- treated
mice (p < 0.05, Figure 4.1 A). These results suggest there are brain region-dependent differences
in ΔFosB-mediated regulation of CDK5 following repeated THC-administration.

Levels of FosB, ∆FosB and CDK5 mRNA and proteins differ depending on THC experience
The finding that both ∆FosB and CDK5 were increased after acute THC injection in
repeated THC-treated mice suggests that these changes occur at either the level of transcription
or translation. To address whether these effects occur at the level of transcription, mRNA levels
of ∆FosB and CDK5 were measured in the prefrontal cortex. Because ∆FosB is a splice variant
of FosB, experiments were first conducted to determine whether FosB protein is also regulated
by THC. Results showed no significant difference using one-way ANOVA, but post-hoc test
determined that FosB-ir was significantly increased in VEH-THC- as compared to VEH-VEH-
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treated mice (79% ± 22% increase compared to VEH-VEH; p < 0.01, Figure 4.2 A). At the
mRNA level, acute THC administration increased FosB mRNA levels by 96% ± 36% compared
to VEH-VEH-treated mice (F3,18 = 3.384 p < 0.05, Figure 4.2 B). In contrast to FosB mRNA
levels, ΔFosB mRNA levels were not increased with acute THC administration but were
increased in THC-THC-treated mice (50% ± 21% compared to VEH-VEH-treated mice (F3,18 =
5.0126 p < 0.05, Figure 4.2 C). CDK5-ir was also enhanced in the prefrontal cortex after THC
injection in VEH-treated mice, so CDK5 mRNA levels were also assessed following THC
administration. Comparisons between treatment groups found no significant differences in
CDK5 mRNA levels. These results suggested similar differences between protein changes and
mRNA for FosB and ΔFosB depending on the drug experience of the animals. FosB
mRNA/protein (Figure 4.3 A) were increased after THC injection in VEH-treated mice and
∆FosB mRNA/protein (Figure 4.3 B) were increased after THC injection in THC-treated mice.
Comparisons of CDK5 mRNA/protein were not similar, however, a comparison of CDK5 mRNA
expressed as a net difference from either repeated vehicle or repeated THC showed that CDK5
mRNA expression significantly differed depending on the drug experience of the animal. Mice
that received THC challenge following repeated vehicle treatment (VEH-THC) had a decrease of
19% ± 16% in CDK5 mRNA, while mice that received THC-challenge following repeated THC
administration (THC-THC) had an increase of 31% ± 14% in CDK5 mRNA (p < 0.05, df = 9,
Figure 4.3 C). Although there was no significant difference between CDK5-ir following these
treatments, there was a trend towards increased CDK5 expression (p = 0.058).
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Figure 4.2 FosB mRNA/protein is increased in the prefrontal cortex in VEH-THC treated mice,
whereas ΔFosB mRNA is increased following THC-THC treatment. (A) Graph representing
FosB-ir in the prefrontal cortex as percent expression in VEH-VEH-treated controls ± SEM.
Graphs representing mRNA levels in prefrontal cortex expressed as VEH-VEH-treated controls
± SEM for (B) FosB, (C) ΔFosB and (D) CDK5. A: One-way ANOVA with Bonferroni post-hoc
test ** p < 0.01, N = 8 per group. N = 5-6 for mRNA, N = 8 for protein.
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Figure 4.3 ΔFosB mRNA/protein is enhanced in prefrontal cortex following THC-challenge in
THC-experienced mice. Comparisons were made between mRNA/protein expression following
THC-challenge in both drug naïve and THC-experienced mice in prefrontal cortex for (A) FosB,
(B) ΔFosB and (C) CDK5. Data presented as the net difference in mRNA/protein expression for
mice that received THC-challenge following repeated vehicle treatment (VEH-THC) and THCchallenge in following repeated THC treatment (THC-THC). Student’s t-test * p < 0.05
compared to net repeated treatment in VEH-THC group.
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Increased phosphorylation of ERK1, but not DARPP-32, occurs in the prefrontal cortex
following THC administration in THC-experienced mice
The enhanced induction of ΔFosB found in the prefrontal cortex following THC injection
in repeated THC-treated mice could occur due to changes in signaling proteins upstream of
ΔFosB. ∆FosB induction can be regulated by phosphorylation of ERK1 at Thr202/Tyr204 and/or
DARPP-32 at threonine 34. Phosphorylation of ERK1 and DARPP-32 was determined by
measuring phosphorylation levels/ total protein levels. ERK1 phosphorylation was significantly
increased by 53% ± 10% in the prefrontal cortex of THC-THC-treated mice compared to VEHVEH-treated mice (p < 0.05, Figure 4.4), but there was no significant difference in ERK1
phosphorylation in VEH-THC- compared to VEH-VEH-treated mice. Phosphorylation of
DARPP-32 at threonine 34 did not significantly differ between any treatment groups in the
prefrontal cortex (Table 4.2). Phosphorylation of ERK1 and DARPP-32 was also determined in
the caudate-putamen, a region in which THC-THC treatment did not enhance ΔFosB induction.
There was no significant change in the phosphorylation of either ERK1 (data not shown) or
DARPP-32 at threonine 34 (Table 4.2) for any treatment condition. These results suggest that
enhanced ΔFosB induction in the prefrontal cortex could be mediated by phosphorylation of
ERK1.
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Figure 4.4 ERK1 phosphorylation is significantly increased in prefrontal cortex following THCchallenge in THC-experienced mice. Graph representing pERK1-ir/Total ERK-ir in the
prefrontal cortex as percent expression in VEH-VEH-treated controls ± SEM. One-way
ANOVA followed by Bonferroni post-hoc test, * p < 0.05. N = 8 per group
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Expression of p35/p25 and tau phosphorylation are increased in the prefrontal cortex following
THC injection in THC-experienced mice
CDK5 phosphorylates several targets, including DARPP-32 at threonine 75 (Bibb et al.,
1999), tau protein at Ser202/Thr205 (Hashiguchi et al., 2002) and GSK3β at Ser9 (Morfini et al.,
2004) when it is dimerized with either p35 or its cleaved form, p25. Therefore, increases in
CDK5, p35 and p25 could lead to an increase in phosphorylation of these proteins. In the
prefrontal cortex, significant differences in p35-ir were found between treatment groups (F3,28 =
7.196, p < 0.01, Figure 4.5 A). Expression of p35 was significantly increased by 21% ± 6% in
THC-THC-treated compared to VEH-VEH-treated (p < 0.001, Figure 4.5 A) or VEH-THCtreated (p < 0.01, Figure 4.5 A) mice. Expression of p35 was also significantly increased by
14% ± 2 % (p < 0.05, Figure 4.5 A) in THC-VEH- compared to VEH-VEH-treated mice. Based
on these results, levels of p25, the cleavage product of p35, were measured. For p25, although
there were no significant differences by one-way ANOVA, post-hoc test determined that THCVEH-treated mice had significantly increased p25-ir (33% ± 9 %, p < 0.05, Figure 4.5 B)
compared to VEH-VEH-treated mice. THC-THC-treated mice also had significantly increased
p25 expression (29% ± 8%, p < 0.05, Figure 4.5 B) compared to VEH-VEH-treated mice.
Studies were then conducted to determine whether increased expression of CDK5 and
p35/p25 occurred in conjunction with changes in the phosphorylation of target proteins in the
prefrontal cortex. Phosphorylation of the Ser202/Thr205 site of tau was significantly increased
by 33% ± 8% in THC-THC-treated mice compared to VEH-VEH-treated mice (p < 0.05, Figure
4.5 C). There were no other significant differences in the phosphorylation of tau between groups.
Phosphorylation of the Ser9 site of GSK3β was significantly decreased by 38% ± 6 % and 38% ±
5% in THC-VEH (p < 0.001, Figure 4.5 D) and THC-THC (p < 0.001, Figure 4.5 D), treated
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mice, respectively, compared to VEH-VEH-treated mice. This suggests that repeated THC
administration decreased phosphorylation of GSK3β at Ser9 and that these levels remained
decreased after THC-challenge. There were no significant differences in the phosphorylation of
DARPP-32 at threonine 75 for any treatment (Table 4.3). These data show that increased CDK5
expression is associated with increased phosphorylation of tau in THC-THC-treated mice,
whereas decreased phosphorylation of GSK3β was found in THC-VEH- and THC-THC-treated
mice.
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Figure 4.5 p35 and p25 expression are increased in the prefrontal cortex following repeated
THC administration whereas pTau is increased and pGSK3 is decreased. (A) p35 expression (B)
p25 expression (C) phosphorylation of tau at Serine 202/Threonine 205 and (D) GSK3β
phosphorylation at serine 9. Values represented as % VEH-VEH controls ± SEM. One-way
ANOVA with Bonferroni post-hoc test. * p < 0.05 and ***p < 0.001 compared to VEH-VEH
controls. ## p < 0.01 compared to THC-VEH administration. N = 8 per group
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Expression of p35 is reduced in the caudate-putamen and substantia nigra of THC-THC-treated
mice
Analysis of signaling proteins related to ∆FosB and CDK5 in the prefrontal cortex
showed that expression of p35/p25 could be regulated by THC treatment. In order to fully assess
these signaling pathways and determine the regional profile of THC-mediated regulation of these
pathways, expression of p35/p25 was measured in additional forebrain regions. Expression of
DARPP-32 was also assessed because D1Rs in these regions are required for THC-mediated
∆FosB induction (Chapter 3). In the nucleus accumbens, there were no significant differences
between any of the treatment groups for expression of p35, p25 (Figure 4.6 A) or
phosphorylation of DARPP-32 at either threonine 34 or threonine 75 (Table 4.2 and 4.3). In the
caudate-putamen, one-way ANOVA determined a significant difference (F3, 28 = 3.108, p < 0.05)
in p35-ir between the VEH-THC (increased by 26% ± 15%) and THC-THC (decreased by 15% ±
5%) compared to VEH-VEH-treated mice (p < 0.05, Figure 4.6 B). Expression of p35 in THCTHC-treated mice was also significantly different (p < 0.05, Figure 4.6 B) from THC-VEHtreated mice (17% ± 9% increase compared to VEH-VEH-treated mice). There were no
significant differences in p25 levels between any of the groups tested. There were no significant
differences in the phosphorylation of DARPP-32 at either the threonine 34 or threonine 75 site
between any of the groups in the caudate-putamen (Table 4.2 and 4.3). Levels of p25 and p35
were also measured in the hippocampus, but there were no significant differences in expression
between the treatment groups (Figure 4.6 C). Expression of DARPP-32 was not detectable in the
hippocampus with 50µg of total protein loaded. Overall, these results show that p35 is regulated
by THC treatment only in the caudate-putamen and that DARPP phosphorylation is not affected
by these THC treatments in the nucleus accumbens or caudate-putamen.
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Results in the caudate-putamen showed that ∆FosB and p35 were regulated by THC
treatment, although the other proteins examined were not affected. CB1Rs on striatal MSNs are
predominantly expressed on axon terminals in the globus pallidus and substantia nigra,
suggesting that THC-mediated regulation of signaling might occur in these projection regions.
ΔFosB expression was not assessed because the globus pallidus and substantia nigra contain
primarily efferent projections from the caudate-putamen and not the cell bodies of origin where
FosB would be expressed. In the globus pallidus, there were no significant differences in CDK5ir, p35-ir or p25-ir (Figure 4.7 A) between the treatment groups. There were also no significant
differences in CDK5-ir in the substantia nigra of any of the THC-treated groups (Figure 4.7 B).
For p35-ir in substantia nigra, there was no significant difference by one-way ANOVA, but posthoc test determined a significant difference between THC-VEH- (26% ± 15% increase) and
THC-THC-treated (17% ± 3% decrease) compared to VEH-VEH-treated mice (p < 0.01, Figure
4.7 B). For p25, one-way ANOVA showed a significant difference between treatments (F1,28 =
3.507 p < 0.05, Figure 4.7 B), and post-hoc test determined a significant difference between
VEH-THC- (13 ± 10% decrease) and THC-VEH-treated mice (27% ± 11% increase) compared
to VEH-VEH-treated mice. There were no significant differences in the phosphorylation of
DARPP-32 at either the threonine 34 or threonine 75 site in the globus pallidus or substantia
nigra (Table 4.2 and 4.3).

These results showed that none of the proteins examined was

regulated by THC in the globus pallidus. However, repeated THC treatment with THC injection
reduced p35-ir in the substantia nigra, which is similar to results in the caudate-putamen. In the
substantia nigra, expression of p25 was regulated differently following a single injection of THC
compared to repeated THC administration.
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Figure 4.6 p35 expression is reduced in the caudate-putamen of THC-THC-treated mice. Graphs
representing p35-ir and p25-ir as percent expression in VEH-VEH-treated controls ±SEM for (A)
nucleus accumbens (B) caudate-putamen and (D) hippocampus. Values are represented as %
VEH-VEH controls ± SEM. Significance was determined with one-way ANOVA and Bonferroni
post-hoc test. # p < 0.05 compared to THC-VEH administration. ^ p < 0.05 compared to THCVEH administration. N = 8 per group
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THC challenge in THC-experienced mice decreases phosphorylation of DARPP-32 at threonine
34 in cerebellum
For ΔFosB, there was a significant difference between treatment groups in the cerebellum
based on one-way ANOVA (F1,28 = 14.98, p < 0.001). Post-hoc test determined a significant
increase in ∆FosB-ir in THC-VEH- (36% ± 4%, p<0.01, Figure 4.7 C) and THC-THC-treated
mice (58% ± 7%, p<0.001, Figure 4.7 C) compared to VEH-VEH-treated mice. ∆FosB
expression was also significantly increased in THC-VEH-treated (p < 0.05, Figure 4.7 C) and
THC-THC-treated mice (p < 0.001, Figure 4.7 C) compared to VEH-THC-treated mice. CDK5ir, p35-ir and p25-ir were not significantly different between treatments (Figure 4.7 C); however,
there was a significant decrease in phosphorylation of DARPP-32 at threonine 34 in THC-THCtreated mice compared to VEH-VEH-treated mice (5.02% ± 0.37% vs. 3.91% ±0.28%, ratio of
T34DARPP32/Total DARPP-32 (Table 4.2). There were no significant differences between
treatment groups in the phosphorylation of DARPP-32 at threonine 75 (Table 4.3).
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Figure 4.7 Expression of p25 was increased following repeated THC administration, whereas
p35 wass decreased after THC injection in THC-experienced mice in substantia nigra. (A)
CDK5-ir, p35-ir and p25-ir in the globus pallidus (B) CDK5-ir, p35-ir and p25-ir in the
substantia nigra, (C) CDK5-ir, p35-ir and p25-ir in the cerebellum. Values represented as %
VEH-VEH controls ± SEM. One-way ANOVA with Bonferroni post-hoc test. ** p < 0.01 and
***p < 0.001 compared to VEH-VEH controls. # p < 0.05, ## p < 0.01, ### p < 0.001 compared
to THC-VEH-treated mice. ^^ p < 0.01 compared to THC-VEH-treated mice. N = 8 per group
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TABLE 4.2
Immunoblot results for phosphorylation of DARPP-32 at threonine 34/total DARPP-32
Brain Region
Prefrontal cortex
Caudate-putamen
Nucleus
accumbens
Globus pallidus
Hippocampus
Substantia Nigra
Cerebellum

VEH-VEH
5.15 ± 1.09
23.00 ± 3.86
19.71 ± 2.40

VEH-THC
4.34 ± 0.99
18.75 ± 2.47
19.72 ± 2.13

THC-VEH
6.26 ± 1.11
23 ± 2.78
19.20 ± 1.40

THC-THC
4.28 ± 0.79
19.56 ± 2.39
19.62 ± 1.50

23.20 ± 3.37
NA
22.86 ± 3.38
5.02 ± 0.38

22.22 ± 3.35
NA
23.51 ± 4.22
4.20 ± 0.43

22.72 ± 3.41
NA
22.57 ± 2.87
4.96 ± 0.36

26.63 ± 3.31
NA
20.45 ± 2.03
3.91 ± 0.28*

Total DARPP-32-ir and DARPP-32-ir phosphorylated at threonine 34 (T34-DARPP-32) were
measured in brain region homogenates as described in Methods. Results are expressed as T34DARPP-32/total DARPP-32 * 100% ± SEM. * p < 0.05 different from vehicle-vehicle controls
by one-way ANOVA and Bonferroni post-hoc test, N = 8 per group.
TABLE 4.3
Immunoblot results for phosphorylation of DARPP-32 at threonine 75/total DARPP-32
Brain Region
Prefrontal cortex
Caudate-putamen
Nucleus
accumbens
Globus pallidus
Hippocampus
Substantia Nigra
Cerebellum

VEH-VEH
19.18 ± 2.27
9.94 ± 0.83
14.79 ± 1.23

VEH-THC
19.63 ± 4.39
8.89 ± 0.72
15.69 ± 1.02

THC-VEH
22.74 ± 5.26
10.21 ± 0.68
14.80 ± 0.81

THC-THC
21.36 ± 2.88
10.05 ± 0.83
16.06 ± 1.52

13.34 ± 0.75
NA
3.36 ± 0.29
43.04 ± 3.74

13.71 ± 0.41
NA
3.18 ± 0.35
48.33 ± 5.14

14.71 ± 1.30
NA
3.48 ± 0.49
42.60 ± 4.60

15.37 ± 1.05
NA
3.45 ± 0.48
45.51 ± 5.65

Total DARPP-32-ir and DARPP-32-ir phosphorylated at threonine 75 (T75-DARPP-32) were
measured in brain region homogenates as described in Methods. Results are expressed as T75DARPP-32/total DARPP-32 * 100% ± SEM, N = 8 per group.
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4.4 Discussion
The present study compared THC-mediated induction of ΔFosB and its target proteins in
drug naïve and THC-experienced mice to determine the effect of prior THC treatment on THCmediated transcription. Protein expression was measured in forebrain regions that mediate the
development of drug abuse and addiction (Koob and Volkow, 2010). In the prefrontal cortex,
caudate-putamen and nucleus accumbens, repeated THC administration increased ΔFosB
expression, in agreement with previous studies performed in our laboratory (Chapter 1). ΔFosB
expression was also assessed in the cerebellum, because this brain region is thought to mediate
extrapyramidal effects of cannabinoids (Castane et al., 2004; Patel and Hillard, 2001). Studies
also determined that ΔFosB is not induced following acute THC injection, which is consistent
with other studies that tested acute administration of morphine (Nye and Nestler, 1996) and
cocaine (Nye et al., 1995).
THC-mediated ΔFosB induction was measured at both 45 minutes and 24 hours after
THC injection, whereas previous studies assessed ∆FosB at 24 hours after THC-administration.
Results showed that there are brain region-dependent differences in the induction of ΔFosB
following THC injection in THC-experienced mice. After acute administration of THC, it was
determined that ΔFosB expression did not change in prefrontal cortex, nucleus accumbens,
caudate-putamen, hippocampus and cerebellum. However, repeated THC administration did
increase ΔFosB expression in the prefrontal cortex, nucleus accumbens, caudate-putamen and
cerebellum, but not in hippocampus. In the prefrontal cortex, ΔFosB induction was enhanced in
THC-experienced mice compared to drug naïve mice that received THC injection. A previous
study showed that cocaine administration enhanced ΔFosB protein/mRNA expression, but not
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FosB protein/mRNA expression, in the nucleus accumbens of cocaine-experienced mice that
received a challenge of cocaine following 28 days of withdrawal (Damez-Werno et al., 2012).
Although this effect was not seen in nucleus accumbens after THC-treatment, it was seen in
prefrontal cortex. ΔFosB mRNA/protein expression was enhanced in THC-experienced mice
that received THC challenge, supporting the idea that THC-experience alters induction of ΔFosB
produced by THC injection. Damez-Werno et al (2012) showed that dimethylation of histone H3
at lysine 9 (H3K9me2) and increased stalled RNA polymerase II (Pol II) binding may have
contributed to the enhancement of ∆FosB induction, but the phosphorylation of ERK was not
involved (Damez-Werno et al., 2012). In the current study, ERK1 phosphorylation was enhanced
in the prefrontal cortex of THC-experienced mice that received THC injection, which is a
possible mechanism that could underlie the enhanced induction of ΔFosB. Genetically modified
mice that have reduced ERK phosphorylation also exhibited reductions in ΔFosB expression
following repeated cocaine administration (Besnard et al., 2011; Fasano et al., 2009), suggesting
a role for ERK phosphorylation in ΔFosB induction. Increased DARPP-32 phosphorylation at
threonine 34 can also regulate ΔFosB induction (Zachariou et al., 2006b); however, there was no
change in phosphorylation of DARPP-32 at this site in the current study. We have previously
reported that DARPP-32 is not necessary for THC-mediated induction of ΔFosB in the striatum
(Chapter 3), which suggests that DARPP-32 is most likely not necessary for enhancement of
∆FosB induction.
ΔFosB transcriptionally regulates the expression of CDK5 and p35 (Bibb et al., 1999;
Chen et al., 2000b; Kumar et al., 2005; Peakman et al., 2003), therefore these proteins were
assessed in brains from the same treatment groups. In the prefrontal cortex, expression of CDK5
and p35 were increased following repeated THC administration, but not by acute THC
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administration, supporting a role for ΔFosB in regulating these proteins. In the prefrontal cortex,
there was a similar enhancement of CDK5 expression as was found for ΔFosB. Therefore,
CDK5 mRNA levels were measured and it was determined that CDK5 mRNA expression was
differed following THC injection in drug naïve (decreased CDK5 mRNA expression) and THC
experienced (increased CDK5 mRNA expression) mice. These results suggest that enhanced
ΔFosB induction also leads to enhanced CDK5 expression through ΔFosB-mediated regulation
of transcription. CDK5 expression was not increased in the nucleus accumbens or caudateputamen, suggesting that although THC induces ΔFosB, it does not appear to regulate CDK5
expression in these regions. This finding is different from studies with cocaine and in mice
overexpressing ΔFosB in the striatum (Bibb et al., 2001a), suggesting that THC negatively
regulates ΔFosB-mediated transcription of CDK5 in the caudate putamen and substantia nigra.
ΔFosB also regulates expression of p35, which dimerizes with CDK5 and facilitates its
kinase function. In the nucleus accumbens and cerebellum, p35 expression did not change with
repeated THC administration, suggesting that ΔFosB does not regulate p35 expression in these
regions following THC administration. In the caudate-putamen, p35 expression differed between
drug naïve and THC-experienced mice that received THC injection. Acute THC administration
actually increased p35 expression, suggesting that a different transcription factor might regulate
p35 induction in the caudate-putamen. In fact, early growth response protein 1 (EGR1), also
known as zif268 and krox-24, has been implicated in the induction of p35 (Utreras et al., 2011)
and is induced in the caudate-putamen by acute THC administration (Mailleux et al., 1994). In
THC-experienced mice, the decrease in p35 expression could be due to either increased calpainmediated cleavage of p35 to p25 (Kusakawa et al., 2000) or through the proteasome pathway as a
result of phosphorylation of p35 (Kerokoski et al., 2002; Patrick et al., 1998; Saito et al., 1998).
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It would appear that the latter is more likely because p25 expression did not increase in the
caudate-putamen following THC injection in THC-experienced mice. There was a similar effect
for p35 in the substantia nigra, where repeated THC administration increased p35 expression, but
THC challenge in THC-experienced mice decreased p35. D1R/dynorphin MSNs in the caudateputamen project to the substantia nigra, therefore it is possible that repeated THC administration
might increase trafficking of p35 from these neurons to axonal projections in the substantia nigra.
It is possible that p35 is also increased in neuronal cells of the substantia nigra. Similar to the
caudate-putamen, the cleavage of p35 to p25 does not explain the decrease of p35 expression in
the substantia nigra following THC injection in THC-experienced mice. However, there was an
increase in p25 expression in the substantia nigra following repeated THC administration,
suggesting that THC mediates increased cleavage of p35 to p25 in this region. There was no
change in CDK5, p35 or p25 expression in the globus pallidus, suggesting that the same
signaling responses that occur in D1R/dynorphin MSNs do not occur in dopamine type 2 receptor
(D2R)/enkephalin MSNs. This would agree with our previous findings that ΔFosB induction in
caudate-putamen is primarily restricted to neurons that express dynorphin (Chapter 3).
Expression of both p35 and p25 increased in the prefrontal cortex, which would increase
the kinase activity of CDK5 (Kusakawa et al., 2000; Tsai et al., 1994). Three substrates of
CDK5: DARPP-32, GSK3β and tau protein were assessed for phosphorylation levels to
determine if increases in p35/p25 would increase CDK5 kinase activity. Phosphorylation of tau
at Ser202/Thr205 was increased in the prefrontal cortex of THC-experienced mice that received
THC injection, whereas DARPP-32 phosphorylation at Thr75 was unchanged and GSK3β
phosphorylation of Ser9 was decreased. Although the increase in phosphorylation of tau would
suggest an increase in CDK5 kinase activity, CDK5 activity assays are necessary to assess CDK5
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activity. Phosphorylation of tau, DARPP-32 and GSK3β involve complex signaling pathways,
so it is not clear why THC injection in THC-experienced mice did not increase phosphorylation
of all three substrates. The finding that tau was phosphorylated in the prefrontal cortex after
repeated THC administration is interesting because previous studies have suggested that
synthetic cannabinoids (WIN55,212-2 and arachidonyl-2-chloroethylamide) are neuroprotective
in Alzheimer’s disease-related mouse models (Aso et al., 2012). The current results suggest that
THC might not be neuroprotective because hyperphosphorylation of tau is actually a symptom of
Alzheimer’s disease and THC-mediated phosphorylation of tau could exacerbate this condition
(Pettegrew et al., 1987).
DARPP-32 phosphorylation was unchanged in most brain regions following either acute
or repeated THC administration. Previous studies in the striatum found that acute administration
of either CP55,940 (Andersson et al., 2005) or THC (Borgkvist et al., 2008) increased
phosphorylation of DARPP-32 at threonine 34 in caudate-putamen and nucleus accumbens of
mice. Other studies have found that acute administration of THC in rats increased DARPP-32
phosphorylation at threonine 34 in the prefrontal cortex (Polissidis et al., 2010). The same dose
of THC and the same strain of mice were used in the current study as Borgkvist et al. (2008);
however, we measured DARPP-32 phosphorylation at 45 minutes. Borgkvist et al. (2008)
showed that phosphorylation of DARPP-32 at threonine 34 was maximal at 30 minutes and was
gone by one hour. Our studies would suggest that the threonine 34 site of DARPP-32 is
dephosphorylated back to baseline levels by 45 minutes. The finding that repeated THC
administration did not increase phosphorylation of DARPP-32 at threonine 75 in the nucleus
accumbens, caudate-putamen or cerebellum, is likely due to the lack of increase in CDK5, p35
and p25 expression in those brain regions. Phosphorylation of DARPP-32 at threonine 34 was
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decreased in the cerebellum following THC injection in THC-experienced mice, suggesting that
THC modulates DARPP-32 phosphorylation in this region.
Studies with other drugs of abuse, like cocaine, have focused on signaling changes in the
nucleus accumbens, whereas THC administration produced few changes in the nucleus
accumbens. However, the current study demonstrates that the neurochemistry of the prefrontal
cortex changes dramatically with administration of THC. Meta-analysis of neuroimaging studies
in adolescent and adult human cannabis users found that alterations in frontal cortex volumes and
cerebral blood flow following both THC administration and during memory-related tasks were
common in many studies (Batalla et al., 2013), suggesting an important role for this region in
continued marijuana use. ΔFosB appears to be an important regulator of these signaling changes
because CDK5 and p35 expression were increased in prefrontal cortex. Moreover, repeated THC
administration regulated other signaling cascades, including increases in ERK1 phosphorylation,
decreases in GSK3β phosphorylation at Ser9 and increases in tau phosphorylation.
Maladaptation of the prefrontal cortex, manifested as alterations in delta and gamma oscillations,
is consistently found in schizophrenia patients (Curley and Lewis, 2012). Positron emission
topography (PET) studies, using the CB1R-specific ligand [11C]JHU75528, determined that
CB1R levels are increased in the frontal cortex, caudate and putamen and globus pallidus, among
others, suggesting that CB1Rs might mediate these changes in gamma oscillations (Wong et al.,
2010). A higher percentage of schizophrenic patients also abuse marijuana compared to
populations of healthy individuals, and it has been suggested that marijuana use exacerbates
disease progression (Bossong and Niesink, 2010; Weiser and Noy, 2005). The changes in
signaling found in prefrontal cortex following repeated THC administration might offer insights
into possible mechanisms underlying this observation.
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The results of these studies suggest that repeated THC treatment alters signaling
pathways such that THC injection produces very different effects in THC-experienced versus
drug naïve mice. These studies are consistent with reports showing that cocaine-mediated
increases in CDK5 and p35 could result from the induction of ΔFosB following repeated drug
administration. However, THC-mediated signaling changes occurred predominantly in the
prefrontal cortex, whereas cocaine-mediated signaling changes were found in the nucleus
accumbens. These findings suggest that drug-induced changes in signaling are both drug- and
brain region-dependent.
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Conclusions and Perspectives

TABLE 5.1
Summary of major findings in this dissertation

Abbreviations: PFC, prefrontal cortex, CPu, caudate-putamen, Acb, nucleus accumbens, AMYG,
amygdala, VTA, ventral tegmental area, SN, substantia nigra
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The thesis chapters, contained herein, addressed the role of the transcription factor,
ΔFosB, in regulating both CB1R signaling and adaptation following repeated THC
administration and some of the possible mechanisms involved in THC-mediated induction of
ΔFosB. It was hypothesized that ΔFosB would reduce CB1R desensitization and contribute to
the brain region-dependent differences in CB1R desensitization that occur following repeated
THC administration. Studies in Chapter 2 were designed primarily to address the relationship
between ∆FosB and CB1R desensitization/downregulation and tolerance. However, the finding
that THC-mediated induction of ΔFosB was more regionally widespread than had been
previously determined (Perrotti et al., 2008), suggests that this transcription factor could play an
important role in other physiological changes following repeated THC administration. Major
findings from these dissertation studies include: 1) that THC-mediated induction of ΔFosB in the
caudate-putamen and nucleus accumbens is CB1R-dependent 2) that THC-mediated induction of
ΔFosB is D1R-dependent in the prefrontal cortex, caudate-putamen, nucleus accumbens and
amygdala 3) that overexpression of ΔFosB in D1R/dynorphin containing MSNs of the striatum
reduce CB1R desensitization in their respective output nuclei, and 4) that the FosB promoter is
primed in the prefrontal cortex such that THC challenge in THC-experienced mice enhances
ΔFosB induction.
These studies investigated possible mechanism(s) that might underlie brain regiondependent differences in CB1R desensitization/downregulation. Studies in Chapter 1 showed an
inverse region-dependent correlation between CB1 R desensitization and ΔFosB induction. It was
determined that regions like the caudate-putamen and nucleus accumbens exhibited significant
ΔFosB induction in the absence of CB1R desensitization, whereas the hippocampus exhibited
significant CB1R desensitization without ΔFosB induction following repeated THC
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administration. In Chapter 1, studies utilizing mice with genetic deletion of CB1Rs determined
that the induction of ΔFosB following repeated THC administration was dependent on CB1R
expression in the caudate-putamen and nucleus accumbens, and that CB1Rs were located on
axonal terminals surrounding ΔFosB positive cells and within the cell bodies of ΔFosB positive
cells. These studies provided evidence that, following repeated THC administration, CB1Rs
were necessary for ΔFosB induction and that ΔFosB could modulate CB1R signaling. These
studies did not address whether CB1Rs located on astrocytes may also play a role in ΔFosB
induction or whether ΔFosB is induced in astrocytes following repeated THC administration
CB1Rs are expressed by astrocytes and function to support neuronal cell viability (Stella, 2010).
Based on the inverse regional correlation between ∆FosB and CB1R desensitization
determined in Chapter 1, studies in Chapter 2 were designed to determine whether
overexpression of ΔFosB could regulate CB1R desensitization following repeated THC
administration. To test this hypothesis, mice overexpressing ΔFosB or ΔcJun, a dominant
negative inhibitor of ΔFosB, were assessed after repeated THC treatment. One group of mice
overexpressed ΔFosB primarily in the D1R/dynorphin MSN population of the striatum, which
project to the substantia nigra (cell bodies of origin in the caudate-putamen) and to the ventral
tegmental area (cell bodies of origin in the nucleus accumbens). These mice also overexpressed
ΔFosB in the hippocampus and parietal cortex. The other group of mice overexpressed ΔcJun in
both the D1R/dynorphin and D2R/enkephalin MSN populations, which project to the globus
pallidus (cell bodies of origin in the caudate-putamen) and to the ventral pallidum (cell bodies of
origin in the nucleus accumbens). These mice also overexpressed ΔcJun in the hippocampus and
parietal cortex. Based on our studies in Chapter 1, it was predicted that overexpression of
ΔFosB would reduce CB1R desensitization in the caudate-putamen, nucleus accumbens, ventral
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tegmental area and substantia nigra. However, it was determined that overexpression of ΔFosB
only reduced CB1R desensitization in the substantia nigra and ventral tegmental area. The
finding that overexpression of ΔFosB did not reduce CB1R desensitization in the caudateputamen and nucleus accumbens is likely due to the limited overexpression of ΔFosB in only the
D1R-positive population of MSNs in these regions. The caudate-putamen and nucleus
accumbens also receive inputs from the cortex, amygdala, hippocampus and thalamus, which
express CB1Rs. Therefore, significant desensitization in these CB1R populations may have
masked attenuation of CB1R desensitization in these regions. Although ΔFosB is significantly
increased in the hippocampus, this region did not exhibit reduced CB1R desensitization. This
finding likely reflects the lack of THC-mediated ΔFosB induction previously shown in the
hippocampus (Chapter 1). This is evidenced by our findings in Chapter 4, where ΔFosB did not
cause induction of CDK5or p35 in the striatum. These results suggest that ΔFosB could regulate
different signaling proteins in a brain region-dependent manner that leads to regulation of CB1R
desensitization. Inhibition of ΔFosB-mediated transcription by overexpression of ΔcJun
enhanced CB1R desensitization in the caudate-putamen, consistent with our hypothesis. The
difference between these results and those in ∆FosB overexpressing mice might reflect the fact
that ΔcJun is overexpressed in both the D1R/dynorphin and D2R/enkephalin MSN populations.
∆cJun overexpression did not enhance desensitization in substantia nigra. It is possible that
ΔcJun also inhibited the transcriptional regulation of other Fos family members, which are
known to regulate the expression of different signaling proteins. The results could also be due to
the dose of THC administered (10-30-60 mg/kg). It could be that the level of ΔFosB produced
by this THC dose is not sufficient to reduce CB1R desensitization, whereas ΔFosB
overexpression induces a higher level of protein induction. These studies focused only on the
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effect of ΔFosB overexpression on CB1R desensitization in the striatum, but not regions like
prefrontal cortex and amygdala where ΔFosB is also induced by THC. Future studies should test
whether overexpression of ∆FosB in the prefrontal cortex and amygdala would reduce
desensitization in these regions. These studies would help support our correlation model
proposed in Chapter 1. It is also important to note that the mice overexpressing ΔFosB were on a
mixed C57BL/6J and FVB genetic background, whereas the mice overexpressing ΔcJun were on
an FVB genetic background. Future studies could address this issue by overexpressing ΔFosB or
ΔcJun using viral vectors in the same mouse strain. This could be an especially important
consideration for in vivo studies assessing the effect of ∆FosB on THC-mediated effects. Results
of studies in both Chapter 1 and Chapter 2 suggest that ΔFosB does not regulate CB1R
desensitization in the hippocampus. However, overexpression of ΔcJun inhibited CB1R
desensitization in this region, suggesting that other Fos family members could regulate CB1R
desensitization in the hippocampus. Using mouse models with overexpression of other Fos
family members, like c-Fos, could determine if c-Fos regulates CB1R desensitization. Using
viral vectors with siRNA, to knockdown c-Fos expression, would serve as a complement to this
study.
The rewarding effects of most drugs of abuse are associated with enhanced dopamine
release in the shell of the nucleus accumbens (Pontieri et al., 1995). Most drugs of abuse also
induce ΔFosB in the nucleus accumbens following repeated administration (Perrotti et al., 2008).
Studies in Chapter 1 showed that THC, which enhances dopamine release (Wu and French,
2000), also induces ΔFosB in the nucleus accumbens, as well as prefrontal cortex, caudateputamen and basolateral amygdala (Polissidis et al., 2010). Further, THC-mediated induction of
ΔFosB is both CB1R- and D1R-mediated in the nucleus accumbens and caudate-putamen and
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D1R-mediated in prefrontal cortex and amygdala. Although it is not certain whether ΔFosB is a
necessary component for the switch from occasional drug use to addiction, the results of these
studies provide evidence that modulation of D1Rs would modulate the induction of ΔFosB and
could alleviate marijuana dependence. These results also highlight the need to focus on
additional brain regions that contribute to addiction since ΔFosB is induced in the prefrontal
cortex and amygdala. These regions appear to be important for drug craving and drug-cued
memory/reinstatement, respectively (Goldstein and Volkow, 2011; Stamatakis et al., 2013).
The results showing that THC-mediated ΔFosB induction is blocked by D1R antagonists
and that the majority of ∆FosB is expressed in D1R/dynorphin MSNs of the striatum are
somewhat surprising since CB1Rs are found on both D1R/dynorphin and D2R/enkephalin MSNs
(Hohmann and Herkenham, 2000). Further, evidence would suggest that CB1Rs and D2Rs can
dimerize (Wager-Miller et al., 2002) and that pharmacological inhibition or genetic deletion of
D2Rs or A2A receptors (which are also located in D2R MSNs and purported to dimerize with
CB1Rs) blocks cannabinoid-mediated phosphorylation of DARPP-32 at threonine 34 (Andersson
et al., 2005; Borgkvist et al., 2008). One explanation, supported by these dissertation studies, is
that DARPP-32 might not be necessary for ΔFosB induction following repeated THC
administration under the conditions tested in these studies. However, ∆FosB induction produced
by an acute administration of a 70 mg/kg dose of THC was abolished in DARPP-32 knockout
mice. It is possible that this dose of THC could produce acute induction of ΔFosB in the
D2R/enkephalin MSN population through a DARPP-32-dependent mechanism. One caveat to
this interpretation is that blockade of D1Rs also inhibits THC-mediated phosphorylation of
DARPP-32 at threonine 34 (Borgkvist et al., 2008). Therefore, it is also possible that CB1R/D2R
mediated signaling could enhance dopamine release and activate D 1Rs, which is one mechanism
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through which THC-mediated ΔFosB induction occurs. However, it is still not clear if
dimerization of CB1Rs and D2Rs could regulate the induction of ΔFosB in the D2R/enkephalin
medium spiny neuron population. The role of dimerization of these receptors in the induction of
ΔFosB could be tested through simultaneous treatment of CB1R and D2R agonists. Another
caveat to this finding is that compensatory adaptations might occur in mice with global, lifelong
deletion of DARPP-32. Future studies could address this possibility using conditional DARPP32 knockout mice with temporally and spatially restricted DARPP-32 deletion. The finding that
genetic deletion of DARPP-32 also enhanced tolerance to the locomotor suppressing effects of
THC suggests that these mice may also have brain region-dependent differences in CB1R
desensitization. This finding was similar to results showing that enhanced tolerance the
locomotor suppressing effects of THC were found in mice with attenuated CB1R desensitization
in the substantia nigra (through overexpression of ΔFosB) and enhanced CB1R desensitization in
the caudate-putamen (through overexpression of ΔcJun). It is not clear if these changes in CB1R
desensitization are directly responsible for enhanced tolerance; however, measuring
desensitization in DARPP-32 knockout mice might offer further evidence for whether
differences in desensitization in these regions might be mediating this enhanced tolerance.
Therefore, it is likely that brain region-dependent differences in CB1R desensitization contribute
to this finding. It is also possible that genetic deletion of DARPP-32 produces adaptations in
CB1R signaling downstream of G-protein activation, perhaps at the effector level, which might
explain the finding that DARPP-32 knockout mice also display increased locomotor suppression
following acute THC administration. Future studies are necessary to determine whether there are
brain region-dependent differences in CB1R-mediated G-protein activity in drug naïve mice and
CB1R desensitization following repeated THC administration between DARPP-32 knockout and
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wild-type. Autoradiographic studies, as performed in Chapter 2, would be appropriate in testing
this hypothesis.
There were also brain region-dependent differences in the regulation of CDK5 and p35,
proteins that are transcriptionally regulated by ΔFosB (Bibb et al., 2001a). Although ΔFosB
expression was increased in the prefrontal cortex, caudate-putamen and nucleus accumbens after
repeated THC administration, CDK5 and p35 expression were only increased in the prefrontal
cortex. This differs from previous studies that showed that cocaine-mediated ΔFosB induction is
associated with increased expression of both CDK5 and p35 in the nucleus accumbens (Bibb et
al., 2001a). This highlights one major difference between these different drugs of abuse and
could explain some of the preclinical rodent data that suggests that THC is not rewarding,
whereas cocaine is consistently found to be rewarding under these preclinical conditions (Tanda
and Goldberg, 2003). The lack of changes in CDK5 and p35 expression in the nucleus
accumbens of THC-treated mice could be due to degradation of the proteins because they are not
as stably expressed as ΔFosB. Studies were performed to address this possibility by measuring
protein levels at both 24 hours (at which time ΔFosB would still be elevated due to its stability)
and 45 minutes (to determine if CDK5 and p35 expression levels were elevated at earlier time
points but degraded by 24 hours) after THC challenge. Based on the results in the prefrontal
cortex, one conclusion is that CDK5 and p35 are continuously regulated by ΔFosB since both
CDK5 and p35 were elevated at the 24 hour time point. However, additional studies would be
needed to determine if CDK5 and p35 are also stable by using radiolabeled amino acids and
measuring the time course of CDK5 and p35 degradation. Assessment at earlier time points
could address the possibility that expression of CDK5 and p35 is increased within 30 minutes,
but rapidly degraded by the 45 minute time point.
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The other interesting finding is that THC-experience appeared to prime the FosB
promoter because THC challenge produced induction of ΔFosB that was not present in drug
naïve mice. This finding supports the importance of determining epigenetic factors that may
occur with long-term drug use and suggests the necessity of targeting these factors for drug
abuse treatment (Renthal and Nestler, 2008). These therapies would have to target and reverse
epigenetic changes to provide effective treatment. Currently, there are no clinically approved
therapies available for altering epigenetic effects (Renthal and Nestler, 2008). The studies in
Chapter 4 also provided evidence for the selective regulation of p35 in D 1R/dynorphin MSNs
because the regulation of this protein by THC was similar in the caudate-putamen and substantia
nigra, whereas there was no effect in globus pallidus, which receives inputs from the
D2R/enkephalin MSN population. Future studies are necessary to determine whether regulation
of p35 is restricted to the D1R/dynorphin MSN population, as it would suggest further
differences in the regulation of these two MSN populations following THC administration.
Studies similar to Chapter 3 could be performed to determine if antagonism of either D 1Rs or
D2Rs blocks this effect. Finally, although CDK5, p35 and p25 were increased in the prefrontal
cortex, only one target of CDK5, tau, exhibited increased phosphorylation as predicted.
Functional assays that measure the kinase activity of CDK5 are necessary to determine whether
CDK5 activity also increased in the prefrontal cortex and to determine if the lack of
phosphorylation of targets of CDK5 was due to other factors. Understanding these signaling
changes may also help elucidate possible mechanisms for marijuana-mediated exacerbation of
the progression of schizophrenia, a disorder that is hypothesized to be heavily influenced by
maladaptive cortical oscillations (Curley and Lewis, 2012), which may relate to the regulation of
neurotransmission by CB1Rs. New therapies are necessary for the treatment of schizophrenia
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because only approximately 50% of patients that receive current medications achieve sustained
remission of positive and negative symptoms (Galderisi et al., 2013). Understanding how THC
may exacerbate these symptoms could provide insight into designing therapeutic strategies that
might alleviate these symptoms.
One consistent finding of the studies in this dissertation is that repeated THC
administration produces specific brain region-dependent induction of ΔFosB. Although the role
that ΔFosB plays in drug abuse is not completely understood, this thesis suggests that both
CB1Rs and D1Rs are involved in its induction by THC. The brain region-dependent induction of
ΔFosB, however, does not necessarily translate into similar ΔFosB-mediated regulation of
transcription, because the expression of well-defined targets of ΔFosB differed among brain
regions. However, it is important to remember that these results were determined using a limited
scope of THC treatment paradigms and time courses. Again, these studies did not address
whether ΔFosB is expressed exclusively in neurons and whether the findings discussed above
could be due to induction of ΔFosB in astroctyes (Stella, 2010). It is possible that ΔFosB
differentially regulates protein expression in neurons and astrocytes. Future studies will need to
identify the protein targets that are regulated by ΔFosB, and in which cell types, to determine if
they regulate CB1R desensitization and whether they contribute to the rewarding effects of drugs
of abuse. Further immunohistochemical characterization could be used to address this question.
Although it is not clear whether ΔFosB is a necessary regulator of CB1R desensitization, these
studies suggest that it could contribute to CB1R desensitization in certain brain circuits. Future
studies could further investigate the brain regions in which ΔFosB regulate CB1R desensitization
using virally-mediated overexpression of ΔFosB, or through use of small molecules that inhibit
ΔFosB. The ability to design cannabinoid-based therapeutics by maximizing their clinical utility
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while minimizing their side effects requires understanding these brain region-dependent
differences in signaling. This is an important consideration for patients with long-term disorders
such as epilepsy and multiple sclerosis, for which THC has shown promise in treating, who will
need to function in their daily lives. If decrements in motor coordination impact their ability to
drive, for instance, then THC treatment would not be entirely beneficial. Further, inhibition of
ΔFosB might be useful for treating marijuana dependence based on preclinical evidence that
∆FosB contributes to the rewarding effects of drugs of abuse.
These results have implications for developing drugs that could mitigate some of the negative
side effects of THC and enhance its therapeutic utility. Recently, Nestler and collaborators have
developed small molecules that could inhibit the function of ΔFosB by screening small
molecules for their ability to prevent ΔFosB from binding to a modified CDK5 promoter (Wang
et al., 2012).

Nucleic acid aptamers provide another strategy for producing selective targets

that could inhibit ΔFosB transcription (Li et al., 2013). The strategy of blocking ΔFosB
transcription could be used to enhance CB1R desensitization in the caudate-putamen and enhance
the development of tolerance to THC-mediated motor impairment. This is based on results in
caudate-putamen that showed overexpression of ΔcJun, which also inhibits ΔFosB
transcriptional regulation, enhanced CB1R desensitization and tolerance to locomotor
suppression. Tolerance to motor impairment does not develop as readily as tolerance to other
THC-mediated effects in human marijuana users (D'Souza et al., 2008), and motor impairment is
a potential concern for the performance of day to day activities in patients. This would suggest
that introducing a small molecular inhibitor in combination with THC could enhance tolerance to
its motor impairing effects, and improve diving safety in patients treated with cannabinoids for
long periods of time. Targeting transcriptional regulation of other Fos family members could
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also mitigate the memory impairing effects of cannabinoids (Nestor et al., 2008). Similar small
molecules and aptamers could be produced to block the Fos family members that may contribute
to THC-mediated CB1R desensitization in hippocampus, which could mitigate memoryimpairing effects. Targeting ΔFosB may also help those who are dependent on marijuana. The
findings of this dissertation have further characterized the brain region-dependent differences in
the receptors /signaling proteins that modulate THC-mediated induction of ΔFosB. It has also
elucidated a role for ΔFosB and other Fos family members in modulating CB1R signaling and
provided evidence for brain region-dependent differences in the transcriptional regulation of
ΔFosB following repeated THC administration. These results provide insights into the
therapeutic potential of targeting ΔFosB for mitigating the long-term side effects of THC.
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